session tracker 2 0 1 4 Pre-meeting Courses:

session
2 0 1 4
tracker
Pre-meeting Courses: Friday, November 14 – Saturday, November 15, 2014
Annual Scientific Sessions: Saturday, November 15 – Wednesday, November 19, 2014
Exhibits: Sunday, November 16 – Tuesday, November 18, 2014
Great Meetings
Come from Great Ideas!
CALL FOR PROPOSALS: 4VCNJUZPVSTFTTJPOJEFBPSTUVEZHSPVQUPQJD
GPSUIF"$3"3)1"OOVBM.FFUJOHBU ACRannualmeeting.org50%":
We are looking for proposals that:
t3FøFDUDMJOJDBMJOOPWBUJPOBOEDVUUJOHFEHFSFTFBSDI
t$POWFZCFTUQSBDUJDFT
t1SFTFOUFWJEFODFCBTFENFEJDJOF
t4UJNVMBUFEJTDVTTJPOBOEDIBMMFOHFNJOETFUT
Tell us about learning models that:
t"EESFTTDIBMMFOHFTJOZPVSBSFBPGQSBDUJDF
Relevant topics may include:
t5FDIOPMPHJDBMBEWBODFTJNQBDUJOHQSBDUJDF
t8PSMEXJEFUSFOETJOQBUJFOU
DBSF
t0VUDPNFTBTTFTTNFOUBOE
IPMJTUJDUSFBUNFOU
t$SFBUFPQQPSUVOJUJFTUPTIBSFJOGPSNBUJPOBDSPTT
HFPHSBQIJDBMEFNPHSBQIJDT
t&ODPVSBHFDPMMBCPSBUJPOCFUXFFOTVCTQFDJBMJUJFT
t1SPNPUFQBSUOFSTIJQBNPOHQIZTJDJBOTBOE
IFBMUIQSPGFTTJPOBMT
Visit ACRannualmeeting.orgGPSTVCNJTTJPOEFUBJMT
%FBEMJOFGPSTVCNJTTJPOTJT Friday, November 21, 2014
session
3
tracker
hƐĞƚŚĞ^ĞƐƐŝŽŶdƌĂĐŬĞƌƚŽƌĞĐŽƌĚLJŽƵƌDͬ,ŽƵƌƐŽĨWĂƌƟĐŝƉĂƟŽŶĂƐLJŽƵŐŽ,
ƚŚĞŶƵƐĞƚŚĞ^ĞƐƐŝŽŶdƌĂĐŬĞƌĂƐĂŐƵŝĚĞƚŽĂƉƉůLJĨŽƌDͬ,ŽƵƌƐŽĨWĂƌƟĐŝƉĂƟŽŶ
online at ǁǁǁ͘ZĂŶŶƵĂůŵĞĞƟŶŐ͘ŽƌŐƚŽŽďƚĂŝŶĂĐĞƌƟĮĐĂƚĞĨŽƌLJŽƵƌƌĞĐŽƌĚƐ͘
&EVDBUJPOBM5SBDLT
>ŽŽŬĨŽƌƚŚĞƐĞŝĐŽŶƐƚŽŶĂǀŝŐĂƚĞƚŚĞŵĞĞƟŶŐďLJƚƌĂĐŬ͗
PR I M A RY T R AC K S
BASIC SCIENCE
BUSINESS/ADMINISTRATION
E
ETHICS
PM
CLINICAL SCIENCE
PAIN MANAGEMENT
PS
CLINICAL PRACTICE
PATIENT SAFETY
S EC O N DA RY T R AC K S
PM
Ed
Educators
FIT
Fellows-In-Training
ĐĐƌĞĚŝƚĂƟŽŶ^ƚĂƚĞŵĞŶƚ͗ The American
College of Rheumatology is accredited by the
ĐĐƌĞĚŝƚĂƟŽŶŽƵŶĐŝůĨŽƌŽŶƟŶƵŝŶŐDĞĚŝĐĂů
ĚƵĐĂƟŽŶ;DͿƚŽƉƌŽǀŝĚĞĐŽŶƟŶƵŝŶŐ
ŵĞĚŝĐĂůĞĚƵĐĂƟŽŶĨŽƌƉŚLJƐŝĐŝĂŶƐ͘
ĞƐŝŐŶĂƟŽŶ^ƚĂƚĞŵĞŶƚ͗ The ACR designates this
ůŝǀĞĞĚƵĐĂƟŽŶĂůĂĐƟǀŝƚLJĨŽƌĂŵĂdžŝŵƵŵŽĨ52.25
DWZĂƚĞŐŽƌLJϭƌĞĚŝƚƐΡ͘WŚLJƐŝĐŝĂŶƐƐŚŽƵůĚ
claim only the credit commensurate with the
ĞdžƚĞŶƚŽĨƚŚĞŝƌƉĂƌƟĐŝƉĂƟŽŶŝŶƚŚĞĂĐƟǀŝƚLJ͘
/ŶƚĞƌŶĂƟŽŶĂůWŚLJƐŝĐŝĂŶƐ͗/ŶƚĞƌŶĂƟŽŶĂůƉŚLJƐŝĐŝĂŶƐ
ǁŚŽƌĞŐŝƐƚĞƌĂƐƉĂƌƚŽĨĂŐƌŽƵƉĂŶĚƌĞƋƵŝƌĞ
DWZĂƚĞŐŽƌLJϭƌĞĚŝƚ;ƐͿΡŵƵƐƚƉƌŽǀŝĚĞ
ƚŚĞĨŽůůŽǁŝŶŐŝŶĨŽƌŵĂƟŽŶƚŽLJŽƵƌƚŽƵƌůĞĂĚĞƌ͗
ĨƵůůŶĂŵĞ͕ŵĂŝůŝŶŐĂĚĚƌĞƐƐ͕ƚĞůĞƉŚŽŶĞĂŶĚĨĂdž
ŶƵŵďĞƌƐĂŶĚĞͲŵĂŝůĂĚĚƌĞƐƐ͘dŚĞŝŶĨŽƌŵĂƟŽŶ
ǁŝůůďĞƵƐĞĚƚŽǀĞƌŝĨLJLJŽƵƌŵĞĞƟŶŐĂƩĞŶĚĂŶĐĞ͘
dŚĞŵĞƌŝĐĂŶDĞĚŝĐĂůƐƐŽĐŝĂƟŽŶŚĂƐĂŶ
ĂŐƌĞĞŵĞŶƚŽĨŵƵƚƵĂůƌĞĐŽŐŶŝƟŽŶŽĨĐŽŶƟŶƵŝŶŐ
ŵĞĚŝĐĂůĞĚƵĐĂƟŽŶĐƌĞĚŝƚǁŝƚŚƚŚĞƵƌŽƉĞĂŶ
hŶŝŽŶŽĨDĞĚŝĐĂů^ƉĞĐŝĂůƟĞƐ͘/ŶƚĞƌŶĂƟŽŶĂů
ƉŚLJƐŝĐŝĂŶƐŝŶƚĞƌĞƐƚĞĚŝŶĐŽŶǀĞƌƟŶŐAMA PRA
ĂƚĞŐŽƌLJϭƌĞĚŝƚΡƚŽDĐƌĞĚŝƚƐŚŽƵůĚ
ĐŽŶƚĂĐƚƚŚĞhD^͘
Pd
PS
Pediatrics
Practice Management
,ĞĂůƚŚWƌŽĨĞƐƐŝŽŶĂůƐ͗WĂƌƟĐŝƉĂŶƚƐŵĂLJĐůĂŝŵ
ŚŽƵƌƐƚŽƌĞĐĞŝǀĞĂĞƌƟĮĐĂƚĞŽĨWĂƌƟĐŝƉĂƟŽŶĨŽƌ
ĂŶĂĐƟǀŝƚLJĚĞƐŝŐŶĂƚĞĚĨŽƌDWZĂƚĞŐŽƌLJϭ
ƌĞĚŝƚ;ƐͿΡ͘&ŽƌŶŽŶͲDƐĞƐƐŝŽŶƐ͕ĂƩĞŶĚĞĞƐŵĂLJ
ĂůƐŽƌĞƋƵĞƐƚĂĐĞƌƟĮĐĂƚĞŽĨƉĂƌƟĐŝƉĂƟŽŶ͘
$-"*.*/($.&$3&%*5
zŽƵŵĂLJĐůĂŝŵLJŽƵƌDĐƌĞĚŝƚĂƚƚŚĞdĞĐŚŶŽůŽŐLJ
ĞŶƚĞƌ͕ůŽĐĂƚĞĚŽŶ>ĞǀĞůϭŝŶƚŚĞEŽƌƚŚ>ŽďďLJ͕
ĚƵƌŝŶŐŽƌĂƚƚŚĞĞŶĚŽĨƚŚĞŵĞĞƟŶŐĨŽƌĂůů
ƐĞƐƐŝŽŶƐĂƩĞŶĚĞĚ͘zŽƵŵĂLJĂůƐŽĐůĂŝŵLJŽƵƌ
ĐƌĞĚŝƚŽŶůŝŶĞĚƵƌŝŶŐĂŶĚĂŌĞƌƚŚĞŵĞĞƟŶŐĂƚ
ZĂŶŶƵĂůŵĞĞŐƟŶŐ͘ŽƌŐ͘
How Do I Claim Credit?/ƚŝƐĂŶDƌĞƋƵŝƌĞŵĞŶƚ
ƚŚĂƚLJŽƵĐůĂŝŵŽŶůLJƚŚĞydĂŵŽƵŶƚŽĨƟŵĞ
ƐƉĞŶƚŝŶĞĂĐŚĞĚƵĐĂƟŽŶĂůƐĞƐƐŝŽŶ͘dŚŝƐĂĐĐƵƌĂƚĞůLJ
ƌĞŇĞĐƚƐƚŚĞĞdžƚĞŶƚŽĨLJŽƵƌƉĂƌƟĐŝƉĂƟŽŶŝŶƚŚĞ
ĂĐƟǀŝƚLJ͘zŽƵŵĂLJĂƩĞŶĚƐĞƐƐŝŽŶƐĨŽƌ>^^ƚŚĂŶ
ƚŚĞŝƌĞŶƟƌĞƚLJĂŶĚĐůĂŝŵƉĂƌƟĂůĐƌĞĚŝƚƚŽƚŚĞ
ŶĞĂƌĞƐƚƋƵĂƌƚĞƌŚŽƵƌ͘EŽƚĞƚŚĂƚLJŽƵŵĂLJEKd
ĐůĂŝŵĐƌĞĚŝƚŚŽƵƌƐĨŽƌĂƩĞŶĚŝŶŐƚǁŽĨƵůůƐĞƐƐŝŽŶƐ
ĂƚĂŐŝǀĞŶƟŵĞŝŶƚŚĞŝƌĞŶƟƌĞƚLJ͘dŚĞƌĞĨŽƌĞ͕ŝĨLJŽƵ
ŝŶĂĐĐƵƌĂƚĞůLJƌĞĐŽƌĚLJŽƵƌĐƌĞĚŝƚŚŽƵƌƐĂŶĚĞdžĐĞĞĚ
ƚŚĞŵĞĞƟŶŐŵĂdžŝŵƵŵŽĨDͬWZĂƚĞŐŽƌLJϭ
ƌĞĚŝƚƐ™, you will need to correct your claim in
ŽƌĚĞƌƚŽƌĞĐĞŝǀĞLJŽƵƌĐĞƌƟĮĐĂƚĞ͘
4
2014 ACR /A R H P A n n u a l M e e t i n g
Example͗zŽƵĂƩĞŶĚŚĂůĨŽĨĂϭͲŚŽƵƌƐĞƐƐŝŽŶĂŶĚ
ŚĂůĨŽĨĂŶŽƚŚĞƌŝŶƚŚĞƐĂŵĞƟŵĞƐůŽƚ͘zŽƵmust
ƌĞƉŽƌƚƚŚĂƚLJŽƵƐƉĞŶƚ͘ϱŚŽƵƌƐŝŶƚŚĞĮƌƐƚƐĞƐƐŝŽŶ
ĂŶĚ͘ϱŝŶƚŚĞƐĞĐŽŶĚƐĞƐƐŝŽŶ͘/ĨLJŽƵĂƩĞŵƉƚƚŽ
ĐůĂŝŵĨƵůůĐƌĞĚŝƚ;ϭŚƌͿĨŽƌĞĂĐŚŽĨƚŚĞƚǁŽƐĞƐƐŝŽŶƐ͕
ƚŚĞĐůĂŝŵƐLJƐƚĞŵŵĂLJŽǀĞƌͲĐĂůĐƵůĂƚĞLJŽƵƌD
ĐƌĞĚŝƚĂŶĚLJŽƵŵĂLJĞdžĐĞĞĚƚŚĞŵĂdžŝŵƵŵŶƵŵďĞƌ
ŽĨĐƌĞĚŝƚŚŽƵƌƐĂůůŽǁĞĚ͘/ŶƚŚŝƐĐĂƐĞLJŽƵǁŽƵůĚŶŽƚ
ďĞĂďůĞƚŽƌĞĐĞŝǀĞLJŽƵƌĐĞƌƟĮĐĂƚĞ͘
How Do I Claim Credit for Poster Sessions? You
ŵĂLJŽŶůLJďĞĂǁĂƌĚĞĚDĐƌĞĚŝƚĨŽƌǀŝĞǁŝŶŐ
ƉŽƐƚĞƌƐĚƵƌŝŶŐƚŚĞϵ͗ϬϬʹϭϭ͗ϬϬƒÃƟŵĞƐůŽƚ͘/ƚ
ŝƐĂŶDƌĞƋƵŝƌĞŵĞŶƚƚŚĂƚƉŽƐƚĞƌƉƌĞƐĞŶƚĞƌƐ
ŵƵƐƚďĞĂǀĂŝůĂďůĞƚŽĞŶŐĂŐĞůĞĂƌŶĞƌƐ͘zŽƵŵƵƐƚ
ƚŚĞƌĞĨŽƌĞĐůĂŝŵKE>zƚŚĞĐƌĞĚŝƚĐŽŵŵĞŶƐƵƌĂƚĞ
ǁŝƚŚƚŚĞĞdžƚĞŶƚĨŽƌLJŽƵƌƉĂƌƟĐŝƉĂƟŽŶŝŶƚŚĞ
ĂĐƟǀŝƚLJĚƵƌŝŶŐƚŚŝƐƟŵĞƐůŽƚ͘zŽƵŵĂLJĐůĂŝŵ
ƉĂƌƟĂůĐƌĞĚŝƚ͘
IMPORTANT LOCATIONS
ZKĸĐĞ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘260; dĞůĞƉŚŽŶĞ͗;ϲϭϳͿϵϱϰͲϯϵϰϬ
ƩĞŶĚĞĞ>ŽƵŶŐĞ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘Ballroom Lobby
Business Center͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘>ĞǀĞůϭ͗EŽƌƚŚ>ŽďďLJ
ĂƌĞĞƌŽŶŶĞĐƟŽŶ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘džŚŝďŝƚ,Ăůů͗ŝƐĐŽǀĞƌLJĞŶƚĞƌ
;ŽŽƚŚηϳϯϭͿ
Child Care͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ĂůůĨŽƌ>ŽĐĂƟŽŶ͖dĞůĞƉŚŽŶĞ͗
;ϲϭϳͿϵϱϰͲϯϰϱϭ
ŽĂƚͬĂŐŐĂŐĞŚĞĐŬ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘>ĞǀĞůϭ͗EŽƌƚŚĞĂƐƚ>ŽďďLJ;ŶĞĂƌϭϱϲͿ
ŽŶĐŝĞƌŐĞĞŶƚĞƌ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘>ĞǀĞůϭ͗EŽƌƚŚ>ŽďďLJ
Discovery Center͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘džŚŝďŝƚ,Ăůů;ŽŽƚŚηϳϯϭͿ
Exhibit Hall͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘džŚŝďŝƚ,Ăůů
First Aid ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘>ĞǀĞůϭ͗EŽƌƚŚ>ŽďďLJ
&ŽƵŶĚĂƟŽŶŽŽƚŚ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘džŚŝďŝƚ,Ăůů͗ŝƐĐŽǀĞƌLJĞŶƚĞƌ
;ŽŽƚŚηϳϯϭͿ
&ŽƵŶĚĂƟŽŶŽŶŽƌƐ͛>ŽƵŶŐĞ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ŽĂƌĚƌŽŽŵ;^ƵŝƚĞϮϬϭͿ
,ŽƚĞůZĞƐĞƌǀĂƟŽŶƐ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘džŚŝďŝƚ>ĞǀĞů͗ZĞŐŝƐƚƌĂƟŽŶ
/ŶĚƵƐƚƌLJͲ^ƵƉƉŽƌƚĞĚ^LJŵƉŽƐŝĂ/ŶĨŽƌŵĂƟŽŶ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘>ĞǀĞůϭ͗EŽƌƚŚ>ŽďďLJ
/ŶŶŽǀĂƟŽŶdŚĞĂƚĞƌ ͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘džŚŝďŝƚ,Ăůů;ŽŽƚŚƐηϭϯϵĂŶĚηϭϰϬϭͿ
>ŽƐƚĂŶĚ&ŽƵŶĚ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ZKĸĐĞ;ϮϲϬͿ
DĞŵďĞƌƐŚŝƉŽŽƚŚ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘džŚŝďŝƚ>ĞǀĞů͗ZĞŐŝƐƚƌĂƟŽŶ
Newsroom͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ϮϱϮ͖dĞůĞƉŚŽŶĞ͗;ϲϭϳͿϵϱϰͲϯϵϰϯ
EƵƌƐŝŶŐDŽƚŚĞƌƐ͛ZŽŽŵ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ϭϲϮͲ
KǀĞƌŇŽǁZŽŽŵƐ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ϭϬϵ͕ϮϬϰĂŶĚϮϱϵ
Poster Hall͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘džŚŝďŝƚ,Ăůů
Prayer Room ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ϭϬϲ
ZĞĐŚĂƌŐĞƌĞĂƐ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ƩĞŶĚĞĞ>ŽƵŶŐĞ͕dĞĐŚŶŽůŽŐLJĞŶƚĞƌ
ĂŶĚtŝͲ&ŝtĂLJ
session
tracker
ZĞŐŝƐƚƌĂƟŽŶ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ džŚŝďŝƚ>ĞǀĞů͗ĂƐƚZĞŐŝƐƚƌĂƟŽŶ
ZĞƐƚĂƵƌĂŶƚZĞƐĞƌǀĂƟŽŶƐ͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘ >ĞǀĞůϭ͗EŽƌƚŚ>ŽďďLJ
ZŝďďŽŶŝƐƚƌŝďƵƟŽŶ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ džŚŝďŝƚ>ĞǀĞů͗ZĞŐŝƐƚƌĂƟŽŶ
^ŚƵƩůĞƵƐ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ >ĞǀĞůϭ;ŶĞĂƌϭϱϲͿ
^ŝŵƉůĞdĂƐŬƐ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ džŚŝďŝƚ,Ăůů͗ŝƐĐŽǀĞƌLJĞŶƚĞƌ
;ŽŽƚŚηϳϯϭͿ
^ƉĞĂŬĞƌZĞĂĚLJZŽŽŵ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ 206
dĞĐŚŶŽůŽŐLJĞŶƚĞƌ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ >ĞǀĞůϭ͗EŽƌƚŚ>ŽďďLJ
sŝƐŝƚŽƌ/ŶĨŽƌŵĂƟŽŶ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ >ĞǀĞůϭ͗EŽƌƚŚ>ŽďďLJ
Wheelchairs͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ KƌĚĞƌƚŚƌŽƵŐŚ^ĐŽŽƚƌŽƵŶĚ͕/ŶĐ͖͘
dĞůĞƉŚŽŶĞ͗;ϴϴϴͿϰϰϭ͘ϳϱϳϱ
tŝͲ&ŝtĂLJ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ džŚŝďŝƚ,Ăůů
^ƉĞĐŝĂůEĞĞĚƐ
/ĨLJŽƵƌĞƋƵŝƌĞƐƉĞĐŝĂůĂƌƌĂŶŐĞŵĞŶƚƐ͕ƉůĞĂƐĞĐŽŶƚĂĐƚƚŚĞZKĸĐĞ;ZŽŽŵϮϲϬͿ͖
dĞůĞƉŚŽŶĞ͗ ;ϲϭϳͿϵϱϰͲϯϵϰϬ͘
ŵĞƌŐĞŶĐLJŽŶƚĂĐƚ/ŶĨŽƌŵĂƟŽŶ
^ƉĂĐĞŝƐƉƌŽǀŝĚĞĚŽŶƚŚĞďĂĐŬŽĨLJŽƵƌďĂĚŐĞƚŽůŝƐƚŶĂŵĞĂŶĚƚĞůĞƉŚŽŶĞŶƵŵďĞƌƐŽĨ
LJŽƵƌĞŵĞƌŐĞŶĐLJĐŽŶƚĂĐƚƐ͘WůĞĂƐĞĐŽŵƉůĞƚĞƚŚŝƐŝŶĨŽƌŵĂƟŽŶďĞĨŽƌĞŝŶƐĞƌƟŶŐLJŽƵƌďĂĚŐĞ
ŝŶLJŽƵƌďĂĚŐĞŚŽůĚĞƌ͘
#PTUPO$POWFOUJPO
BOE&YIJCJUJPO$FOUFS
ΎůůŝŵƉŽƌƚĂŶƚůŽĐĂƟŽŶƐĂƌĞůŽĐĂƚĞĚŝŶƚŚĞŽƐƚŽŶŽŶǀĞŶƟŽŶĂŶĚdžŚŝďŝƟŽŶĞŶƚĞƌ͘
WƌŝŶƟŶŐŽĨƚŚŝƐƉƵďůŝĐĂƟŽŶŝƐƐƵƉƉŽƌƚĞĚďLJŵŐĞŶ͕/ŶĐ͘
5
6
2014 ACR /A R H P A n n u a l M e e t i n g
Meeting At-A-Glance
FRIDAY & SATURDAY, NOVEMBER 14 – 15, 2014
FRIDAY, NOVEMBER 14, 2014
Location
Time
Title
ϲ͗ϯϬƒÃʹ
ϲ͗ϬϬÖÃ
ZͬZ,WZĞŐŝƐƚƌĂƟŽŶ
džŚŝďŝƚ
͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘ >ĞǀĞů;ĂƐƚ
ZĞŐŝƐƚƌĂƟŽŶͿ
CME/Hours
of Participation
WZ͵Dd/E'KhZ^^
ϳ͗ϰϱƒÃʹ
ϱ͗ϯϬÖÃ
ACR Musculoskeletal Ultrasound Course for
ZŚĞƵŵĂƚŽůŽŐŝƐƚƐʹĂLJKŶĞŽĨdǁŽ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭϬϵ
ϵ͗ϬϬƒÃʹ
ϱ͗ϬϬÖÃ
ZĚǀĂŶĐĞĚZŚĞƵŵĂƚŽůŽŐLJŽĚŝŶŐŽƵƌƐĞ͗ĞǀĞůŽƉŝŶŐ
džƉĞƌƚƐŝŶZŚĞƵŵĂƚŽůŽŐLJŽĚŝŶŐĂŶĚ/ͲϭϬͲD
͘ ͘ ͘ ͘ Ϯϱϳ
ϭ͗ϬϬÖÃʹ
ϲ͗ϬϬÖÃ
ZĂƐŝĐZĞƐĞĂƌĐŚŽŶĨĞƌĞŶĐĞ͗ŵĞƌŐŝŶŐWĞƌƐƉĞĐƟǀĞƐ
ŽŶƚŚĞDŝĐƌŽďŝŽŵĞŝŶƚŚĞZŚĞƵŵĂƟĐŝƐĞĂƐĞƐʹĂLJKŶĞ
of Two ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϮϭϬ
…
ϰ͘ϳϱŚƌƐ͘
ϭ͗ϬϬÖÃʹ
ϲ͗ϬϬÖÃ
ZůŝŶŝĐĂůZĞƐĞĂƌĐŚŽŶĨĞƌĞŶĐĞ͗WĂƟĞŶƚͲĞŶƚĞƌĞĚ
KƵƚĐŽŵĞƐŝŶZŚĞƵŵĂƚŽůŽŐLJʹĂLJKŶĞŽĨdǁŽ
͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϮϬϱ
…
ϰ͘ϱŚƌƐ͘
ϭ͗ϬϬÖÃʹ
ϲ͗ϭϬÖÃ
Zͬ/DDĂŝŶƚĞŶĂŶĐĞŽĨĞƌƟĮĐĂƟŽŶ>ĞĂƌŶŝŶŐ^ĞƐƐŝŽŶʹ
ϮϬϭϰhƉĚĂƚĞŝŶZŚĞƵŵĂƚŽůŽŐLJ
͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ Ϯϱϴ
…
ϰ͘ϳϱŚƌƐ͘
…
ϴ͘ϮϱŚƌƐ͘
SATURDAY, NOVEMBER 15, 2014
Location
Time
Title
ϲ͗ϯϬƒÃʹ
ϲ͗ϯϬÖÃ
ZͬZ,WZĞŐŝƐƚƌĂƟŽŶ
džŚŝďŝƚ
͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘ >ĞǀĞů;ĂƐƚ
ZĞŐŝƐƚƌĂƟŽŶͿ
CME/Hours
of Participation
WZ͵Dd/E'KhZ^^
ϳ͗ϭϱƒÃʹ
ϱ͗ϱϬÖÃ
ACR Musculoskeletal Ultrasound Course for
ZŚĞƵŵĂƚŽůŽŐŝƐƚƐʹĂLJdǁŽŽĨdǁŽ
͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭϬϵ
…
ϵ͘ϬϬŚƌƐ͘
ϳ͗ϰϱƒÃʹ
ϰ͗ϯϬÖÃ
ZůŝŶŝĐĂůZĞƐĞĂƌĐŚŽŶĨĞƌĞŶĐĞ͗WĂƟĞŶƚͲĞŶƚĞƌĞĚ
KƵƚĐŽŵĞƐŝŶZŚĞƵŵĂƚŽůŽŐLJʹĂLJdǁŽŽĨdǁŽ
͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϮϬϱ
…
ϳ͘ϳϱŚƌƐ͘
ϴ͗ϬϬƒÃʹ
ϰ͗ϬϬÖÃ
ZWƌĂĐƟĐĞDĂŶĂŐĞŵĞŶƚWƌĞͲŵĞĞƟŶŐŽƵƌƐĞ
͘ ͘ ͘ ͘ Ϯϱϳ
…
ϳ͘ϬŚƌƐ͘
ͶĚĞŶŽƚĞƐtĞƐƟŶtĂƚĞƌĨƌŽŶƚƌŽŽŵůŽĐĂƟŽŶ
session
7
tracker
SATURDAY & SUNDAY, NOVEMBER 15 – 16, 2014
Meeting At-A-Glance
Location
CME/Hours
Time
Title
ϴ͗ϬϬƒÃʹ
ϰ͗ϬϬÖÃ
ACR Review Course
ϴ͗ϬϬƒÃʹ
ϰ͗ϯϬÖÃ
ZĂƐŝĐZĞƐĞĂƌĐŚŽŶĨĞƌĞŶĐĞ͗ŵĞƌŐŝŶŐWĞƌƐƉĞĐƟǀĞƐ
ŽŶƚŚĞDŝĐƌŽďŝŽŵĞŝŶƚŚĞZŚĞƵŵĂƟĐŝƐĞĂƐĞƐʹĂLJdǁŽŽĨ
Two ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϮϭϬ
…
ϲ͘ϮϱŚƌƐ͘
ϴ͗ϬϬƒÃʹ
ϰ͗ϯϬÖÃ
Z,WůŝŶŝĐĂů&ŽĐƵƐŽƵƌƐĞ͗ŝĂŐŶŽƐƟĐ/ŵĂŐŝŶŐhƐĞ
ŝŶŝīĞƌĞŶƟĂůŝĂŐŶŽƐŝƐĨŽƌŽŵŵŽŶZŚĞƵŵĂƟĐĂŶĚ
DƵƐĐƵůŽƐŬĞůĞƚĂůŽŶĚŝƟŽŶƐ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ Ϯϱϰ
…
ϳ͘ϬŚƌƐ͘
ϵ͗ϬϬƒÃʹ
ϰ͗ϬϬÖÃ
DDĞĚŝĐĂůĚƵĐĂƟŽŶZĞƐĞĂƌĐŚĞƌƟĮĐĂƚĞ;DZͿ
tŽƌŬƐŚŽƉ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϮϬϰ
of Participation
͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ džŚŝďŝƚ,Ăůů …
ϲ͘ϬŚƌƐ͘
SCIENTIFIC SESSIONS
ϰ͗ϯϬÖÃʹ
ϲ͗ϭϱÖÃ
ZͬZ,WKƉĞŶŝŶŐ>ĞĐƚƵƌĞĂŶĚǁĂƌĚƐ
KƉĞŶŝŶŐ>ĞĐƚƵƌĞ͗WϰDĞĚŝĐŝŶĞ/ƐdƌĂŶƐĨŽƌŵŝŶŐ,ĞĂůƚŚĂƌĞ͗
>ŽŶŐŝƚƵĚŝŶĂů͕&ƌĂŵŝŶŐŚĂŵͲůŝŬĞ^ƚƵĚLJŽĨϭϬϬ͕ϬϬϬtĞůůWĂƟĞŶƚƐ
KǀĞƌϮϬͲϮϱzĞĂƌƐ
͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ džŚŝďŝƚ,Ăůů
ϲ͗ϭϱÖÃʹ
ϴ͗ϬϬÖÃ
EĞƚǁŽƌŬŝŶŐǀĞŶƚ
ZͬZ,WKƉĞŶŝŶŐZĞĐĞƉƟŽŶ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ Ballroom East
and West
…
Ϭ͘ϳϱŚƌƐ͘
SUNDAY, NOVEMBER 16, 2014
Location
CME/Hours
Time
Title
ϲ͗ϯϬƒÃʹ
ϲ͗ϬϬÖÃ
ZͬZ,WZĞŐŝƐƚƌĂƟŽŶ
džŚŝďŝƚ
͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘ >ĞǀĞů;ĂƐƚ
ZĞŐŝƐƚƌĂƟŽŶͿ
ϳ͗ϯϬƒÃʹ
ϴ͗ϯϬƒÃ
ACR Sessions
…
ϭ͘ϬŚƌ͘
ŐĞĞĨŽƌĞĞĂƵƚLJ͗ŽůĐŚŝĐŝŶĞ͕ƐƉŝƌŝŶ͕DĞƚŚŽƚƌĞdžĂƚĞĂŶĚ
dŚĞŝƌDĞĐŚĂŶŝƐŵƐŽĨĐƟŽŶ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ Ϯϱϯ
WĞĚŝĂƚƌŝĐZŚĞƵŵĂƚŽůŽŐLJdŽǁŶ,Ăůů ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭϬϰ
zĞĂƌŝŶZĞǀŝĞǁ
͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ džŚŝďŝƚ,Ăůů
ϳ͗ϯϬƒÃʹ
ϴ͗ϯϬƒÃ
EĞƚǁŽƌŬŝŶŐǀĞŶƚ
ZͬZ,W&ŝƌƐƚͲƟŵĞƩĞŶĚĞĞKƌŝĞŶƚĂƟŽŶ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭϬϮ
ͶĚĞŶŽƚĞƐtĞƐƟŶtĂƚĞƌĨƌŽŶƚƌŽŽŵůŽĐĂƟŽŶ
of Participation
8
2014 ACR /A R H P A n n u a l M e e t i n g
Meeting At-A-Glance
SUNDAY, NOVEMBER 16, 2014
Location
Time
Title
ϳ͗ϰϱƒÃʹ
ϵ͗ϭϱƒÃ
ACR Meet the Professor Sessions
ĂƐŝĐ/ŵŵƵŶŽůŽŐLJĨŽƌůŝŶŝĐĂůZŚĞƵŵĂƚŽůŽŐŝƐƚƐ;ϬϬϭͿ͘ ͘ ͘ ͘ ͘ ͘ ͘
ƌLJƐƚĂů͗ŝĂŐŶŽƐŝƐĂŶĚDĂŶĂŐĞŵĞŶƚŽĨ'ŽƵƚ;ϬϬϮͿ
PM
͘ ͘ ͘ ͘ ͘ ͘
ƵƚĂŶĞŽƵƐsĂƐĐƵůŝƟƐ;ϬϬϯͿ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
&ŝďƌŽŵLJĂůŐŝĂϮϬϭϰ͗hƉĚĂƚĞŽŶDĂŶĂŐĞŵĞŶƚ;ϬϬϰͿ
PM
͘ ͘ ͘ ͘ ͘ ͘
DĂĐƌŽƉŚĂŐĞĐƟǀĂƟŽŶ^LJŶĚƌŽŵĞ;ϬϬϱͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
WĂŝŶ͗ǀĂůƵĂƟŽŶĂŶĚdƌĞĂƚŵĞŶƚŽĨĂĐŬWĂŝŶ;ϬϬϲͿ
PM
͘ ͘ ͘ ͘ ͘ ͘
WƐŽƌŝĂƟĐƌƚŚƌŝƟƐ;ϬϬϳͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
ZĞĂĐƟǀĞƌƚŚƌŝƟƐ͗ŶhƉĚĂƚĞ;ϬϬϴͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
ZŚĞƵŵĂƚŽŝĚƌƚŚƌŝƟƐ͗ŚĂůůĞŶŐŝŶŐĂƐĞƐ;ϬϬϵͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
^LJƐƚĞŵŝĐ>ƵƉƵƐƌLJƚŚĞŵĂƚŽƐƵƐ͗ŝĸĐƵůƚƚŽdƌĞĂƚ^LJƐƚĞŵŝĐ
>ƵƉƵƐƌLJƚŚĞŵĂƚŽƐƵƐ;ϬϭϬͿ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
WĂŝŶĞ
;>ŽďďLJͿ
KƟƐ
;>ŽďďLJͿ
,ĂŶĐŽĐŬ
;>ŽďďLJͿ
ZĞǀĞƌĞ
;>ŽďďLJͿ
^ƚŽŶĞ
;>ŽďďLJͿ
Webster
;>ŽďďLJͿ
Adams
;DĞnjnjĂŶŝŶĞͿ
ůĐŽƩ
;DĞnjnjĂŶŝŶĞͿ
ŽƵŐůĂƐ
;DĞnjnjĂŶŝŶĞͿ
CME/Hours
of Participation
…
ϭ͘ϱŚƌƐ͘
&ĂŶĞƵŝů
;DĞnjnjĂŶŝŶĞͿ
ϳ͗ϰϱƒÃʹ
ϵ͗ϰϱƒÃ
ZtŽƌŬƐŚŽƉƐ
:ŽŝŶƚ/ŶũĞĐƟŽŶdĞĐŚŶŝƋƵĞƐ;ϮϬϭͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭϱϮ
EĂŝůĨŽůĚĂƉŝůůĂƌŽƐĐŽƉLJ;ϮϬϮͿ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭϲϭ
dĂŝŚŝŝŶZŚĞƵŵĂƟĐŝƐĞĂƐĞ;ϮϬϯͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭϱϰ
…
Ϯ͘ϬŚƌƐ͘
ϴ͗ϯϬƒÃʹ
ϭϬ͗ϬϬƒÃ
ACR Sessions
Z͗DĂŝŶƚĞŶĂŶĐĞŽĨĞƌƟĮĐĂƟŽŶ^ĞƐƐŝŽŶKŶĞ
ŽĨdŚƌĞĞʹsĂƐĐƵůŝƟƐ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
ƵƌƌĞŶƚhŶĚĞƌƐƚĂŶĚŝŶŐŽĨDĂůŝŐŶĂŶĐŝĞƐŝŶŽŶŶĞĐƟǀĞ
dŝƐƐƵĞŝƐĞĂƐĞƐ
͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
FIT ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
E
PM
Ed
Ethics and Rheumatology
/ŶĨŽƌŵĂƟǀĞĂŶĚƌŝƟĐĂůWĞĞƌZĞǀŝĞǁĨŽƌƚŚĞZ:ŽƵƌŶĂůƐ͗
'ƵŝĚĞƚŽWƌŽǀŝĚŝŶŐdžĐĞůůĞŶƚWĞĞƌZĞǀŝĞǁŽĨ
FIT ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
DĂŶƵƐĐƌŝƉƚƐ
KƐƚĞŽƉŽƌŽƐŝƐ͗ƵƌƌĞŶƚŽŶĐĞƉƚƐĨŽƌƚŚĞůŝŶŝĐŝĂŶ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
WƌĂĐƟĐĞ/ƐƐƵĞƐ͗,ĞĂůƚŚĂƌĞŽƵŶƚLJ,ƵŶƚĞƌƐ͗ůŽƐĞƌ
>ŽŽŬĂƚZƐ͕ƵĚŝƚƐĂŶĚDĞĚŝĐĂůŽĐƵŵĞŶƚĂƟŽŶ ͘ ͘ ͘ ͘ ͘ ͘ ͘
dŚĞDŝĐƌŽďŝŽŵĞŝŶ,ĞĂůƚŚĂŶĚŝƐĞĂƐĞ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
tŚĞŶWŝůůƐƌĞEŽƚŶŽƵŐŚ͗DƵůƟĚŝƐĐŝƉůŝŶĂƌLJƉƉƌŽĂĐŚĞƐƚŽ
Pd
PS ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
PM
WĞĚŝĂƌŝĐWĂŝŶĂŶĚ,LJƉĞƌŵŽďŝůŝƚLJ
…
ϭ͘ϱŚƌƐ͘
ϱϮ
Ballroom East
Ϯϱϰ
Ϯϱϳ
džŚŝďŝƚ,Ăůů
ϭϲϬ
Ϯϱϴ
ϭϬϰ
ͶĚĞŶŽƚĞƐtĞƐƟŶtĂƚĞƌĨƌŽŶƚƌŽŽŵůŽĐĂƟŽŶ
session
9
tracker
SUNDAY, NOVEMBER 16, 2014
Meeting At-A-Glance
Location
Time
Title
ϴ͗ϯϬƒÃʹ
ϰ͗ϬϬÖÃ
ACR Poster Session A and Poster Tours
ďƐƚƌĂĐƚƐ;ηϭͲϴϭϰͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ WŽƐƚĞƌ,Ăůů
WŽƐƚĞƌ,ĂůůDŽƌŶŝŶŐ^ŶĂĐŬƌĞĂŬ;ϴ͗ϯϬʹϭϬ͗ϬϬƒÃͿ
CME/Hours
of Participation
…
Ϯ͘ϬŚƌƐ͘
;džŚŝďŝƚ,ĂůůͿ
Poster Presenters Available
ϵ͗ϬϬʹϭϭ͗ϬϬƒÃ
Guided Poster Tours
ϵ͗ϬϬʹϵ͗ϰϱƒÃ
ϯϬϭʹ&ĞůůŽǁƐKŶůLJ͗,ŽǁƚŽEĂǀŝŐĂƚĞƚŚĞWŽƐƚĞƌ,Ăůů
ϯϬϮʹWĂŝŶ͗ĂƐŝĐĂŶĚůŝŶŝĐĂůƐƉĞĐƚƐ
ϯϬϯʹWĂƐƚWƌĞƐŝĚĞŶƚ͛ƐWŝĐŬƐWŽƐƚĞƌdŽƵƌ
ϯϬϰʹWĂƐƚWƌĞƐŝĚĞŶƚ͛ƐWŝĐŬƐWŽƐƚĞƌdŽƵƌ
ϯϬϱʹZŚĞƵŵĂƚŽŝĚƌƚŚƌŝƟƐdƌĞĂƚŵĞŶƚʹ^ŵĂůůDŽůĞĐƵůĞƐ͕
ŝŽůŽŐŝĐƐĂŶĚ'ĞŶĞdŚĞƌĂƉLJWŽƐƚĞƌdŽƵƌ
ϯϬϲʹ^LJƐƚĞŵŝĐ>ƵƉƵƐƌLJƚŚĞŵĂƚŽƐƵƐ͗ůŝŶŝĐĂůƐƉĞĐƚƐ
WŽƐƚĞƌdŽƵƌ
ϭϬ͗ϭϱʹϭϭ͗ϬϬƒÃ
ϯϬϳʹŶƟƉŚŽƐƉŚŽůŝƉŝĚ^LJŶĚƌŽŵĞWŽƐƚĞƌdŽƵƌ
ϯϬϴʹDĞƚĂďŽůŝĐĂŶĚƌLJƐƚĂůƌƚŚƌŽƉĂƚŚŝĐƐWŽƐƚĞƌdŽƵƌ
ϯϬϵʹWĂƐƚWƌĞƐŝĚĞŶƚ͛ƐWŝĐŬƐWŽƐƚĞƌdŽƵƌ
ϯϭϬʹZŚĞƵŵĂƚŽŝĚƌƚŚƌŝƟƐ͗ůŝŶŝĐĂůƐƉĞĐƚƐWŽƐƚĞƌdŽƵƌ
ϯϭϭʹ^LJƐƚĞŵŝĐ>ƵƉƵƐƌLJƚŚĞŵĂƚŽƐƵƐ͗ůŝŶŝĐĂůƐƉĞĐƚƐ
WŽƐƚĞƌdŽƵƌ
ϯϭϮʹsĂƐĐƵůŝƟƐWŽƐƚĞƌdŽƵƌ
ϵ͗ϬϬƒÃʹ
ϭϬ͗ϬϬƒÃ
ACR Sessions
Z/ŵŵƵŶŽůŽŐLJhƉĚĂƚĞ͗EĞǁ/ŵŵƵŶŽůŽŐLJŽĨƚŚĞ
^ƉŽŶĚLJůŽĂƌƚŚƌŽƉĂƚŚŝĞƐ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϮϭϬ
ĚǀŽĐĂĐLJ͗DĞĞƚƚŚĞdžƉĞƌƚʹ^ĞŶĂƚŽƌ͛ƐWĞƌƐƉĞĐƟǀĞ
ŽŶĚǀŽĐĂĐLJĞƐƚWƌĂĐƟĐĞƐ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭϬϮ
^ĂƌĐŽŝĚŽƐŝƐŝŶϮϬϭϰ
͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ Ballroom
West
^ŽĐŝĂůDĞĚŝĂŽŽƚĂŵƉ͗dǁŝƩĞƌĂƐŝĐƐ
͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭϱϯ
…
ϭ͘ϬŚƌ͘
ϵ͗ϬϬƒÃʹ
ϭϬ͗ϬϬƒÃ
ARHP Session
Z,W<ĞLJŶŽƚĞĚĚƌĞƐƐ͗,ĂƉƉŝŶĞƐƐ&ƌŽŵƚŚĞ/ŶƐŝĚĞKƵƚ
…
ϭ͘ϬŚƌ͘
͘ ͘ ϭϬϳ
ϭϬ͗ϬϬƒÃʹ Exhibits
ϱ͗ϬϬÖÃ
džŚŝďŝƚ,ĂůůDŽƌŶŝŶŐ^ŶĂĐŬƌĞĂŬ;ϭϬ͗ϬϬʹϭϭ͗ϬϬƒÃͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ džŚŝďŝƚ,Ăůů
džŚŝďŝƚ,ĂůůŌĞƌŶŽŽŶ^ŶĂĐŬƌĞĂŬ;Ϯ͗ϬϬʹϯ͗ϬϬÖÃͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ džŚŝďŝƚ,Ăůů
ͶĚĞŶŽƚĞƐtĞƐƟŶtĂƚĞƌĨƌŽŶƚƌŽŽŵůŽĐĂƟŽŶ
10 2014 ACR /A R H P A n n u a l M e e t i n g
Meeting At-A-Glance
Time
SUNDAY, NOVEMBER 16, 2014
Location
Title
CME/Hours
of Participation
ϭϬ͗ϯϬƒÃʹ Exhibits
ϭϭ͗ϭϱƒÃ
/ŶŶŽǀĂƟŽŶdŚĞĂƚĞƌ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ džŚŝďŝƚ,Ăůů
;ŽŽƚŚηϭϯϵͿ
^ĞĞƉĂŐĞϰϰĨŽƌƚŚĞ/ŶŶŽǀĂƟŽŶdŚĞĂƚĞƌ>ŝƐƟŶŐ
ϭϬ͗ϯϬƒÃʹ ZtŽƌŬƐŚŽƉƐ
ϭϮ͗ϯϬÖÃ
ĞLJŽŶĚDƵƐĐƵůŽƐŬĞůĞƚĂůhůƚƌĂƐŽƵŶĚĨŽƌZŚĞƵŵĂƚŽůŽŐŝƐƚƐ
;ϮϬϰͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
ůŝŶŝĐĂůŶĂƚŽŵLJĂŶĚWŚLJƐŝĐĂůdžĂŵ͗ƐƐĞŶƟĂůdŽŽůƐŝŶhƉƉĞƌ
džƚƌĞŵŝƚLJZĞŐŝŽŶĂůWĂŝŶ^LJŶĚƌŽŵĞƐ;ϮϬϱͿ PM ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
,ŝƐƚŽƉĂƚŚŽůŽŐLJŽĨZŚĞƵŵĂƟĐ>ƵŶŐŝƐĞĂƐĞ;ϮϬϲͿ͘͘͘͘͘͘͘͘͘͘͘
^LJŶŽǀŝĂů&ůƵŝĚŶĂůLJƐŝƐĂŶĚƌLJƐƚĂů/ĚĞŶƟĮĐĂƟŽŶ;ϮϬϳͿ͘ ͘ ͘ ͘ ͘ ͘
…
Ϯ͘ϬŚƌƐ͘
ϭϱϵ
ϭϱϮ
ϭϱϰ
ϭϲϭ
ϭϭ͗ϬϬƒÃʹ ACR Sessions
EŽŽŶ
Bone Biology
͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϮϭϬ
EĞǁZZĞĐŽŵŵĞŶĚĂƟŽŶƐĨŽƌƚŚĞDĂŶĂŐĞŵĞŶƚŽĨ
PS ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ Ballroom East
PM
ZŚĞƵŵĂƚŽŝĚƌƚŚƌŝƟƐ
…
ϭ͘ϬŚƌ͘
ϭϭ͗ϬϬƒÃʹ ARHP Sessions
EŽŽŶ
īŽƌĚĂďůĞĂƌĞĐƚ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ Ϯϱϳ
/ŵŵƵŶŽůŽŐLJŽŽƚĂŵƉ/͗dŚĞĂƐŝĐƐŽĨdĂƌŐĞƚĞĚ
dŚĞƌĂƉŝĞƐ
͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϱϮ
tŚĂƚĂŶƌĂŝŶ/ŵĂŐŝŶŐdĞůůhƐďŽƵƚWŚĂƌŵĂĐŽůŽŐŝĐĂŶĚ
PM ͘ ͘ ͘ ͘ ͘ Ϯϱϰ
EŽŶͲWŚĂƌŵĂĐŽůŽŐŝĐdƌĞĂƚŵĞŶƚŽĨŚƌŽŶŝĐWĂŝŶ͍
…
ϭ͘ϬŚƌ͘
ϭϭ͗ϬϬƒÃʹ ZWůĞŶĂƌLJ^ĞƐƐŝŽŶ/͗ŝƐĐŽǀĞƌLJϮϬϭϰ
…
ϭϮ͗ϯϬÖÃ
ďƐƚƌĂĐƚƐ;ηϴϭϱͲϴϭϵͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ džŚŝďŝƚ,Ăůů ϭ͘ϱŚƌƐ͘
ϭϭ͗ϯϬƒÃʹ Exhibits
ϭϮ͗ϭϱÖÃ
/ŶŶŽǀĂƟŽŶdŚĞĂƚĞƌ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ džŚŝďŝƚ,Ăůů
;ŽŽƚŚηϭϰϬϭͿ
^ĞĞƉĂŐĞϰϰĨŽƌƚŚĞ/ŶŶŽǀĂƟŽŶdŚĞĂƚĞƌ>ŝƐƟŶŐ͘
ϭϮ͗ϯϬÖÃʹ Exhibits
ϭ͗ϭϱÖÃ
/ŶŶŽǀĂƟŽŶdŚĞĂƚĞƌ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ džŚŝďŝƚ,Ăůů
;ŽŽƚŚηϭϯϵͿ
^ĞĞƉĂŐĞϰϰĨŽƌƚŚĞ/ŶŶŽǀĂƟŽŶdŚĞĂƚĞƌ>ŝƐƟŶŐ͘
ϭϮ͗ϯϬÖÃʹ EĞƚǁŽƌŬŝŶŐǀĞŶƚ
Ϯ͗ϭϱÖÃ
Z,WEĞƚǁŽƌŬŝŶŐ&ŽƌƵŵ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
ϭϮ͗ϰϱÖÃʹ ACR Session
Ϯ͗ϭϱÖÃ
Z<ŶŽǁůĞĚŐĞŽǁů͗WƌĞůŝŵŝŶĂƌLJZŽƵŶĚ
Commonwealth Ballroom
͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ Ballroom
West
…
ϭ͘ϱŚƌƐ͘
ͶĚĞŶŽƚĞƐtĞƐƟŶtĂƚĞƌĨƌŽŶƚƌŽŽŵůŽĐĂƟŽŶ
session
11
tracker
SUNDAY, NOVEMBER 16, 2014
Time
Meeting At-A-Glance
Title
Location
ϭϮ͗ϰϱÖÃʹ ACR Meet the Professor Sessions
Ϯ͗ϭϱÖÃ
ŶŬLJůŽƐŝŶŐ^ƉŽŶĚLJůŝƟƐ͗ϮϬϭϰhƉĚĂƚĞ;ϬϭϭͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
WĂŝŶĞ
;>ŽďďLJͿ
KƟƐ
ŶŬLJůŽƐŝŶŐ^ƉŽŶĚLJůŝƟƐ͗ŝƐĞĂƐĞDŽĚŝĮĐĂƟŽŶ;ϬϭϮͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
;>ŽďďLJͿ
ĞƌŵĂƚŽůŽŐŝĐĂůDĂŶŝĨĞƐƚĂƟŽŶƐŽĨZŚĞƵŵĂƟĐ
ŝƐĞĂƐĞƐ;ϬϭϯͿ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
,ĞƌĞĚŝƚĂƌLJŶŐŝŽĞĚĞŵĂhƉĚĂƚĞ;ϬϭϰͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
WĞĚŝĂƚƌŝĐ^LJƐƚĞŵŝĐ>ƵƉƵƐƌLJƚŚĞŵĂƚŽƐƵƐ;ϬϭϱͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
ZŚĞƵŵĂƚŽŝĚƌƚŚƌŝƟƐ͗ŝŽůŽŐŝĐĂůŐĞŶƚƐ;ϬϭϲͿ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
^LJƐƚĞŵŝĐ>ƵƉƵƐƌLJƚŚĞŵĂƚŽƐƵƐ͗EŽǀĞůdƌĞĂƚŵĞŶƚƐ;ϬϭϳͿ͘ ͘ ͘ ͘ ͘
sĂĐĐŝŶĂƟŽŶƐĨŽƌWĂƟĞŶƚƐŽŶŝŽůŽŐŝĐdŚĞƌĂƉŝĞƐ;ϬϭϴͿ ͘ ͘ ͘ ͘ ͘ ͘ ͘
sĂƐĐƵůŝƟƐ͗hƉĚĂƚĞ;ϬϭϵͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
tŚĂƚ/ƐEŽƚĞŶƚƌĂůEĞƌǀŽƵƐŶŐŝŝƟƐ͗DĂŬŝŶŐƚŚĞZŝŐŚƚ
ŝĂŐŶŽƐŝƐ;ϬϮϬͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
CME/Hours
of Participation
…
ϭ͘ϱŚƌƐ͘
,ĂŶĐŽĐŬ
;>ŽďďLJͿ
ZĞǀĞƌĞ
;>ŽďďLJͿ
^ƚŽŶĞ
;>ŽďďLJͿ
Webster
;>ŽďďLJͿ
Adams
;DĞnjnjĂŶŝŶĞͿ
ůĐŽƩ
;DĞnjnjĂŶŝŶĞͿ
ŽƵŐůĂƐ
;DĞnjnjĂŶŝŶĞͿ
&ĂŶĞƵŝů
;DĞnjnjĂŶŝŶĞͿ
ϭ͗ϬϬÖÃʹ
Ϯ͗ϬϬÖÃ
ACR Sessions
…
ϭ͘ϬŚƌ͘
ǀŽŝĚŝŶŐůĞĐƚƌŽŶŝĐ,ĞĂůƚŚZĞĐŽƌĚƌƌŽƌƐĂŶĚdŚĞŝƌ
;^ŽŵĞƟŵĞƐͿƌŝƟĐĂůŽŶƐĞƋƵĞŶĐĞƐ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ Ϯϱϰ
PS ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭϱϳ
PM
džŝĂů^ƉŽŶĚLJůŽĂƌƚŚƌŝƟƐ'ƵŝĚĞůŝŶĞƐ
FIT
PM ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ džŚŝďŝƚ,Ăůů
'ŽƵƚDĂŶĂŐĞŵĞŶƚŝŶϮϬϭϰ
,ŽǁƚŚĞ'ƵƚWƌŝŵĞƐƚŚĞ/ŵŵƵŶĞ^LJƐƚĞŵ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭϬϮ
WƌĂĐƟĐĞ/ƐƐƵĞƐ͗dŚĞZŽĂĚƚŽ/ϭϬ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭϱϭ
ZŚĞƵŵĂƚŽůŽŐLJZĞƐĞĂƌĐŚ&ŽƵŶĚĂƟŽŶDĞŵŽƌŝĂů>ĞĐƚƵƌĞƐŚŝƉƚŽ
,ŽŶŽƌƌ͘^ƚĞƉŚĞŶ͘DĂůĂǁŝƐƚĂ͕D͗/ŶŶĂƚĞ/ŵŵƵŶŝƚLJĂƚƚŚĞ
E ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭϬϰ
ŽƌĞŽĨZŚĞƵŵĂƟĐŝƐĞĂƐĞ
dŚĞƵƩĞƌŇLJīĞĐƚ͗>ƵƉƵƐZĂƐŚĞƐĂŶĚdŚĞŝƌDŝŵŝĐƐ ͘ ͘ ͘ ͘ ͘ Ballroom East
ϭ͗ϭϱÖÃʹ
ϯ͗ϭϱÖÃ
ZtŽƌŬƐŚŽƉƐ
ĚǀĂŶĐĞĚDƵƐĐƵůŽƐŬĞůĞƚĂůhůƚƌĂƐŽƵŶĚ;ϮϬϴͿ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭϱϵ
ůŝŶŝĐĂůŶĂƚŽŵLJĂŶĚWŚLJƐŝĐĂůdžĂŵ͗ƐƐĞŶƟĂůdŽŽůƐŝŶ
>ŽǁĞƌdžƚƌĞŵŝƚLJZĞŐŝŽŶĂůWĂŝŶ^LJŶĚƌŽŵĞƐ;ϮϬϵͿ PM ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭϱϮ
ϭ͗ϯϬÖÃʹ
Ϯ͗ϭϱÖÃ
Exhibits
/ŶŶŽǀĂƟŽŶdŚĞĂƚĞƌ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ džŚŝďŝƚ,Ăůů
;ŽŽƚŚηϭϰϬϭͿ
^ĞĞƉĂŐĞϰϰĨŽƌƚŚĞ/ŶŶŽǀĂƟŽŶdŚĞĂƚĞƌ>ŝƐƟŶŐ͘
Ϯ͗ϯϬÖÃʹ
ϯ͗ϭϱÖÃ
Exhibits
/ŶŶŽǀĂƟŽŶdŚĞĂƚĞƌ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ džŚŝďŝƚ,Ăůů
;ŽŽƚŚηϭϯϵͿ
^ĞĞƉĂŐĞϰϰĨŽƌƚŚĞ/ŶŶŽǀĂƟŽŶdŚĞĂƚĞƌ>ŝƐƟŶŐ͘
ͶĚĞŶŽƚĞƐtĞƐƟŶtĂƚĞƌĨƌŽŶƚƌŽŽŵůŽĐĂƟŽŶ
…
Ϯ͘ϬŚƌƐ͘
12 2014 ACR /A R H P A n n u a l M e e t i n g
Meeting At-A-Glance
SUNDAY, NOVEMBER 16, 2014
Location
Time
Title
Ϯ͗ϯϬÖÃʹ
ϰ͗ϬϬÖÃ
ACR Sessions
ƵƚŽŝŵŵƵŶŝƚLJŝŶ/ŵŵƵŶŽĚĞĮĐŝĞŶĐLJ
͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
PM
Ed ͘ ͘ ͘ ͘
ĚƵĐĂƚŽƌ͗DĞĚŝĐĂůĚƵĐĂƟŽŶ͗dŚĞzĞĂƌŝŶZĞǀŝĞǁ
EĞǁ&ƌŽŶƟĞƌƐŝŶKƐƚĞŽĂƌƚŚƌŝƟƐdƌĞĂƚŵĞŶƚ͗dŚĞZŽůĞ
ŽĨtĞŝŐŚƚ>ŽƐƐ͕^ƵƌŐĞƌLJĂŶĚƵƌƌĞŶƚdƌĞĂƚŵĞŶƚ
FIT ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
'ƵŝĚĞůŝŶĞƐ
dŚĞ'ƌĞĂƚĞďĂƚĞ͗ĞůŝŵƵŵĂďĨŽƌƚŚĞdƌĞĂƚŵĞŶƚŽĨ^LJƐƚĞŵŝĐ
>ƵƉƵƐƌLJƚŚĞŵĂƚŽƐƵƐ
͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
Ϯ͗ϯϬÖÃʹ
ϰ͗ϬϬÖÃ
ACR Concurrent Abstract Sessions
;ηϴϮϬͲϴϮϱͿƉŝĚĞŵŝŽůŽŐLJĂŶĚWƵďůŝĐ,ĞĂůƚŚ/͗ƌƵŐĂŶĚ
sĂĐĐŝŶĞ^ĂĨĞƚLJ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
;ηϴϮϲͲϴϯϭͿDĞƚĂďŽůŝĐĂŶĚƌLJƐƚĂůƌƚŚƌŽƉĂƚŚŝĞƐ/͗
ůŝŶŝĐĂůƐƉĞĐƚƐ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
;ηϴϯϮͲϴϯϳͿDŝƐĐĞůůĂŶĞŽƵƐZŚĞƵŵĂƟĐĂŶĚ/ŶŇĂŵŵĂƚŽƌLJ
ŝƐĞĂƐĞƐ
͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
;ηϴϯϴͲϴϰϯͿZŚĞƵŵĂƚŽŝĚƌƚŚƌŝƟƐʹůŝŶŝĐĂůƐƉĞĐƚƐ/͗
ĂƌĚŝŽǀĂƐĐƵůĂƌŝƐĞĂƐĞZŝƐŬ
͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
;ηϴϰϰͲϴϰϵͿZŚĞƵŵĂƚŽŝĚƌƚŚƌŝƟƐʹ^ŵĂůůDŽůĞĐƵůĞƐ͕
ŝŽůŽŐŝĐƐĂŶĚ'ĞŶĞdŚĞƌĂƉLJ/͗^ĂĨĞƚLJŽĨŝŽůŽŐŝĐƐĂŶĚ
^ŵĂůůDŽůĞĐƵůĞƐŝŶZŚĞƵŵĂƚŽŝĚƌƚŚƌŝƟƐʹDĂůŝŐŶĂŶĐLJ
ĂŶĚ/ŶĨĞĐƟŽŶ
͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
;ηϴϱϬͲϴϱϱͿ^ƉŽŶĚLJůŽĂƌƚŚƌŽƉĂƚŚŝĞƐĂŶĚWƐŽƌŝĂƟĐƌƚŚƌŝƟƐ/ʹ
EŽǀĞůdƌĞĂƚŵĞŶƚƐĨŽƌdžŝĂů^ƉŽŶĚLJůŽĂƌƚŚƌŝƟƐ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
;ηϴϱϲͲϴϲϭͿ^LJƐƚĞŵŝĐ>ƵƉƵƐƌLJƚŚĞŵĂƚŽƐƵƐʹAnimal
DŽĚĞůƐ
͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
;ηϴϲϮͲϴϲϳͿ^LJƐƚĞŵŝĐ>ƵƉƵƐƌLJƚŚĞŵĂƚŽƐƵƐʹůŝŶŝĐĂůƐƉĞĐƚƐ
ĂŶĚdƌĞĂƚŵĞŶƚ͗ĂƌĚŝŽǀĂƐĐƵůĂƌŝƐĞĂƐĞĂŶĚWƌĞŐŶĂŶĐLJ ͘ ͘ ͘
;ηϴϲϴͲϴϳϯͿ^LJƐƚĞŵŝĐ>ƵƉƵƐƌLJƚŚĞŵĂƚŽƐƵƐʹ,ƵŵĂŶƟŽůŽŐLJ
ĂŶĚWĂƚŚŽŐĞŶĞƐŝƐ/͗WĂƚŚǁĂLJƐŽĨ/ŶŇĂŵŵĂƟŽŶͬ/ŶũƵƌLJ ͘ ͘ ͘ ͘
;ηϴϳϰͲϴϳϵͿ^LJƐƚĞŵŝĐ^ĐůĞƌŽƐŝƐ͕&ŝďƌŽƐŝŶŐ^LJŶĚƌŽŵĞƐĂŶĚ
ZĂLJŶĂƵĚ͛ƐʹůŝŶŝĐĂůƐƉĞĐƚƐĂŶĚdŚĞƌĂƉĞƵƟĐƐ/͗^LJƐƚĞŵŝĐ
^ĐůĞƌŽƐŝƐ͕ĚǀĂŶĐĞƐŝŶdŚĞƌĂƉLJ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
;ηϴϴϬͲϴϴϱͿsĂƐĐƵůŝƟƐ/ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
ϱϮ
ϭϬϮ
CME/Hours
of Participation
…
ϭ͘ϱŚƌƐ͘
ϮϬϱ
džŚŝďŝƚ,Ăůů
…
ϭ͘ϱŚƌƐ͘
Ϯϱϯ
ϭϬϰ
ϭϲϬ
Ballroom
East
Ballroom
West
ϮϭϬ
ϭϱϯ
Ϯϱϴ
ϭϬϳ
ϭϱϳ
ϭϱϲ
Ϯ͗ϯϬÖÃʹ
ϰ͗ϬϬÖÃ
ARHP Sessions
'ŽŽŐůĞDŝŶĞĮĞůĚ͗ŵƉŽǁĞƌŝŶŐWĂƟĞŶƚƐƚŽǀĂůƵĂƚĞKŶůŝŶĞ
FIT ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ Ϯϱϱ
PM
Ed
Resources
WƌĂĐƟĐĂůWƌĂĐƟĐĞDĂŶĂŐĞŵĞŶƚ^ĞƐƐŝŽŶKŶĞ͗/ŵƉƌŽǀĞYƵĂůŝƚLJ
ĂŶĚĸĐŝĞŶĐLJ
͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ Ϯϱϲ
^ƉŽƌƚƐDĞĚŝĐŝŶĞĨŽƌƚŚĞZŚĞƵŵĂƚŽůŽŐLJWƌŽǀŝĚĞƌ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭϱϭ
zŽƵŶŐĚƵůƚƐǁŝƚŚZŚĞƵŵĂƟĐŝƐĞĂƐĞ͗dŚĞWĂƟĞŶƚ
Pd
PS ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ Ϯϱϰ
WĞƌƐƉĞĐƟǀĞ
…
ϭ͘ϱŚƌƐ͘
Ϯ͗ϯϬÖÃʹ
ϰ͗ϬϬÖÃ
ARHP Concurrent Abstract Session
;ηϴϴϲͲϴϵϭͿdžĞŵƉůĂƌLJďƐƚƌĂĐƚƐ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ Ϯϱϳ
…
ϭ͘ϱŚƌƐ͘
ͶĚĞŶŽƚĞƐtĞƐƟŶtĂƚĞƌĨƌŽŶƚƌŽŽŵůŽĐĂƟŽŶ
session
13
tracker
SUNDAY, NOVEMBER 16, 2014
Meeting At-A-Glance
Location
CME/Hours
Time
Title
ϯ͗ϯϬÖÃʹ
ϰ͗ϭϱÖÃ
Exhibits
/ŶŶŽǀĂƟŽŶdŚĞĂƚĞƌ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ džŚŝďŝƚ,Ăůů
;ŽŽƚŚηϭϰϬϭͿ
^ĞĞƉĂŐĞϰϰĨŽƌƚŚĞ/ŶŶŽǀĂƟŽŶdŚĞĂƚĞƌ>ŝƐƟŶŐ͘
ϰ͗ϬϬÖÃʹ
ϲ͗ϬϬÖÃ
ZtŽƌŬƐŚŽƉƐ
DĂŐŶĞƟĐZĞƐŽŶĂŶĐĞ/ŵĂŐŝŶŐŝŶƚŚĞŝĂŐŶŽƐŝƐ
ĂŶĚDĂŶĂŐĞŵĞŶƚŽĨ^ƉŽŶĚLJůŽĂƌƚŚƌŝƟƐ͗ůŝŶŝĐŝĂŶ͛Ɛ
'ƵŝĚĞ;ϮϭϬͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭϱϵ
DƵƐĐůĞ/ŶǀŽůǀĞŵĞŶƚŝŶZŚĞƵŵĂƟĐŝƐĞĂƐĞƐ;ϮϭϭͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭϲϭ
KƐƚĞŽƉŽƌŽƐŝƐ͗/ŶƚĞƌƉƌĞƟŶŐƵĂůŶĞƌŐLJyͲZĂLJďƐŽƌƉƟŽŵĞƚƌLJ
ĂŶĚůŝŶŝĐĂůZŝƐŬ&ĂĐƚŽƌƐ͗dŚĞEĞǁ&ƌĂĐƚƵƌĞZŝƐŬƐƐĞƐƐŵĞŶƚ
ůŐŽƌŝƚŚŵ;ϮϭϮͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭϱϰ
WŚLJƐŝĐĂůdžĂŵŝŶĂƟŽŶ^ŬŝůůƐĨŽƌ/ŵƉƌŽǀĞĚĞƚĞĐƟŽŶŽĨ
^LJŶŽǀŝƟƐĂŶĚĞƌǀŝĐĂůdŚŽƌĂĐŽůƵŵďĂƌŝƐŽƌĚĞƌƐ;ϮϭϯͿ ͘ ͘ ͘ ͘ ͘ ͘ ϭϱϮ
…
Ϯ͘ϬŚƌƐ͘
ϰ͗ϯϬÖÃʹ
ϲ͗ϬϬÖÃ
ACR Sessions
͘ ͘ ͘ ͘ ϱϮ
dŚĞƌĂƉĞƵƟĐdĂƌŐĞƟŶŐŽĨƚŚĞ/ŶŶĂƚĞ/ŵŵƵŶĞ^LJƐƚĞŵ
͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ Ballroom East
dŚŝĞǀĞƐ͛DĂƌŬĞƚ͗^ŚŽǁDĞzŽƵƌĞƐƚĂƐĞƐ
…
ϭ͘ϱŚƌƐ͘
ϰ͗ϯϬÖÃʹ
ϲ͗ϬϬÖÃ
ACR Concurrent Abstract Sessions
…
ϭ͘ϱŚƌƐ͘
;ηϴϵϮͲϴϵϳͿ&ŝďƌŽŵLJĂůŐŝĂ͕^ŽŌdŝƐƐƵĞŝƐŽƌĚĞƌƐ͕
ZĞŐŝŽŶĂůĂŶĚ^ƉĞĐŝĮĐůŝŶŝĐĂůWĂŝŶ^LJŶĚƌŽŵĞƐ/͗ZĞƐĞĂƌĐŚ
PM ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭϬϰ
WĞƌƐƉĞĐƟǀĞƐ
;ηϴϵϴͲϵϬϯͿ,ĞĂůƚŚ^ĞƌǀŝĐĞƐZĞƐĞĂƌĐŚ͗ZŝƐŬƐƐĞƐƐŵĞŶƚĂŶĚ
͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭϱϭ
KƵƚĐŽŵĞƐŽĨZŚĞƵŵĂƟĐŝƐĞĂƐĞ
;ηϵϬϰͲϵϬϵͿ/ŵĂŐŝŶŐŽĨZŚĞƵŵĂƟĐŝƐĞĂƐĞƐ͗hůƚƌĂƐŽƵŶĚ ͘ ͘ ϮϭϬ
;ηϵϭϬͲϵϭϱͿDƵƐĐůĞŝŽůŽŐLJ͕DLJŽƐŝƟƐĂŶĚDLJŽƉĂƚŚŝĞƐ ͘ ͘ ͘ ͘ ϭϲϬ
;ηϵϭϲͲϵϮϭͿKƐƚĞŽƉŽƌŽƐŝƐĂŶĚDĞƚĂďŽůŝĐŽŶĞŝƐĞĂƐĞʹ
ůŝŶŝĐĂůƐƉĞĐƚƐĂŶĚWĂƚŚŽŐĞŶĞƐŝƐ͗ůŝŶŝĐĂůKƐƚĞŽƉŽƌŽƐŝƐ͗
͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭϱϯ
dƌĞĂƚŵĞŶƚĂŶĚ^ĂĨĞƚLJ
PM ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭϱϲ
;ηϵϮϮͲϵϮϳͿWĂŝŶ͗ĂƐŝĐĂŶĚůŝŶŝĐĂůƐƉĞĐƚƐ/
;ηϵϮϴͲϵϯϯͿWĞĚŝĂƚƌŝĐZŚĞƵŵĂƚŽůŽŐLJʹClinical and
Pd
PS ͘ ͘ ͘ ͘ Ϯϱϯ
dŚĞƌĂƉĞƵƟĐƐƉĞĐƚƐ͗:ƵǀĞŶŝůĞ/ĚŝŽƉĂƚŚŝĐƌƚŚƌŝƟƐ
͘ ͘ ͘ ͘ ͘ ϭϬϳ
;ηϵϯϰͲϵϯϵͿZŚĞƵŵĂƚŽŝĚƌƚŚƌŝƟƐʹŶŝŵĂůDŽĚĞůƐ/
;ηϵϰϬͲϵϰϱͿZŚĞƵŵĂƚŽŝĚƌƚŚƌŝƟƐʹůŝŶŝĐĂůƐƉĞĐƚƐ//͗
ZĞŵŝƐƐŝŽŶĂŶĚĞͲĞƐĐĂůĂƟŽŶŽĨdŚĞƌĂƉLJ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ džŚŝďŝƚ,Ăůů
;ηϵϰϲͲϵϱϭͿZŚĞƵŵĂƚŽŝĚƌƚŚƌŝƟƐʹ^ŵĂůůDŽůĞĐƵůĞƐ͕ŝŽůŽŐŝĐƐ
ĂŶĚ'ĞŶĞdŚĞƌĂƉLJ//͗EŽǀĞůdŚĞƌĂƉŝĞƐŝŶZŚĞƵŵĂƚŽŝĚ
͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ Ballroom
ƌƚŚƌŝƟƐʹĂƌůLJŝŶĞǀĞůŽƉŵĞŶƚ
;ηϵϱϮͲϵϱϳͿ^ƉŽŶĚLJůŽĂƌƚŚƌŽƉĂƚŚŝĞƐĂŶĚWƐŽƌŝĂƟĐƌƚŚƌŝƟƐ//ʹ West
EŽǀĞůdƌĞĂƚŵĞŶƚƐĨŽƌWƐŽƌŝĂƟĐƌƚŚƌŝƟƐ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ Ϯϱϴ
;ηϵϱϴͲϵϲϯͿ^LJƐƚĞŵŝĐ>ƵƉƵƐƌLJƚŚĞŵĂƚŽƐƵƐʹůŝŶŝĐĂůƐƉĞĐƚƐ
ĂŶĚdƌĞĂƚŵĞŶƚ͗>ƵƉƵƐEĞƉŚƌŝƟƐ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϮϬϱ
;ηϵϲϰͲϵϲϵͿ^LJƐƚĞŵŝĐ^ĐůĞƌŽƐŝƐ͕&ŝďƌŽƐŝŶŐ^LJŶĚƌŽŵĞƐ
ĂŶĚZĂLJŶĂƵĚ͛ƐʹWĂƚŚŽŐĞŶĞƐŝƐ͕ŶŝŵĂůDŽĚĞůƐĂŶĚ
͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭϱϳ
'ĞŶĞƟĐƐ/
ͶĚĞŶŽƚĞƐtĞƐƟŶtĂƚĞƌĨƌŽŶƚƌŽŽŵůŽĐĂƟŽŶ
of Participation
14 2014 ACR /A R H P A n n u a l M e e t i n g
Meeting At-A-Glance
SUNDAY, NOVEMBER 16, 2014
Location
Time
Title
ϰ͗ϯϬÖÃʹ
ϲ͗ϬϬÖÃ
ACR Meet the Professor Sessions
ƌLJƐƚĂů͗ŝĂŐŶŽƐŝƐĂŶĚDĂŶĂŐĞŵĞŶƚŽĨ'ŽƵƚ;ϬϮϭͿ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
WĂŝŶĞ
;>ŽďďLJͿ
KƟƐ
/ŶĨĞĐƟŽŶƐǁŝƚŚŝŽůŽŐŝĐƐ;ϬϮϮͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
;>ŽďďLJͿ
,ĂŶĐŽĐŬ
/ŶŇĂŵŵĂƚŽƌLJLJĞŝƐĞĂƐĞͬhǀĞŝƟƐ;ϬϮϯͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
;>ŽďďLJͿ
CME/Hours
of Participation
…
ϭ͘ϱŚƌƐ͘
WĞĚŝĂƚƌŝĐƐ͗ŝĸĐƵůƚƚŽdƌĞĂƚ:ƵǀĞŶŝůĞ/ĚŝŽƉĂƚŚŝĐ
PS ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
ƌƚŚƌŝƟƐ;ϬϮϰͿ Pd
ZĞǀĞƌĞ
;>ŽďďLJͿ
^ƚŽŶĞ
WŽůLJŵLJĂůŐŝĂZŚĞƵŵĂƟĐĂ;ϬϮϱͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
;>ŽďďLJͿ
Webster
WƵůŵŽŶĂƌLJ,LJƉĞƌƚĞŶƐŝŽŶŝŶƚŚĞZŚĞƵŵĂƟĐŝƐĞĂƐĞƐ;ϬϮϲͿ͘ ͘ ͘
;>ŽďďLJͿ
Adams
ZŚĞƵŵĂƚŽŝĚƌƚŚƌŝƟƐ͗ŝŽůŽŐŝĐĂůŐĞŶƚƐ;ϬϮϳͿ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
;DĞnjnjĂŶŝŶĞͿ
ZŚĞƵŵĂƚŽůŽŐLJWƌĂĐƟĐĞϭϬϭ͗^ƚĂƌƟŶŐKƵƚŝŶWƌĂĐƟĐĞĨŽƌƚŚĞ
'ƌĂĚƵĂƟŶŐ&ĞůůŽǁ;ϬϮϴͿ FIT ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
ůĐŽƩ
;DĞnjnjĂŶŝŶĞͿ
ŽƵŐůĂƐ
^LJƐƚĞŵŝĐ>ƵƉƵƐƌLJƚŚĞŵĂƚŽƐƵƐ͗EŽǀĞůdƌĞĂƚŵĞŶƚƐ;ϬϮϵͿ͘ ͘ ͘ ͘
;DĞnjnjĂŶŝŶĞͿ
&ĂŶĞƵŝů
sŝƚĂŵŝŶĂŶĚŽŶĞ,ĞĂůƚŚ;ϬϯϬͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
;DĞnjnjĂŶŝŶĞͿ
ϰ͗ϯϬÖÃʹ
ϲ͗ϬϬÖÃ
ACR/ARHP Combined Abstract Session
;ηϵϳϬͲϵϳϱͿZͬZ,WŽŵďŝŶĞĚďƐƚƌĂĐƚ^ĞƐƐŝŽŶ͗
ƉŝĚĞŵŝŽůŽŐLJĂŶĚWƵďůŝĐ,ĞĂůƚŚ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭϬϵ
…
ϭ͘ϱŚƌƐ͘
ϰ͗ϯϬÖÃʹ
ϲ͗ϬϬÖÃ
ARHP Sessions
͞^ĂLJtŚĂƚ͍͗͟/ŵƉůŝĐĂƟŽŶƐŽĨĚŽůĞƐĐĞŶƚĞǀĞůŽƉŵĞŶƚ
ĂŶĚĞŚĂǀŝŽƌŝŶŽŵŵƵŶŝĐĂƟŶŐtŝƚŚ,ĞĂůƚŚĂƌĞ
Pd
PS
WƌŽǀŝĚĞƌƐ
͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ Ϯϱϱ
ƵƌƌĞŶƚdƌĞŶĚƐŝŶ^ĞůĨͲDĂŶĂŐĞŵĞŶƚĂŶĚZŚĞƵŵĂƚŽůŽŐŝĐĂƌĞ͗
ŵ,ĞĂůƚŚ͕Ğ,ĞĂůƚŚ͕ŝŐŝƚĂůdĞĐŚŶŽůŽŐLJĂŶĚŵĞƌŐŝŶŐƚŚŝĐĂů
E ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ Ϯϱϰ
ŽŶƐŝĚĞƌĂƟŽŶƐ
DƵůƟĚŝƐĐŝƉůŝŶĂƌLJDĂŶĂŐĞŵĞŶƚŽĨ^ĐůĞƌŽĚĞƌŵĂ
͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭϬϮ
WƌĂĐƟĐĂůWƌĂĐƟĐĞDĂŶĂŐĞŵĞŶƚ^ĞƐƐŝŽŶdǁŽ͗EĂǀŝŐĂƚĞ,/W
ĂŶĚWƌĞǀĞŶƚƵĚŝƚƐ
͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ Ϯϱϲ
…
ϭ͘ϱŚƌƐ͘
ϰ͗ϯϬÖÃʹ
ϲ͗ϬϬÖÃ
ARHP Concurrent Abstract Session
;ηϵϳϲͲϵϴϭͿKƐƚĞŽĂƌƚŚƌŝƟƐ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ Ϯϱϳ
…
ϭ͘ϱŚƌƐ͘
ϲ͗ϯϬÖÃʹ
ϵ͗ϯϬÖÃ
/ŶĚƵƐƚƌLJͲ^ƵƉƉŽƌƚĞĚ^LJŵƉŽƐŝĂ
^ĞĞƉƌŽŐƌĂŵŬƉĂŐĞϮϯϵŽƌŶŶƵĂůDĞĞƟŶŐƉƉ
ĨŽƌƚŚĞůŝƐƚŽĨƐLJŵƉŽƐŝĂ͘
ͶĚĞŶŽƚĞƐtĞƐƟŶtĂƚĞƌĨƌŽŶƚƌŽŽŵůŽĐĂƟŽŶ
session
15
tracker
MONDAY, NOVEMBER 17, 2014
Meeting At-A-Glance
MONDAY, NOVEMBER 17, 2014
Location
CME/Hours
Time
Title
ϳ͗ϬϬƒÃʹ
ϲ͗ϬϬÖÃ
ZͬZ,WZĞŐŝƐƚƌĂƟŽŶ
džŚŝďŝƚ
͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘ >ĞǀĞů;ĂƐƚ
ZĞŐŝƐƚƌĂƟŽŶͿ
ϳ͗ϯϬƒÃʹ
ϴ͗ϯϬƒÃ
ACR Sessions
ĚƵĐĂƚŽƌ͗ƵůƟǀĂƟŶŐƚŚĞŽŵƉĞƚĞŶƚDĞĚŝĐĂůĚƵĐĂƚŽƌ͗
PM
Ed ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭϬϮ
'ƌŽǁŝŶŐŽŶĐĞƌŶ
DĞŶŝƐĐƵƐŝŽůŽŐLJŝŶKƐƚĞŽĂƌƚŚƌŝƟƐ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭϬϰ
ZŚĞƵŵĂƚŽůŽŐLJZĞƐĞĂƌĐŚ&ŽƵŶĚĂƟŽŶWĂƵů<ůĞŵƉĞƌĞƌ͕D
DĞŵŽƌŝĂů>ĞĐƚƵƌĞƐŚŝƉ͗'ĞŶĞͲŶǀŝƌŽŶŵĞŶƚ/ŶƚĞƌĂĐƟŽŶƐĂƐĂ
ĂƐŝƐĨŽƌhŶƌĂǀĞůůŝŶŐĚĂƉƟǀĞ/ŵŵƵŶŝƚLJĂŶĚWƌĞƉĂƌŝŶŐĨŽƌ
dŽůĞƌŝnjŝŶŐdŚĞƌĂƉŝĞƐŝŶZŚĞƵŵĂƚŽŝĚƌƚŚƌŝƟƐ
͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ Ballroom East
…
ϭ͘ϬŚƌ͘
ϳ͗ϯϬƒÃʹ
ϴ͗ϯϬƒÃ
ARHP Sessions
^ƚĂƚƐŽŽƚĂŵƉ͗dŚĞīĞĐƚ^ŝnjĞ͗tŚĂƚ/Ɛ/ƚĂŶĚ,ŽǁĂŶzŽƵ
hƐĞ/ƚ͍ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭϱϭ
hƉĚĂƚĞŽŶ&ŝŶĚŝŶŐƐĨƌŽŵ>ĂƌŐĞZĞŐŝƐƚƌŝĞƐ͗ŵƉŚĂƐŝƐŽŶ
,ĞĂůƚŚŝƐƉĂƌŝƟĞƐŝŶZŚĞƵŵĂƚŽŝĚƌƚŚƌŝƟƐ
͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ Ϯϱϱ
tŚĂƚƌĞŝŽƐŝŵŝůĂƌƐ͍ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭϱϯ
…
ϭ͘ϬŚƌ͘
ϳ͗ϰϱƒÃʹ
ϵ͗ϭϱƒÃ
ACR Meet the Professor Sessions
ŶŬLJůŽƐŝŶŐ^ƉŽŶĚLJůŝƟƐ͗ϮϬϭϰhƉĚĂƚĞ;ϬϯϭͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
…
ϭ͘ϱŚƌƐ͘
WĂŝŶĞ
;>ŽďďLJͿ
ĂƐŝĐ/ŵŵƵŶŽůŽŐLJĨŽƌůŝŶŝĐĂůZŚĞƵŵĂƚŽůŽŐŝƐƚƐ;ϬϯϮͿ͘ ͘ ͘ ͘ ͘ ͘ ͘
KƟƐ
;>ŽďďLJͿ
ŽŶƚƌŽǀĞƌƐŝĞƐŝŶ^ũƂŐƌĞŶ͛Ɛ^LJŶĚƌŽŵĞ;ϬϯϯͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
,ĂŶĐŽĐŬ
;>ŽďďLJͿ
ĞƌŵĂƚŽůŽŐŝĐĂůDĂŶŝĨĞƐƚĂƟŽŶƐŽĨZŚĞƵŵĂƟĐ
ŝƐĞĂƐĞƐ;ϬϯϰͿ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
ZĞǀĞƌĞ
;>ŽďďLJͿ
KƐƚĞŽĂƌƚŚƌŝƟƐ͗hƉĚĂƚĞϮϬϭϰ;ϬϯϱͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
^ƚŽŶĞ
;>ŽďďLJͿ
WƌĞŐŶĂŶĐLJĂŶĚZŚĞƵŵĂƟĐŝƐĞĂƐĞƐ;ϬϯϲͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
Webster
;>ŽďďLJͿ
ZĞĂĐƟǀĞƌƚŚƌŝƟƐ͗ŶhƉĚĂƚĞ;ϬϯϳͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
Adams
;DĞnjnjĂŶŝŶĞͿ
ZŚĞƵŵĂƚŽŝĚƌƚŚƌŝƟƐ͗ŚĂůůĞŶŐŝŶŐĂƐĞƐ;ϬϯϴͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
ůĐŽƩ
;DĞnjnjĂŶŝŶĞͿ
^LJƐƚĞŵŝĐ>ƵƉƵƐƌLJƚŚĞŵĂƚŽƐƵƐ͗ŝĸĐƵůƚƚŽdƌĞĂƚ^LJƐƚĞŵŝĐ
>ƵƉƵƐƌLJƚŚĞŵĂƚŽƐƵƐ;ϬϯϵͿ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
ŽƵŐůĂƐ
;DĞnjnjĂŶŝŶĞͿ
sĂƐĐƵůŝƟƐ͗hƉĚĂƚĞ;ϬϰϬͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
&ĂŶĞƵŝů
;DĞnjnjĂŶŝŶĞͿ
ͶĚĞŶŽƚĞƐtĞƐƟŶtĂƚĞƌĨƌŽŶƚƌŽŽŵůŽĐĂƟŽŶ
of Participation
16 2014 ACR /A R H P A n n u a l M e e t i n g
Meeting At-A-Glance
MONDAY, NOVEMBER 17, 2014
Location
CME/Hours
Time
Title
ϳ͗ϰϱƒÃʹ
ϵ͗ϰϱƒÃ
ZͬZ,WtŽƌŬƐŚŽƉƐ
ĚǀĂŶĐĞĚDƵƐĐƵůŽƐŬĞůĞƚĂůhůƚƌĂƐŽƵŶĚ;ϮϭϰͿ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭϱϵ
ŽŵƉůĞŵĞŶƚĂƌLJĂŶĚůƚĞƌŶĂƟǀĞdŚĞƌĂƉŝĞƐŝŶZŚĞƵŵĂƟĐ
ŝƐĞĂƐĞ;ϮϭϱͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭϲϭ
KƐƚĞŽƉŽƌŽƐŝƐ͗/ŶƚĞƌƉƌĞƟŶŐƵĂůŶĞƌŐLJyͲZĂLJďƐŽƌƉƟŽŵĞƚƌLJ
ĂŶĚůŝŶŝĐĂůZŝƐŬ&ĂĐƚŽƌƐ͗dŚĞEĞǁ&ƌĂĐƚƵƌĞZŝƐŬƐƐĞƐƐŵĞŶƚ
ůŐŽƌŝƚŚŵ;ϮϭϲͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭϱϰ
dŚĞZŚĞƵŵĂƚŽůŽŐŝĐDƵƐĐƵůŽƐŬĞůĞƚĂů^ĐƌĞĞŶŝŶŐdžĂŵ͕
ǁŝƚŚŵƉŚĂƐŝƐŽŶKďũĞĐƟǀĞŝƐĞĂƐĞͲ^ƉĞĐŝĮĐ
DĞĂƐƵƌĞŵĞŶƚƐ;ϮϭϳͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭϱϮ
ϴ͗ϯϬƒÃʹ
ϭϬ͗ϬϬƒÃ
ACR Sessions
…
ϭ͘ϱŚƌƐ͘
Z͗DĂŝŶƚĞŶĂŶĐĞŽĨĞƌƟĮĐĂƟŽŶ^ĞƐƐŝŽŶdǁŽ
ŽĨdŚƌĞĞʹ^ĞƌŽŶĞŐĂƟǀĞ^ƉŽŶĚůLJŽĂƌƚŚƌŽƉĂƚŚŝĞƐĂŶĚ
/ŶĨĞĐƟŽƵƐŝƐĞĂƐĞƐ
͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϱϮ
,ŽƚdŽƉŝĐƐŝŶZŚĞƵŵĂƚŽŝĚƌƚŚƌŝƟƐ͗ŽŵƉĂƌĂƟǀĞ
īĞĐƟǀĞŶĞƐƐĂŶĚ,ĂƌŵƐŽĨŝŽůŽŐŝĐƐ͕ĂŶĚDĂŶĂŐĞŵĞŶƚŽĨ
ŝƐĞĂƐĞͲDŽĚŝĨLJŝŶŐŶƟƌŚĞƵŵĂƟĐƌƵŐƐ;DZƐͿ
FIT ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ džŚŝďŝƚ,Ăůů
ĂŶĚŝŽůŽŐŝĐƐŝŶƚŚĞWĞƌŝŽƉĞƌĂƟǀĞWĞƌŝŽĚ
:ƵǀĞŶŝůĞĞƌŵĂƚŽŵLJŽƐŝƟƐ͗ůŝŶŝĐĂů͕WĂƚŚŽŐĞŶŝĐĂŶĚ
Pd
PS ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭϬϳ
dŚĞƌĂƉĞƵƟĐ^ƚĂƚĞŽĨƚŚĞƌƚ
WƌĂĐƟĐĂůhƐĞŽĨZĞŐŝƐƚƌŝĞƐ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϮϬϰ
WƌĂĐƟĐĞ/ƐƐƵĞƐ͗WƌĂĐƟĐĞ^ƵĐĐĞƐƐŝŶĂŶŶǀŝƌŽŶŵĞŶƚŽĨ
͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭϬϵ
dƌĂŶƐŝƟŽŶ
^ƚƌĂƚĞŐŝĞƐĨŽƌĐĂĚĞŵŝĐ^ƵĐĐĞƐƐ͗dŚĞZŽĂĚŵĂƉ&ƌŽŵDĞŶƚĞĞ
PM
Ed ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭϱϲ
ƚŽDĞŶƚŽƌ
^LJƐƚĞŵƐŝŽůŽŐLJŽĨ>ƵƉƵƐEĞƉŚƌŝƟƐ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ Ϯϱϯ
dŚĞZ'ŽƵƚDĂŶĂŐĞŵĞŶƚ'ƵŝĚĞůŝŶĞƐ͗,ĂǀĞdŚĞLJ'ŽƩĞŶhƐ
PS ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ Ballroom
PM
ƚŽtŚĞƌĞtĞtĂŶƚƚŽĞ͍
West
of Participation
…
Ϯ͘ϬŚƌƐ͘
ͶĚĞŶŽƚĞƐtĞƐƟŶtĂƚĞƌĨƌŽŶƚƌŽŽŵůŽĐĂƟŽŶ
session
17
tracker
MONDAY, NOVEMBER 17, 2014
Meeting At-A-Glance
Location
Time
Title
ϴ͗ϯϬƒÃʹ
ϰ͗ϬϬÖÃ
ZͬZ,WWŽƐƚĞƌ^ĞƐƐŝŽŶ͕dŚŝĞǀĞƐ͛DĂƌŬĞƚWŽƐƚĞƌƐ
and Poster Tours
ďƐƚƌĂĐƚƐ;ηϵϴϮͲϭϳϵϯͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ WŽƐƚĞƌ,Ăůů
WŽƐƚĞƌ,ĂůůDŽƌŶŝŶŐ^ŶĂĐŬƌĞĂŬ;ϴ͗ϯϬʹϭϬ͗ϬϬƒÃͿ
CME/Hours
of Participation
…
Ϯ͘ϬŚƌƐ͘
;džŚŝďŝƚ,ĂůůͿ
Poster Presenters Available
ϵ͗ϬϬʹϭϭ͗ϬϬƒÃ
Guided Poster Tours
ϵ͗ϬϬʹϵ͗ϰϱƒÃ
ϯϭϯʹƉŝĚĞŵŝŽůŽŐLJĂŶĚ,ĞĂůƚŚ^ĞƌǀŝĐĞƐZĞƐĞĂƌĐŚWŽƐƚĞƌ
Tour
ϯϭϰʹ&ŝďƌŽŵLJĂůŐŝĂ͕^ŽŌdŝƐƐƵĞŝƐŽƌĚĞƌƐ͕ZĞŐŝŽŶĂůĂŶĚ
^ƉĞĐŝĮĐůŝŶŝĐĂůWĂŝŶ^LJŶĚƌŽŵĞƐWŽƐƚĞƌdŽƵƌ
ϯϭϱʹ/ŵĂŐŝŶŐŽĨZŚĞƵŵĂƟĐŝƐĞĂƐĞƐWŽƐƚĞƌdŽƵƌ
ϯϭϲʹWĞĚŝĂƚƌŝĐZŚĞƵŵĂƚŽůŽŐLJ͗ůŝŶŝĐĂůƐƉĞĐƚƐWŽƐƚĞƌdŽƵƌ
ϯϭϳʹZŚĞƵŵĂƚŽŝĚƌƚŚƌŝƟƐ͗ůŝŶŝĐĂůƐƉĞĐƚƐWŽƐƚĞƌdŽƵƌ
ϯϭϴʹ^LJƐƚĞŵŝĐ^ĐůĞƌŽƐŝƐ͕&ŝďƌŽƐŝŶŐ^LJŶĚƌŽŵĞƐĂŶĚZĂLJŶĂƵĚ͛Ɛʹ
WĂƚŚŽŐĞŶĞƐŝƐ͕ŶŝŵĂůDŽĚĞůƐĂŶĚ'ĞŶĞƟĐƐWŽƐƚĞƌdŽƵƌ
ϭϬ͗ϭϱʹϭϭ͗ϬϬƒÃ
ϯϭϵʹWĞĚŝĂƚƌŝĐZŚĞƵŵĂƚŽůŽŐLJ͗ůŝŶŝĐĂůƐƉĞĐƚƐWŽƐƚĞƌdŽƵƌ
ϯϮϬʹZŚĞƵŵĂƚŽŝĚƌƚŚƌŝƟƐdƌĞĂƚŵĞŶƚʹ^ŵĂůůDŽůĞĐƵůĞƐ͕
ŝŽůŽŐŝĐƐĂŶĚ'ĞŶĞdŚĞƌĂƉLJWŽƐƚĞƌdŽƵƌ
ϯϮϭʹZŚĞƵŵĂƚŽŝĚƌƚŚƌŝƟƐ͗ůŝŶŝĐĂůƐƉĞĐƚƐWŽƐƚĞƌdŽƵƌ
ϯϮϮʹ^ƉŽŶĚLJůŽĂƌƚŚƌŽƉĂƚŚŝĞƐĂŶĚWƐŽƌŝĂƟĐƌƚŚƌŝƟƐ͗ůŝŶŝĐĂů
ƐƉĞĐƚƐĂŶĚdƌĞĂƚŵĞŶƚWŽƐƚĞƌdŽƵƌ
ϯϮϯʹ^LJƐƚĞŵŝĐ>ƵƉƵƐƌLJƚŚĞŵĂƚŽƐƵƐ͗ůŝŶŝĐĂůƐƉĞĐƚƐWŽƐƚĞƌ
Tour
ϯϮϰʹsĂƐĐƵůŝƟƐWŽƐƚĞƌdŽƵƌ
ϵ͗ϬϬƒÃʹ
ϭϬ͗ϬϬƒÃ
ACR Sessions
…
ϭ͘ϬŚƌ͘
&ƵŶĐƟŽŶĂů'ĞŶŽŵŝĐƐŽĨZŚĞƵŵĂƚŽŝĚƌƚŚƌŝƟƐ͗&ƌŽŵ'ĞŶĞƐƚŽ
&ƵŶĐƟŽŶƚŽdŚĞƌĂƉLJ ͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘ ϭϬϰ
>ĞŐŝƐůĂƟǀĞhƉĚĂƚĞ͗ŚĂƚǁŝƚŚŽŶŐƌĞƐƐ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭϬϮ
WƌŽƐƚŚĞƟĐĞǀŝĐĞ/ŶĨĞĐƟŽŶƐ͕Žƌ/ŶĨĞĐƟŽŶĂƐĂdŚƌĞĂƚƚŽƚŚĞ
PS ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ Ballroom East
ŝŽŶŝĐDĂŶ
^ŽĐŝĂůDĞĚŝĂŽŽƚĂŵƉ͗ůŽŐŐŝŶŐĨŽƌĞŐŝŶŶĞƌƐ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭϱϯ
ϵ͗ϬϬƒÃʹ
ϭϬ͗ϬϬƒÃ
ARHP Session
Z,WŝƐƟŶŐƵŝƐŚĞĚ>ĞĐƚƵƌĞƌ͗DĂŝŶƚĂŝŶŝŶŐ,ĞĂůƚŚĂŶĚ
tĞůůͲĞŝŶŐĞƐƉŝƚĞ>ŝǀŝŶŐǁŝƚŚĂZŚĞƵŵĂƟĐŝƐĞĂƐĞ ͘ ͘ ͘ ͘ ͘ Ϯϱϰ
ϭϬ͗ϬϬƒÃʹ Exhibits
ϱ͗ϬϬÖÃ
džŚŝďŝƚ,ĂůůDŽƌŶŝŶŐ^ŶĂĐŬƌĞĂŬ;ϭϬ͗ϬϬʹϭϭ͗ϬϬƒÃͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ džŚŝďŝƚ,Ăůů
džŚŝďŝƚ,ĂůůŌĞƌŶŽŽŶ^ŶĂĐŬƌĞĂŬ;Ϯ͗ϬϬʹϯ͗ϬϬÖÃͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ džŚŝďŝƚ,Ăůů
ͶĚĞŶŽƚĞƐtĞƐƟŶtĂƚĞƌĨƌŽŶƚƌŽŽŵůŽĐĂƟŽŶ
…
ϭ͘ϬŚƌ͘
18 2014 ACR /A R H P A n n u a l M e e t i n g
Meeting At-A-Glance
Time
MONDAY, NOVEMBER 17, 2014
Location
Title
CME/Hours
of Participation
ϭϬ͗ϯϬƒÃʹ Exhibits
ϭϭ͗ϭϱƒÃ
/ŶŶŽǀĂƟŽŶdŚĞĂƚĞƌ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ džŚŝďŝƚ,Ăůů
;ŽŽƚŚηϭϯϵͿ
^ĞĞƉĂŐĞϰϰĨŽƌƚŚĞ/ŶŶŽǀĂƟŽŶdŚĞĂƚĞƌ>ŝƐƟŶŐ͘
ϭϬ͗ϯϬƒÃʹ ZtŽƌŬƐŚŽƉƐ
ϭϮ͗ϯϬÖÃ
,ŝƐƚŽƉĂƚŚŽůŽŐLJŽĨsĂƐĐƵůŝƟƐ;ϮϭϴͿ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
<ŶĞĞƌĂĐĞƐ͕&ŽŽƚKƌƚŚŽƐĞƐĂŶĚ^ŚŽĞ'ĞĂƌĨŽƌDĂŶĂŐŝŶŐ
<ŶĞĞKƐƚĞŽĂƌƚŚƌŝƟƐ;ϮϭϵͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
DƵƐĐƵůŽƐŬĞůĞƚĂůhůƚƌĂƐŽƵŶĚ;ϮϮϬͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
ZĞŶĂů,ŝƐƚŽƉĂƚŚŽůŽŐLJŝŶ^LJƐƚĞŵŝĐ>ƵƉƵƐƌLJƚŚĞŵĂƚŽƐƵƐĂŶĚ
sĂƐĐƵůŝƟƐ;ϮϮϭͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
ϭϱϰ
…
Ϯ͘ϬŚƌƐ͘
ϭϱϮ
ϭϱϵ
ϭϲϭ
ϭϭ͗ϬϬƒÃʹ ACR Sessions
EŽŽŶ
Z/ŵŵƵŶŽůŽŐLJhƉĚĂƚĞ͗/ŶŶĂƚĞ>LJŵƉŚŽŝĚĞůůƐ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϱϮ
Z<ŶŽǁůĞĚŐĞŽǁů͗&ŝŶĂůZŽƵŶĚ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ Ballroom
West
…
ϭ͘ϬŚƌ͘
ϭϭ͗ϬϬƒÃʹ ARHP Sessions
EŽŽŶ
ǀŝĚĞŶĐĞŽĨƚŚĞĞŶĞĮƚƐĂŶĚZŝƐŬƐŽĨĂŶŶĂďŝƐĂŶĚ
ĂŶŶĂďŝŶŽŝĚƐĨŽƌdƌĞĂƟŶŐŚƌŽŶŝĐWĂŝŶ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ Ϯϱϵ
/ŵŵƵŶŽůŽŐLJŽŽƚĂŵƉ//͗dŚĞĂƐŝĐƐŽĨƵƚŽŝŵŵƵŶŝƚLJĂŶĚ
/ŵŵƵŶŽĚĞĮĐŝĞŶĐLJ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ Ϯϱϳ
^ƚĂƚƐŽŽƚĂŵƉ͗^ƚĂƟƐƟĐĂůŶĂůLJƐŝƐŽĨKƌĚŝŶĂůĂƚĂ ͘ ͘ ͘ ͘ ͘ Ϯϱϰ
…
ϭ͘ϬŚƌ͘
ϭϭ͗ϬϬƒÃʹ ZWůĞŶĂƌLJ^ĞƐƐŝŽŶ//͗ŝƐĐŽǀĞƌLJϮϬϭϰ
…
ϭϮ͗ϯϬÖÃ
ďƐƚƌĂĐƚƐ;ηϭϳϵϰͲϭϳϵϵͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ džŚŝďŝƚ,Ăůů ϭ͘ϱŚƌƐ͘
ϭϭ͗ϯϬƒÃʹ Exhibits
ϭϮ͗ϭϱÖÃ
/ŶŶŽǀĂƟŽŶdŚĞĂƚĞƌ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ džŚŝďŝƚ,Ăůů
;ŽŽƚŚηϭϰϬϭͿ
^ĞĞƉĂŐĞϰϰĨŽƌƚŚĞ/ŶŶŽǀĂƟŽŶdŚĞĂƚĞƌ>ŝƐƟŶŐ͘
EŽŽŶʹ
Ϯ͗ϬϬÖÃ
EĞƚǁŽƌŬŝŶŐǀĞŶƚ
Z,WEĞƚǁŽƌŬŝŶŐĂƚEŽŽŶ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
Commonwealth Ballroom
ϭϮ͗ϯϬÖÃʹ Exhibits
ϭ͗ϭϱÖÃ
/ŶŶŽǀĂƟŽŶdŚĞĂƚĞƌ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ džŚŝďŝƚ,Ăůů
;ŽŽƚŚηϭϯϵͿ
^ĞĞƉĂŐĞϰϰĨŽƌƚŚĞ/ŶŶŽǀĂƟŽŶdŚĞĂƚĞƌ>ŝƐƟŶŐ͘
ͶĚĞŶŽƚĞƐtĞƐƟŶtĂƚĞƌĨƌŽŶƚƌŽŽŵůŽĐĂƟŽŶ
session
19
tracker
MONDAY, NOVEMBER 17, 2014
Time
Meeting At-A-Glance
Location
Title
ϭϮ͗ϰϱÖÃʹ ACR Meet the Professor Sessions
Ϯ͗ϭϱÖÃ
ĚƵůƚ/ŶŇĂŵŵĂƚŽƌLJDLJŽƉĂƚŚLJ;ϬϰϭͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
WĞĚŝĂƚƌŝĐZŚĞƵŵĂƚŽůŽŐLJĨŽƌĚƵůƚZŚĞƵŵĂƚŽůŽŐŝƐƚƐ;ϬϰϮͿ
Pd
PS
͘ ͘ ͘
WƐŽƌŝĂƟĐƌƚŚƌŝƟƐ;ϬϰϯͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
ZŚĞƵŵĂƚŽŝĚƌƚŚƌŝƟƐ͗ŝŽůŽŐŝĐĂůŐĞŶƚƐ;ϬϰϰͿ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
ZŚĞƵŵĂƚŽŝĚƌƚŚƌŝƟƐ͗ŚĂůůĞŶŐŝŶŐĂƐĞƐ;ϬϰϱͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
^ĐůĞƌŽĚĞƌŵĂDŝŵŝĐƐ;ϬϰϲͿ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
^Ɵůů͛ƐŝƐĞĂƐĞĂŶĚƵƚŽŝŶŇĂŵŵĂƚŽƌLJ^LJŶĚƌŽŵĞƐ;ϬϰϳͿ͘ ͘ ͘ ͘ ͘ ͘
^LJƐƚĞŵŝĐ>ƵƉƵƐƌLJƚŚĞŵĂƚŽƐƵƐ͗ĞŶƚƌĂůEĞƌǀŽƵƐ
^LJƐƚĞŵ;ϬϰϴͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
WĂŝŶĞ
;>ŽďďLJͿ
KƟƐ
;>ŽďďLJͿ
,ĂŶĐŽĐŬ
;>ŽďďLJͿ
ZĞǀĞƌĞ
;>ŽďďLJͿ
^ƚŽŶĞ
;>ŽďďLJͿ
Webster
;>ŽďďLJͿ
Adams
;DĞnjnjĂŶŝŶĞͿ
CME/Hours
of Participation
…
ϭ͘ϱŚƌƐ͘
ůĐŽƩ
;DĞnjnjĂŶŝŶĞͿ
^LJƐƚĞŵŝĐ^ĐůĞƌŽƐŝƐ͗ŝƐĞĂƐĞ^ƚĂŐŝŶŐĂŶĚ^ƵďƐĞƫŶŐŝŶ
ůŝŶŝĐĂůWƌĂĐƟĐĞ ;ϬϰϵͿ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
ŽƵŐůĂƐ
;DĞnjnjĂŶŝŶĞͿ
&ĂŶĞƵŝů
sĂƐĐƵůŝƟƐDŝŵŝĐƐ;ϬϱϬͿ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
;DĞnjnjĂŶŝŶĞͿ
ϭ͗ϬϬÖÃʹ
Ϯ͗ϬϬÖÃ
ACR Sessions
PM ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
ůĂƐƐŝĮĐĂƟŽŶƌŝƚĞƌŝĂĨŽƌ'ŽƵƚ
͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
ůĂƐƐŝĮĐĂƟŽŶƌŝƚĞƌŝĂĨŽƌDLJŽƐŝƟƐ
EĞŽŶĂƚĂů>ƵƉƵƐ͗&ƌŽŵĞŶĐŚƚŽĞĚƐŝĚĞ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
ZŚĞƵŵĂƚŽůŽŐLJŽŶƚŚĞ^ƚƌĞĞƚ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
dĞůŽŵĞƌĞƐ͕dĞůŽŵĞƌĂƐĞĂŶĚƚŚĞŐŝŶŐ/ŵŵƵŶĞ^LJƐƚĞŵ
ϮϬϱ
ϭϬϳ
Ballroom East
Ballroom
West
͘ ͘ ͘ ϱϮ
ϭ͗ϭϱÖÃʹ
ϯ͗ϭϱÖÃ
ZtŽƌŬƐŚŽƉƐ
:ŽŝŶƚ/ŶũĞĐƟŽŶdĞĐŚŶŝƋƵĞƐ;ϮϮϮͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭϱϮ
DĂŐŶĞƟĐZĞƐŽŶĂŶĐĞ/ŵĂŐŝŶŐŝŶƚŚĞŝĂŐŶŽƐŝƐĂŶĚ
DĂŶĂŐĞŵĞŶƚŽĨ^ƉŽŶĚLJůŽĂƌƚŚƌŝƟƐ͗ůŝŶŝĐŝĂŶ͛Ɛ
'ƵŝĚĞ;ϮϮϯͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭϱϵ
^LJŶŽǀŝĂů&ůƵŝĚŶĂůLJƐŝƐĂŶĚƌLJƐƚĂů/ĚĞŶƟĮĐĂƟŽŶ;ϮϮϰͿ͘ ͘ ͘ ͘ ͘ ͘ ϭϲϭ
ϭ͗ϯϬÖÃʹ
Ϯ͗ϭϱÖÃ
Exhibits
/ŶŶŽǀĂƟŽŶdŚĞĂƚĞƌ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ džŚŝďŝƚ,Ăůů
;ŽŽƚŚηϭϰϬϭͿ
^ĞĞƉĂŐĞϰϰĨŽƌƚŚĞ/ŶŶŽǀĂƟŽŶdŚĞĂƚĞƌ>ŝƐƟŶŐ͘
Ϯ͗ϯϬÖÃʹ
ϯ͗ϭϱÖÃ
Exhibits
/ŶŶŽǀĂƟŽŶdŚĞĂƚĞƌ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ džŚŝďŝƚ,Ăůů
;ŽŽƚŚηϭϯϵͿ
^ĞĞƉĂŐĞϰϰĨŽƌƚŚĞ/ŶŶŽǀĂƟŽŶdŚĞĂƚĞƌ>ŝƐƟŶŐ͘
ͶĚĞŶŽƚĞƐtĞƐƟŶtĂƚĞƌĨƌŽŶƚƌŽŽŵůŽĐĂƟŽŶ
…
ϭ͘ϬŚƌ͘
…
Ϯ͘ϬŚƌƐ͘
20 2014 ACR /A R H P A n n u a l M e e t i n g
Meeting At-A-Glance
MONDAY, NOVEMBER 17, 2014
Location
CME/Hours
Time
Title
Ϯ͗ϯϬÖÃʹ
ϰ͗ϬϬÖÃ
ACR Sessions
ůŝŶŝĐĂůŚĂůůĞŶŐĞƐŝŶ^ũƂŐƌĞŶ͛Ɛ^LJŶĚƌŽŵĞ͗EĞƵƌŽůŽŐŝĐĂů
ŽŵƉůŝĐĂƟŽŶƐĂŶĚ>LJŵƉŚŽŵĂZŝƐŬ
͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϮϬϱ
&ŽƌĞĨƌŽŶƚƐŝŶ>ƵƉƵƐEĞƉŚƌŝƟƐ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ Ballroom East
/ŶƐŝŐŚƚŝŶƚŽ>ƵŶŐ&ŝďƌŽƐŝƐ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϱϮ
…
ϭ͘ϱŚƌƐ͘
Ϯ͗ϯϬÖÃʹ
ϰ͗ϬϬÖÃ
ACR Concurrent Abstract Sessions
;ηϭϴϬϬͲϭϴϬϱͿƉŝĚĞŵŝŽůŽŐLJĂŶĚWƵďůŝĐ,ĞĂůƚŚ//͗
KƐƚĞŽĂƌƚŚƌŝƟƐ͕^ĞĚĞŶƚĂƌLJĞŚĂǀŝŽƌĂŶĚDŽƌĞ
͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
;ηϭϴϬϲͲϭϴϭϭͿ,ĞĂůƚŚ^ĞƌǀŝĐĞƐZĞƐĞĂƌĐŚ͗/ŵƉƌŽǀŝŶŐ
ůŝŶŝĐĂůWƌĂĐƟĐĞ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
;ηϭϴϭϮͲϭϴϭϳͿ/ŶŶĂƚĞ/ŵŵƵŶŝƚLJĂŶĚZŚĞƵŵĂƟĐŝƐĞĂƐĞ
͘ ͘ ͘
;ηϭϴϭϴͲϭϴϮϯͿKƐƚĞŽĂƌƚŚƌŝƟƐʹůŝŶŝĐĂůƐƉĞĐƚƐ/͗/ŵĂŐŝŶŐ
ŝŶKƐƚĞŽĂƌƚŚƌŝƟƐ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
;ηϭϴϮϰͲϭϴϮϵͿWĞĚŝĂƚƌŝĐZŚĞƵŵĂƚŽůŽŐLJʹClinical
ĂŶĚdŚĞƌĂƉĞƵƟĐƐƉĞĐƚƐ͗WĞĚŝĂƚƌŝĐ^LJƐƚĞŵŝĐ>ƵƉƵƐ
Pd
PS ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
Erythematosus
;ηϭϴϯϬͲϭϴϯϱͿYƵĂůŝƚLJDĞĂƐƵƌĞƐĂŶĚYƵĂůŝƚLJŽĨĂƌĞ ͘ ͘ ͘ ͘ ͘
;ηϭϴϯϲͲϭϴϰϭͿZŚĞƵŵĂƚŽŝĚƌƚŚƌŝƟƐʹůŝŶŝĐĂůƐƉĞĐƚƐ///͗
DĂůŝŐŶĂŶĐŝĞƐ͕sĂĐĐŝŶĂƟŽŶƐ͕WƌĞŐŶĂŶĐLJĂŶĚ^ƵƌŐĞƌLJ
͘ ͘ ͘ ͘ ͘
;ηϭϴϰϮͲϭϴϰϳͿZŚĞƵŵĂƚŽŝĚƌƚŚƌŝƟƐʹ^ŵĂůůDŽůĞĐƵůĞƐ͕
ŝŽůŽŐŝĐƐĂŶĚ'ĞŶĞdŚĞƌĂƉLJ///͗/ŶŶŽǀĂƟǀĞdŚĞƌĂƉĞƵƟĐ
^ƚƌĂƚĞŐŝĞƐŝŶZŚĞƵŵĂƚŽŝĚƌƚŚƌŝƟƐ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
;ηϭϴϰϴͲϭϴϱϯͿ^ƉŽŶĚLJůŽĂƌƚŚƌŽƉĂƚŚŝĞƐĂŶĚWƐŽƌŝĂƟĐƌƚŚƌŝƟƐ
IIIʹůŝŶŝĐĂůƐƉĞĐƚƐŽĨWƐŽƌŝĂƟĐƌƚŚƌŝƟƐ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
;ηϭϴϱϰͲϭϴϱϵͿ^LJƐƚĞŵŝĐ>ƵƉƵƐƌLJƚŚĞŵĂƚŽƐƵƐʹClinical
ƐƉĞĐƚƐĂŶĚdƌĞĂƚŵĞŶƚ͗ŽŵƉůŝĐĂƟŽŶƐŽĨ^LJƐƚĞŵŝĐ>ƵƉƵƐ
Erythematosus ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
…
ϭ͘ϱŚƌƐ͘
;ηϭϴϲϬͲϭϴϲϱͿsĂƐĐƵůŝƟƐ//
of Participation
Ϯϱϯ
ϭϲϬ
ϭϱϲ
ϭϬϰ
ϭϱϳ
ϭϱϯ
ϮϭϬ
džŚŝďŝƚ,Ăůů
Ϯϱϴ
Ballroom
West
͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭϬϳ
Ϯ͗ϯϬÖÃʹ
ϰ͗ϬϬÖÃ
ACR/ARHP Combined Abstract Session
;ηϭϴϲϲͲϭϴϳϭͿZͬZ,WŽŵďŝŶĞĚďƐƚƌĂĐƚ^ĞƐƐŝŽŶ͗
Pd
PS ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭϬϮ
WĞĚŝĂƚƌŝĐZŚĞƵŵĂƚŽůŽŐLJ
…
ϭ͘ϱŚƌƐ͘
Ϯ͗ϯϬÖÃʹ
ϰ͗ϬϬÖÃ
ARHP Sessions
ůƚĞƌŶĂƟǀĞDĞĚŝĐŝŶĞ͗WƌĞƐĞŶƟŶŐƚŚĞǀŝĚĞŶĐĞĨŽƌZŚĞƵŵĂƟĐ
PM ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ Ϯϱϳ
ŽŶĚŝƟŽŶƐ
ŝŽŵĂƌŬĞƌƐŝŶZŚĞƵŵĂƟĐĂƌĞ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ Ϯϱϰ
^ƚĂƚƐŽŽƚĂŵƉ͗ĂůůƚŽŝŵƐĨŽƌZĞƐĞĂƌĐŚĞƌƐ͊Ŷ
/ŶƚĞƌĂĐƟǀĞ^ĞƐƐŝŽŶƚŽKďƚĂŝŶ&ĞĞĚďĂĐŬŽŶzŽƵƌ^ƉĞĐŝĮĐ
ŝŵƐ^ĞĐƟŽŶ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ Ϯϱϲ
dŚƌŝǀŝŶŐǁŝƚŚZŚĞƵŵĂƟĐŝƐĞĂƐĞ͗ƵůƟǀĂƟŶŐZĞƐŝůŝĞŶĐĞ ͘ ͘ ͘ ͘ Ϯϱϱ
…
ϭ͘ϱŚƌƐ͘
ͶĚĞŶŽƚĞƐtĞƐƟŶtĂƚĞƌĨƌŽŶƚƌŽŽŵůŽĐĂƟŽŶ
session
21
tracker
Meeting At-A-Glance
MONDAY, NOVEMBER 17, 2014
Location
Time
Title
ϯ͗ϯϬÖÃʹ
ϰ͗ϭϱÖÃ
Exhibits
/ŶŶŽǀĂƟŽŶdŚĞĂƚĞƌ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ džŚŝďŝƚ,Ăůů
;ŽŽƚŚηϭϰϬϭͿ
^ĞĞƉĂŐĞϰϰĨŽƌƚŚĞ/ŶŶŽǀĂƟŽŶdŚĞĂƚĞƌ>ŝƐƟŶŐ͘
ϰ͗ϬϬÖÃʹ
ϲ͗ϬϬÖÃ
ZͬZ,WtŽƌŬƐŚŽƉƐ
ĞƌŵĂƚŽƉĂƚŚŽůŽŐLJŽĨZŚĞƵŵĂƟĐŝƐĞĂƐĞƐ;ϮϮϱͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
:ŽŝŶƚ/ŶũĞĐƟŽŶƐ;<ŶĞĞ͕ŶŬůĞ͕^ŚŽƵůĚĞƌĂŶĚtƌŝƐƚͿ;ϮϮϲͿ͘ ͘ ͘ ͘ ͘
D,YͬZW/ϯĂŶĚZ,hDK͗YƵĂŶƟƚĂƟǀĞ͕^ƚĂŶĚĂƌĚ͕
^ĐŝĞŶƟĮĐ^ƵŵŵĂƌŝĞƐŽĨWĂƟĞŶƚ,ŝƐƚŽƌLJĂŶĚWŚLJƐŝĐĂůdžĂŵ͕
ƚŽǁĂƌĚĞƩĞƌůŝŶŝĐĂůĞĐŝƐŝŽŶƐĂŶĚKƵƚĐŽŵĞƐ;ϮϮϳͿ͘ ͘ ͘ ͘ ͘ ͘ ͘
DƵƐĐƵůŽƐŬĞůĞƚĂůhůƚƌĂƐŽŶŽŐƌĂƉŚLJ͗ĂƐŝĐ;ϮϮϴͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
ϭϲϭ
ϭϱϮ
ACR Session
ůŝŶŝĐŽƉĂƚŚŽůŽŐŝĐŽŶĨĞƌĞŶĐĞ
ϰ͗ϯϬÖÃʹ
ϲ͗ϬϬÖÃ
ACR Sessions
ĂƌĞĞƌKƉƉŽƌƚƵŶŝƟĞƐŝŶZŚĞƵŵĂƚŽůŽŐLJ͗DĂŬŝŶŐ
a Choice
͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϮϬϰ
ƵƌďƐŝĚĞŽŶƐƵůƚƐʹƐŬƚŚĞdžƉĞƌƚƐ
͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ Ballroom
West
&ŝďƌŽƟĐŽŵƉůŝĐĂƟŽŶƐŽĨ^ĐůĞƌŽĚĞƌŵĂ
͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭϲϬ
dŚĞZŽůĞŽĨŽŶĞŝŶƚŚĞWĂƚŚŽŐĞŶĞƐŝƐŽĨKƐƚĞŽĂƌƚŚƌŝƟƐ ͘ ͘ ͘ ϭϬϮ
dƌĞĂƟŶŐWĂŝŶŽĞƐŶ͛ƚ,ĂǀĞƚŽĞĂWĂŝŶ͗WƌĂĐƟĐĂůƉƉƌŽĂĐŚĞƐ
Pd
PS ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϮϬϱ
PM
ƚŽWĂŝŶDĂŶĂŐĞŵĞŶƚ
ͶĚĞŶŽƚĞƐtĞƐƟŶtĂƚĞƌĨƌŽŶƚƌŽŽŵůŽĐĂƟŽŶ
FIT
of Participation
…
Ϯ͘ϬŚƌƐ͘
ϭϱϰ
ϭϱϵ
ϰ͗ϯϬÖÃʹ
ϱ͗ϯϬÖÃ
PM
Ed
CME/Hours
͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ Ballroom East
…
ϭ͘ϬŚƌ͘
…
ϭ͘ϱŚƌƐ͘
22 2014 ACR /A R H P A n n u a l M e e t i n g
Meeting At-A-Glance
MONDAY, NOVEMBER 17, 2014
Location
CME/Hours
Time
Title
ϰ͗ϯϬÖÃʹ
ϲ͗ϬϬÖÃ
ACR Concurrent Abstract Sessions
…
ϭ͘ϱŚƌƐ͘
;ηϭϴϳϮͲϭϴϳϳͿƉŝĚĞŵŝŽůŽŐLJĂŶĚWƵďůŝĐ,ĞĂůƚŚ///͗'ŽƵƚĂŶĚ
^LJƐƚĞŵŝĐ>ƵƉƵƐƌLJƚŚĞŵĂƚŽƐƵƐ
͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ Ϯϱϯ
;ηϭϴϳϴͲϭϴϴϯͿ&ŝďƌŽŵLJĂůŐŝĂ͕^ŽŌdŝƐƐƵĞŝƐŽƌĚĞƌƐ͕ZĞŐŝŽŶĂů
ĂŶĚ^ƉĞĐŝĮĐůŝŶŝĐĂůWĂŝŶ^LJŶĚƌŽŵĞƐ//͗ůŝŶŝĐĂů
PM ϭϬϰ
WĞƌƐƉĞĐƟǀĞƐ
;ηϭϴϴϰͲϭϴϴϵͿ'ĞŶĞƟĐƐ͕'ĞŶŽŵŝĐƐĂŶĚWƌŽƚĞŽŵŝĐƐ/͗
ƉŝŐĞŶĞƟĐDĞĐŚĂŶŝƐŵƐŝŶƵƚŽŝŵŵƵŶŝƚLJ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭϱϲ
;ηϭϴϵϬͲϭϴϵϱͿ/ŵĂŐŝŶŐŽĨZŚĞƵŵĂƟĐŝƐĞĂƐĞƐ͗yͲƌĂLJ͕
DZ/ĂŶĚd ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϱϮ
;ηϭϴϵϲͲϭϵϬϭͿWĞĚŝĂƚƌŝĐZŚĞƵŵĂƚŽůŽŐLJʹWĂƚŚŽŐĞŶĞƐŝƐĂŶĚ
Pd
PS ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭϱϳ
'ĞŶĞƟĐƐ
;ηϭϵϬϮͲϭϵϬϳͿZŚĞƵŵĂƚŽŝĚƌƚŚƌŝƟƐʹůŝŶŝĐĂůƐƉĞĐƚƐ/s͗
WƌŽŵŝƐŝŶŐŝŽŵĂƌŬĞƌƐ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ Ϯϱϴ
;ηϭϵϬϴͲϭϵϭϯͿZŚĞƵŵĂƚŽŝĚƌƚŚƌŝƟƐʹ^ŵĂůůDŽůĞĐƵůĞƐ͕
ŝŽůŽŐŝĐƐĂŶĚ'ĞŶĞdŚĞƌĂƉLJ/s͗^ĂĨĞƚLJŽĨŝŽůŽŐŝĐƐĂŶĚ^ŵĂůů
DŽůĞĐƵůĞƐŝŶZŚĞƵŵĂƚŽŝĚƌƚŚƌŝƟƐʹĂƌĚŝŽǀĂƐĐƵůĂƌĂŶĚ
KƚŚĞƌ^LJƐƚĞŵƐ
͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ džŚŝďŝƚ,Ăůů
;ηϭϵϭϰͲϭϵϭϵͿ^ƉŽŶĚLJůŽĂƌƚŚƌŽƉĂƚŚŝĞƐĂŶĚWƐŽƌŝĂƟĐƌƚŚƌŝƟƐʹ
WĂƚŚŽŐĞŶĞƐŝƐ͕ƟŽůŽŐLJ͗&ƌŽŵ'ĞŶĞƐƚŽLJƚŽŬŝŶĞƐ
͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭϱϯ
;ηϭϵϮϬͲϭϵϮϱͿ^LJƐƚĞŵŝĐ>ƵƉƵƐƌLJƚŚĞŵĂƚŽƐƵƐʹClinical
ƐƉĞĐƚƐĂŶĚdƌĞĂƚŵĞŶƚ͗ŝŽŵĂƌŬĞƌƐŝŶ^LJƐƚĞŵŝĐ>ƵƉƵƐ
Erythematosus ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϮϭϬ
;ηϭϵϮϲͲϭϵϯϭͿ^LJƐƚĞŵŝĐ^ĐůĞƌŽƐŝƐ͕&ŝďƌŽƐŝŶŐ^LJŶĚƌŽŵĞƐ
ĂŶĚZĂLJŶĂƵĚ͛ƐʹůŝŶŝĐĂůƐƉĞĐƚƐĂŶĚdŚĞƌĂƉĞƵƟĐƐ//͗
ƉƉƌŽĂĐŚĞƐƚŽĂƌĚŝĂĐĂŶĚsĂƐĐƵůĂƌDĂŶŝĨĞƐƚĂƟŽŶƐŝŶ
^LJƐƚĞŵŝĐ^ĐůĞƌŽƐŝƐ
͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭϬϳ
of Participation
ͶĚĞŶŽƚĞƐtĞƐƟŶtĂƚĞƌĨƌŽŶƚƌŽŽŵůŽĐĂƟŽŶ
session
23
tracker
MONDAY, NOVEMBER 17, 2014
Meeting At-A-Glance
Time
Title
ϰ͗ϯϬÖÃʹ
ϲ͗ϬϬÖÃ
ACR Meet the Professor Sessions
ŶƟƉŚŽƐƉŚŽůŝƉŝĚ^LJŶĚƌŽŵĞ;ϬϱϭͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
ĞŚĕĞƚ͛Ɛ^LJŶĚƌŽŵĞ;ϬϱϮͿ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
/ŵŵƵŶŽĚĞĮĐŝĞŶĐLJ^LJŶĚƌŽŵĞƐ;ϬϱϯͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
/ŶĨĞĐƟŽŶƐǁŝƚŚŝŽůŽŐŝĐƐ;ϬϱϰͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
DLJŽƉĂƚŚLJ͗/ƐƐƵĞƐŝŶŝĂŐŶŽƐŝƐĂŶĚdƌĞĂƚŵĞŶƚ;ϬϱϱͿ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
WƵůŵŽŶĂƌLJDĂŶŝĨĞƐƚĂƟŽŶƐŽĨZŚĞƵŵĂƟĐŝƐĞĂƐĞ;ϬϱϲͿ͘ ͘ ͘ ͘ ͘ ͘
ZĂLJŶĂƵĚ͛ƐĂŶĚŝŐŝƚĂů/ƐĐŚĞŵŝĂ;ϬϱϳͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
Location
WĂŝŶĞ
;>ŽďďLJͿ
KƟƐ
;>ŽďďLJͿ
,ĂŶĐŽĐŬ
;>ŽďďLJͿ
ZĞǀĞƌĞ
;>ŽďďLJͿ
^ƚŽŶĞ
;>ŽďďLJͿ
Webster
;>ŽďďLJͿ
Adams
;DĞnjnjĂŶŝŶĞͿ
CME/Hours
of Participation
…
ϭ͘ϱŚƌƐ͘
^ĂĨĞƚLJŽĨƌƵŐƐhƐĞĚƚŽdƌĞĂƚZŚĞƵŵĂƚŽŝĚ
ƌƚŚƌŝƟƐ;ϬϱϴͿ PS ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
ůĐŽƩ
;DĞnjnjĂŶŝŶĞͿ
^LJƐƚĞŵŝĐ>ƵƉƵƐƌLJƚŚĞŵĂƚŽƐƵƐ͗>ƵƉƵƐEĞƉŚƌŝƟƐ;ϬϱϵͿ ͘ ͘ ͘ ͘ ͘ ͘
ŽƵŐůĂƐ
;DĞnjnjĂŶŝŶĞͿ
sĂƐĐƵůŝƟƐ͗&ĂĐƚŽƌƐdŚĂƚ/ŶŇƵĞŶĐĞŝƐĞĂƐĞWĂƩĞƌŶƐ;ϬϲϬͿ͘ ͘ ͘ ͘ ͘
&ĂŶĞƵŝů
;DĞnjnjĂŶŝŶĞͿ
ϰ͗ϯϬÖÃʹ
ϲ͗ϬϬÖÃ
ϰ͗ϯϬÖÃʹ
ϲ͗ϬϬÖÃ
ARHP Sessions
ĞƐƚWƌĂĐƟĐĞƐŽĨdŽƚĂů<ŶĞĞƌƚŚƌŽƉůĂƐƚLJʹ&ƌŽŵ^ƵƌŐĞƌLJ
ƚŽZĞŚĂďŝůŝƚĂƟŽŶ
͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
&ƌŽŵ/ŶŇĂŵŵĂƟŽŶƚŽƚŚĞƌŽƐĐůĞƌŽƐŝƐ͗dŚĞĂƐĞŽĨ
/ŶŇĂŵŵĂƚŽƌLJZŚĞƵŵĂƟĐŝƐĞĂƐĞƐ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
ZŽůĞŽĨEƵƚƌŝƟŽŶŝŶZŚĞƵŵĂƟĐŝƐĞĂƐĞƐ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
dŚĞŵĞƌŐŝŶŐĞŵĂŶĚĨŽƌDĞĚŝĐŝŶĂůĂŶŶĂďŝƐďLJzŽƵŶŐ
Pd
PS ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
Adults and Beyond
…
ϭ͘ϱŚƌƐ͘
Ϯϱϰ
Ϯϱϲ
Ϯϱϳ
Ϯϱϱ
ARHP Concurrent Abstract Sessions
;ηϭϵϯϮͲϭϵϯϳͿ,ĞĂůƚŚŝƐƉĂƌŝƟĞƐͬ^ŽĐŝĂůĞƚĞƌŵŝŶĂŶƚƐ
PM
Ed ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭϬϵ
ŽĨ,ĞĂůƚŚ
ͶĚĞŶŽƚĞƐtĞƐƟŶtĂƚĞƌĨƌŽŶƚƌŽŽŵůŽĐĂƟŽŶ
…
ϭ͘ϱŚƌƐ͘
24 2014 ACR /A R H P A n n u a l M e e t i n g
Meeting At-A-Glance
MONDAY & TUESDAY, NOVEMBER 17 – 18, 2014
Location
Time
Title
ϲ͗ϯϬÖÃʹ
ϳ͗ϰϱÖÃ
^ƚƵĚLJ'ƌŽƵƉƐ
ZDƵƐĐƵůŽƐŬĞůĞƚĂůhůƚƌĂƐŽƵŶĚ^ƚƵĚLJ'ƌŽƵƉ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
ŶƟƉŚŽƐƉŚŽůŝƉŝĚ^LJŶĚƌŽŵĞdĂƐŬ&ŽƌĐĞ^ƚƵĚLJ'ƌŽƵƉ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
ĂƉŝůůĂƌŽƐĐŽƉLJŝŶZŚĞƵŵĂƟĐŝƐĞĂƐĞƐ^ƚƵĚLJ'ƌŽƵƉ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
ŚŝůĚŚŽŽĚsĂƐĐƵůŝƟƐ^ƚƵĚLJ'ƌŽƵƉ͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘
ůŝŶŝĐĂůŶĂƚŽŵLJ^ƚƵĚLJ'ƌŽƵƉ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
ƌLJƐƚĂů^ƚƵĚLJ'ƌŽƵƉ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
ĞŐŽƐŝƐĞĂƐĞ^ƚƵĚLJ'ƌŽƵƉ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
,LJƉĞƌŵŽďŝůŝƚLJ^ƚƵĚLJ'ƌŽƵƉ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
/ŶƚĞƐƟŶĂů>ƵŶŐŝĞƐĞĂƐĞ'ƌŽƵƉ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
DĂĐƌŽƉŚĂŐĞĐƟǀĂƟŽŶ^LJŶĚƌŽŵĞ;D^Ϳ^ƚƵĚLJ'ƌŽƵƉ͘ ͘ ͘ ͘ ͘ ͘
DLJŽƐŝƟƐ^ƚƵĚLJ'ƌŽƵƉ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
KƐƚĞŽĂƌƚŚƌŝƟƐ^ƚƵĚLJ'ƌŽƵƉ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
WĞĚŝĂƚƌŝĐZŚĞƵŵĂƚŽůŽŐŝƐƚƐ/ŶƚĞƌĞƐƚĞĚŝŶDĞĚŝĂůĚƵĐĂƟŽŶ
^ƚƵĚLJ'ƌŽƵƉ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
dŚĞ͞tŚLJĂŶĚ,Žǁ͟ŽĨŝƐĞĂƐĞƌŝƚĞƌŝĂ^ƚƵĚLJ'ƌŽƵƉ ͘ ͘ ͘ ͘ ͘ ͘ ͘
sĞƚĞƌĂŶƐīĂŝƌƐZŚĞƵŵĂƚŽůŽŐLJ^ƚƵĚLJ'ƌŽƵƉ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
CME/Hours
of Participation
ϭϬϵ
ϭϱϳ
Ϯϱϲ
Ϯϱϱ
Ϯϱϵ
ϭϬϮ
ϭϬϳ
ϭϬϰ
ϭϲϬ
ϭϱϲ
ϭϱϯ
Ϯϱϳ
ϭϱϭ
Ϯϱϰ
ϮϬϰ
TUESDAY, NOVEMBER 18, 2014
Location
Time
Title
ϳ͗ϬϬƒÃʹ
ϲ͗ϬϬÖÃ
ZͬZ,WZĞŐŝƐƚƌĂƟŽŶ
džŚŝďŝƚ
͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘ >ĞǀĞů;ĂƐƚ
ZĞŐŝƐƚƌĂƟŽŶͿ
ϳ͗ϯϬƒÃʹ
ϴ͗ϯϬƒÃ
ACR Sessions
'ůLJĐŽƐLJůĂƟŽŶĂŶĚ'ůLJĐĂŶŝŶĚŝŶŐWƌŽƚĞŝŶƐŝŶ
/ŵŵƵŶĞ&ƵŶĐƟŽŶ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϮϬϱ
,ĞƉĂƟƟƐŝŶϮϬϭϰ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ Ballroom
West
E ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭϱϭ
WĂƟĞŶƚĐĐĞƐƐƚŽŝŽůŽŐŝĐƐĐƌŽƐƐƚŚĞ'ůŽďĞ
ϳ͗ϯϬƒÃʹ
ϴ͗ϯϬƒÃ
ARHP Sessions
ůŝŶŝĐĂů&ĞĂƚƵƌĞƐŽĨĞŶƚƌĂůEĞƌǀŽƵƐ^LJƐƚĞŵ>ƵƉƵƐ
ĂŶĚŝĂŐŶŽƐŝƐŽĨŽŐŶŝƟǀĞĞĮĐŝƚƐĂŶĚWƐLJĐŚŝĂƚƌŝĐ
ŝƐŽƌĚĞƌƐ
͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ Ϯϱϰ
DƵƐĐůĞĂŶĚĚŝƉŽƐĞdŝƐƐƵĞŝŶZŚĞƵŵĂƟĐŝƐĞĂƐĞƐ͗
>ŽĐĂƟŽŶŝƐǀĞƌLJƚŚŝŶŐ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ Ϯϱϳ
CME/Hours
of Participation
…
ϭŚƌ͘
ͶĚĞŶŽƚĞƐtĞƐƟŶtĂƚĞƌĨƌŽŶƚƌŽŽŵůŽĐĂƟŽŶ
session
25
tracker
TUESDAY, NOVEMBER 18, 2014
Meeting At-A-Glance
Time
Title
ϳ͗ϰϱƒÃʹ
ϵ͗ϭϱƒÃ
ACR Meet the Professor Sessions
ŶƟƉŚŽƐƉŚŽůŝƉŝĚ^LJŶĚƌŽŵĞ;ϬϲϭͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
ŽŶƚƌŽǀĞƌƐŝĞƐŝŶ^ũƂŐƌĞŶ͛Ɛ^LJŶĚƌŽŵĞ;ϬϲϮͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
&ŽŽƚǁĞĂƌŝŶKƌƚŚŽĂƌƚŚƌŝƟƐ;ϬϲϯͿ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
KƐƚĞŽƉŽƌŽƐŝƐ͗EŽǀĞůdƌĞĂƚŵĞŶƚƐ;ϬϲϰͿ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
PS ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
WĞĚŝĂƚƌŝĐƐ͗WĞƌŝŽĚŝĐ&ĞǀĞƌƐŝŶŚŝůĚƌĞŶ;ϬϲϱͿ Pd
ZŚĞƵŵĂƚŽŝĚƌƚŚƌŝƟƐ͗KƵƚĐŽŵĞDĞĂƐƵƌĞƐŝŶůŝŶŝĐĂů
WƌĂĐƟĐĞ;ϬϲϲͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
^ĂĨĞƚLJŽĨƌƵŐƐhƐĞĚƚŽdƌĞĂƚZŚĞƵŵĂƚŽŝĚ
ƌƚŚƌŝƟƐ;ϬϲϳͿ PS ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
^LJƐƚĞŵŝĐ>ƵƉƵƐƌLJƚŚĞŵĂƚŽƐƵƐ͗ĞŶƚƌĂůEĞƌǀŽƵƐ
^LJƐƚĞŵ;ϬϲϴͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
^LJƐƚĞŵŝĐ^ĐůĞƌŽƐŝƐ͗ŝƐĞĂƐĞ^ƚĂŐŝŶŐĂŶĚ^ƵďƐĞƫŶŐŝŶ
ůŝŶŝĐĂůWƌĂĐƟĐĞ;ϬϲϵͿ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
sĂƐĐƵůŝƟƐ͗&ĂĐƚŽƌƐdŚĂƚ/ŶŇƵĞŶĐĞŝƐĞĂƐĞWĂƩĞƌŶƐ;ϬϳϬͿ͘ ͘ ͘ ͘ ͘
ϳ͗ϰϱƒÃʹ
ϵ͗ϰϱƒÃ
ϴ͗ϯϬƒÃʹ
ϭϬ͗ϬϬƒÃ
ZͬZ,WtŽƌŬƐŚŽƉƐ
ĚǀĂŶĐĞĚDƵƐĐƵůŽƐŬĞůĞƚĂůhůƚƌĂƐŽƵŶĚ͗/ŵĂŐĞKƉƟŵŝnjĂƟŽŶ
ĂŶĚWĂƚŚŽůŽŐLJZĞĐŽŐŶŝƟŽŶ;ϮϮϵͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
ĂƐŝĐ^ƚĂƟƐƟĐĂůŽŶĐĞƉƚƐĨŽƌƚŚĞDĞĚŝĐĂůZĞƐĞĂƌĐŚĞƌ;ϮϯϬͿ͘ ͘
:ŽŝŶƚ/ŶũĞĐƟŽŶƐ;<ŶĞĞ͕ŶŬůĞ͕^ŚŽƵůĚĞƌĂŶĚtƌŝƐƚͿ;ϮϯϭͿ͘ ͘ ͘ ͘ ͘
DĂŐŶĞƟĐZĞƐŽŶĂŶĐĞ/ŵĂŐŝŶŐŽĨWĞƌŝƉŚĞƌĂů:ŽŝŶƚƐŝŶ
ZŚĞƵŵĂƚŽůŽŐLJWƌĂĐƟĐĞ;ϮϯϮͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
ACR Sessions
ŝŽĞŶĞƌŐĞƟĐƐĂŶĚŶĞƌŐLJZĞŐƵůĂƟŽŶ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
Z͗DĂŝŶƚĞŶĂŶĐĞŽĨĞƌƟĮĐĂƟŽŶ^ĞƐƐŝŽŶdŚƌĞĞ
of Three
͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
ĚƵĐĂƚŽƌ͗ŝƌĞĐƚKďƐĞƌǀĂƟŽŶŽĨůŝŶŝĐĂů^ŬŝůůƐ͗ĚƵĐĂƟŽŶĂůůLJ
PS ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
PM
Ed
/ŶĚŝĐĂƚĞĚ͕dŚĞƌĂƉĞƵƟĐĂůůLJZĞƋƵŝƌĞĚ
Pd
PS ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
DĂĐƌŽƉŚĂŐĞƐ'ŽŶĞtŝůĚ
DLJŽƐŝƟƐDŝŵŝĐƐ͗ůŝŶŝĐĂůĂŶĚDŽůĞĐƵůĂƌŝĂŐŶŽƐŝƐ ͘͘͘͘͘͘͘
ZŚĞƵŵĂƚŽůŽŐLJZĞƐĞĂƌĐŚ&ŽƵŶĚĂƟŽŶ͗ŝƐĞĂƐĞdĂƌŐĞƚĞĚ
ZĞƐĞĂƌĐŚ͗^ƉĞĐŝĂů^ĞƐƐŝŽŶ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
ZŝƐŬĂŶĚZŝƐŬDĂŶĂŐĞŵĞŶƚŽĨĂƌĚŝŽǀĂƐĐƵůĂƌŝƐĞĂƐĞŝŶ
WĂƟĞŶƚƐǁŝƚŚZŚĞƵŵĂƚŽŝĚƌƚŚƌŝƟƐĂŶĚKƚŚĞƌ^LJƐƚĞŵŝĐ
ZŚĞƵŵĂƟĐŝƐĞĂƐĞƐ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
ͶĚĞŶŽƚĞƐtĞƐƟŶtĂƚĞƌĨƌŽŶƚƌŽŽŵůŽĐĂƟŽŶ
Location
WĂŝŶĞ
;>ŽďďLJͿ
KƟƐ
;>ŽďďLJͿ
,ĂŶĐŽĐŬ
;>ŽďďLJͿ
ZĞǀĞƌĞ
;>ŽďďLJͿ
^ƚŽŶĞ
;>ŽďďLJͿ
Webster
;>ŽďďLJͿ
Adams
;DĞnjnjĂŶŝŶĞͿ
ůĐŽƩ
;DĞnjnjĂŶŝŶĞͿ
ŽƵŐůĂƐ
;DĞnjnjĂŶŝŶĞͿ
&ĂŶĞƵŝů
;DĞnjnjĂŶŝŶĞͿ
CME/Hours
of Participation
…
ϭ͘ϱŚƌƐ͘
…
Ϯ͘ϬŚƌƐ͘
ϭϱϵ
ϭϲϭ
ϭϱϮ
ϭϱϰ
Ϯϱϯ
ϱϮ
ϭϬϮ
ϭϬϰ
Ballroom
East
ϭϱϯ
džŚŝďŝƚ,Ăůů
…
ϭ͘ϱŚƌƐ͘
26 2014 ACR /A R H P A n n u a l M e e t i n g
Meeting At-A-Glance
TUESDAY, NOVEMBER 18, 2014
Location
Time
Title
ϴ͗ϯϬƒÃʹ
ϰ͗ϬϬÖÃ
ZͬZ,WWŽƐƚĞƌ^ĞƐƐŝŽŶ͕>ĂƚĞͲƌĞĂŬŝŶŐĂŶĚdŚŝĞǀĞƐ͛
Market Posters and Poster Tours
ďƐƚƌĂĐƚƐ;ηϭϵϯϴͲϮϳϴϬͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ WŽƐƚĞƌ,Ăůů
CME/Hours
of Participation
…
Ϯ͘ϬŚƌƐ͘
;džŚŝďŝƚ,ĂůůͿ
WŽƐƚĞƌ,ĂůůDŽƌŶŝŶŐ^ŶĂĐŬƌĞĂŬ;ϴ͗ϯϬʹϭϬ͗ϬϬƒÃͿ
Poster Presenters Available
ϵ͗ϬϬʹϭϭ͗ϬϬƒÃ
Guided Poster Tours
ϵ͗ϬϬʹϵ͗ϰϱƒÃ
ϯϮϱʹKƐƚĞŽĂƌƚŚƌŝƟƐʹůŝŶŝĐĂůƐƉĞĐƚƐWŽƐƚĞƌdŽƵƌ
ϯϮϲʹYƵĂůŝƚLJDĞĂƐƵƌĞƐĂŶĚYƵĂůŝƚLJŽĨĂƌĞWŽƐƚĞƌdŽƵƌ
ϯϮϳʹZŚĞƵŵĂƚŽŝĚƌƚŚƌŝƟƐʹůŝŶŝĐĂůƐƉĞĐƚƐWŽƐƚĞƌdŽƵƌ
ϯϮϴʹZŚĞƵŵĂƚŽŝĚƌƚŚƌŝƟƐdƌĞĂƚŵĞŶƚʹ^ŵĂůůDŽůĞĐƵůĞƐ͕
ŝŽůŽŐŝĐƐĂŶĚ'ĞŶĞdŚĞƌĂƉLJWŽƐƚĞƌdŽƵƌ
ϯϮϵʹ^ƉŽŶĚLJůŽĂƌƚŚƌŽƉĂƚŚŝĞƐĂŶĚWƐŽƌŝĂƟĐƌƚŚƌŝƟƐ͗ůŝŶŝĐĂů
ƐƉĞĐƚƐĂŶĚdƌĞĂƚŵĞŶƚWŽƐƚĞƌdŽƵƌ
ϯϯϬʹ^LJƐƚĞŵŝĐ^ĐůĞƌŽƐŝƐ͕&ŝďƌŽƐŝŶŐ^LJŶĚƌŽŵĞƐĂŶĚZĂLJŶĂƵĚ͛Ɛ
ʹůŝŶŝĐĂůƐƉĞĐƚƐĂŶĚdŚĞƌĂƉĞƵƟĐƐWŽƐƚĞƌdŽƵƌ
ϭϬ͗ϭϱʹϭϭ͗ϬϬƒÃ
ϯϯϭʹƉŝĚĞŵŝŽůŽŐLJĂŶĚ,ĞĂůƚŚ^ĞƌǀŝĐĞƐZĞƐĞĂƌĐŚ
WŽƐƚĞƌdŽƵƌ
ϯϯϮʹ,ĞĂůƚŚ^ĞƌǀŝĐĞƐZĞƐĞĂƌĐŚWŽƐƚĞƌdŽƵƌ
ϯϯϯʹZŚĞƵŵĂƚŽŝĚƌƚŚƌŝƟƐ,ƵŵĂŶƟŽůŽŐLJĂŶĚ
WĂƚŚŽŐĞŶĞƐŝƐWŽƐƚĞƌdŽƵƌ
ϯϯϰʹZŚĞƵŵĂƚŽŝĚƌƚŚƌŝƟƐdƌĞĂƚŵĞŶƚʹ^ŵĂůůDŽůĞĐƵůĞƐ͕
ŝŽůŽŐŝĐƐĂŶĚ'ĞŶĞdŚĞƌĂƉLJWŽƐƚĞƌdŽƵƌ
ϯϯϱʹZŚĞƵŵĂƚŽůŽŐLJϯϲϬWŽƐƚĞƌdŽƵƌ
ϯϯϲʹ^LJƐƚĞŵŝĐ>ƵƉƵƐƌLJƚŚĞŵĂƚŽƐƵƐ͗ůŝŶŝĐĂůƐƉĞĐƚƐWŽƐƚĞƌ
WŽƐƚĞƌdŽƵƌ
ϵ͗ϬϬƒÃʹ
ϭϬ͗ϬϬƒÃ
ACR Sessions
PS ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭϬϳ
PM
ACR-EULARWDZ'ƵŝĚĞůŝŶĞƐ
DĞƚĂŝŶŇĂŵŵĂƟŽŶ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭϱϲ
ZŚĞƵŵĂƚŽůŽŐLJZĞƐĞĂƌĐŚ&ŽƵŶĚĂƟŽŶKƐĐĂƌ^͘'ůƵĐŬDĞŵŽƌŝĂů
>ĞĐƚƵƌĞƐŚŝƉ͗ŵĞƌŐŝŶŐdŚĞƌĂƉŝĞƐŝŶŽŶĞŝƐĞĂƐĞƐ͗ĞůůƵůĂƌ
Basis and Challenges ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϮϭϬ
…
ϭ͘ϬŚƌ͘
ϵ͗ϬϬƒÃʹ
ϭϬ͗ϬϬƒÃ
ARHP Sessions
DLJĐŽďĂĐƚĞƌŝƵŵ/ŶĨĞĐƟŽŶƐŝŶ/ŵŵƵŶŽĐŽŵƉƌŽŵŝƐĞĚ
WĂƟĞŶƚƐ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϮϬϰ
PM ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭϱϳ
RheumChat
^ƚĂƚƐŽŽƚĂŵƉ͗dŚĞWƌĞǀĂůĞŶĐĞZĂƟŽĂƐĂŶůƚĞƌŶĂƟǀĞ
ƚŽƚŚĞKĚĚƐZĂƟŽĨŽƌƌŽƐƐͲ^ĞĐƟŽŶĂů^ƚƵĚŝĞƐ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ Ϯϱϵ
…
ϭ͘ϬŚƌ͘
ͶĚĞŶŽƚĞƐtĞƐƟŶtĂƚĞƌĨƌŽŶƚƌŽŽŵůŽĐĂƟŽŶ
session
27
tracker
TUESDAY, NOVEMBER 18, 2014
Time
Title
Meeting At-A-Glance
Location
CME/Hours
of Participation
ϭϬ͗ϬϬƒÃʹ Exhibits
Ϯ͗ϯϬÖÃ
džŚŝďŝƚ,ĂůůDŽƌŶŝŶŐ^ŶĂĐŬƌĞĂŬ;ϭϬ͗ϬϬʹϭϭ͗ϬϬƒÃͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ džŚŝďŝƚ,Ăůů
ϭϬ͗ϯϬƒÃʹ Exhibits
ϭϭ͗ϭϱƒÃ
/ŶŶŽǀĂƟŽŶdŚĞĂƚĞƌ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ džŚŝďŝƚ,Ăůů
;ŽŽƚŚηϭϯϵͿ
^ĞĞƉĂŐĞϰϰĨŽƌƚŚĞ/ŶŶŽǀĂƟŽŶdŚĞĂƚĞƌ>ŝƐƟŶŐ͘
ϭϬ͗ϯϬƒÃʹ ZtŽƌŬƐŚŽƉƐ
ϭϮ͗ϯϬÖÃ
DƵƐĐƵůŽƐŬĞůĞƚĂůhůƚƌĂƐŽƵŶĚ;ϮϯϯͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭϱϵ
ZĞŶĂů,ŝƐƚŽƉĂƚŚŽůŽŐLJŝŶ^LJƐƚĞŵŝĐ>ƵƉƵƐƌLJƚŚĞŵĂƚŽƐƵƐ
ĂŶĚsĂƐĐƵůŝƟƐ;ϮϯϰͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭϲϭ
yͲZĂLJŚĂůůĞŶŐĞƐŝŶZŚĞƵŵĂƟĐŝƐĞĂƐĞƐ;ϮϯϱͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭϱϰ
…
Ϯ͘ϬŚƌƐ͘
ϭϭ͗ϬϬƒÃʹ ACR Sessions
EŽŽŶ
DĞƐĞŶĐŚLJŵĂů^ƚĞŵĞůůƐ͗ŝŽůŽŐLJĂŶĚhƐĞŝŶZŚĞƵŵĂƟĐ
ŝƐĞĂƐĞƐ
͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ Ϯϱϯ
WƌŽƚĞĐƟŶŐŽŶĞ,ĞĂůƚŚŝŶWĞĚŝĂƚƌŝĐZŚĞƵŵĂƟĐ
Pd
PS ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭϬϰ
ŝƐĞĂƐĞƐ
…
ϭ͘ϬŚƌ͘
ϭϭ͗ϬϬƒÃʹ ARHP Sessions
EŽŽŶ
/ŵŵƵŶŽůŽŐLJŽŽƚĂŵƉ///͗ƉƉůLJŝŶŐWƌŝŶĐŝƉůĞƐŽĨ
E ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ Ϯϱϳ
/ŵŵƵŶŽůŽŐLJƚŽdƌĞĂƚŵĞŶƚĞĐŝƐŝŽŶƐ
WĂƚŚǁĂLJƐƚŽZĞƐŝůŝĞŶĐĞ͗ŝŽƉƐLJĐŚŽƐŽĐŝĂůDĞĐŚĂŶŝƐŵƐĨŽƌ
PM ͘ ͘ ͘ ͘ Ϯϱϱ
ƚŚĞ'ĞŶĞƌĂƟŽŶŽĨWŽƐŝƟǀĞīĞĐƚŝŶŚƌŽŶŝĐWĂŝŶ
WƌŽǀŝĚŝŶŐǀŝĚĞŶĐĞĨŽƌDŝĚͲ>ĞǀĞůWƌŽǀŝĚĞƌƐŝŶZŚĞƵŵĂƚŽůŽŐLJ
WƌĂĐƟĐĞ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ Ϯϱϲ
…
ϭ͘ϬŚƌ͘
ϭϭ͗ϬϬƒÃʹ ZWůĞŶĂƌLJ^ĞƐƐŝŽŶ///͗ŝƐĐŽǀĞƌLJϮϬϭϰ
…
ϭϮ͗ϯϬÖÃ
ďƐƚƌĂĐƚƐ;ηϮϳϴϭͲϮϳϴϲͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ džŚŝďŝƚ,Ăůů ϭ͘ϱŚƌƐ͘
ϭϭ͗ϯϬƒÃʹ Exhibits
ϭϮ͗ϭϱÖÃ
/ŶŶŽǀĂƟŽŶdŚĞĂƚĞƌ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ džŚŝďŝƚ,Ăůů
;ŽŽƚŚηϭϰϬϭͿ
^ĞĞƉĂŐĞϰϰĨŽƌƚŚĞ/ŶŶŽǀĂƟŽŶdŚĞĂƚĞƌ>ŝƐƟŶŐ͘
ϭϮ͗ϭϱÖÃʹ Exhibits
ϭ͗ϬϬÖÃ
/ŶŶŽǀĂƟŽŶdŚĞĂƚĞƌ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ džŚŝďŝƚ,Ăůů
;ŽŽƚŚηϭϯϵͿ
^ĞĞƉĂŐĞϰϰĨŽƌƚŚĞ/ŶŶŽǀĂƟŽŶdŚĞĂƚĞƌ>ŝƐƟŶŐ͘
ͶĚĞŶŽƚĞƐtĞƐƟŶtĂƚĞƌĨƌŽŶƚƌŽŽŵůŽĐĂƟŽŶ
28 2014 ACR /A R H P A n n u a l M e e t i n g
Meeting At-A-Glance
Time
TUESDAY, NOVEMBER 18, 2014
Location
Title
ϭϮ͗ϰϱÖÃʹ ACR Meet the Professor Sessions
Ϯ͗ϭϱÖÃ
ŶƟƉŚŽƐƉŚŽůŝƉŝĚ^LJŶĚƌŽŵĞ;ϬϳϭͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
ŚĂůůĞŶŐŝŶŐĂƐĞƐŝŶKƐƚĞŽƉŽƌŽƐŝƐDĂŶĂŐĞŵĞŶƚ;ϬϳϮͿ͘ ͘ ͘ ͘ ͘ ͘
ƌLJƐƚĂů͗ŝĂŐŶŽƐŝƐĂŶĚDĂŶĂŐĞŵĞŶƚŽĨ'ŽƵƚ;ϬϳϯͿ
PM
͘ ͘ ͘ ͘ ͘ ͘
EŽŶͲƐƵƌŐŝĐĂůdƌĞĂƚŵĞŶƚƐĨŽƌKƐƚĞŽĂƌƚŚƌŝƟƐ;ϬϳϰͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
KƐƚĞŽĂƌƚŚƌŝƟƐ͗hƉĚĂƚĞϮϬϭϰ;ϬϳϱͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
WƐŽƌŝĂƟĐƌƚŚƌŝƟƐ;ϬϳϲͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
^ƉŽŶĚLJůŽĂƌƚŚƌŽƉĂƚŚLJ͗ŶhƉĚĂƚĞ;ϬϳϳͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
^LJƐƚĞŵŝĐ>ƵƉƵƐƌLJƚŚĞŵĂƚŽƐƵƐ͗>ƵƉƵƐEĞƉŚƌŝƟƐ;ϬϳϴͿ ͘ ͘ ͘ ͘ ͘ ͘
dĞŵƉŽƌĂůƌƚĞƌŝƟƐ;ϬϳϵͿ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
sĂĐĐŝŶĂƟŽŶƐĨŽƌWĂƟĞŶƚƐŽŶŝŽůŽŐŝĐdŚĞƌĂƉŝĞƐ;ϬϴϬͿ ͘ ͘ ͘ ͘ ͘ ͘ ͘
ϭ͗ϬϬÖÃʹ
Ϯ͗ϬϬÖÃ
ϭ͗ϬϬÖÃʹ
Ϯ͗ϬϬÖÃ
ACR Sessions
Clinical Issues Associated with the Use of
PS ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
DĞƚŚŽƚƌĞdžĂƚĞ
,ĞŶĐŚ>ĞĐƚƵƌĞƐŚŝƉ͗tŚLJ^ƚĞƌŽŝĚƐtŽƌŬŝŶ^ŽŵĞ
/ŶŇĂŵŵĂƚŽƌLJŝƐĞĂƐĞƐƵƚEŽƚŝŶKƚŚĞƌƐ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
EĞǁZĞŐƵůĂƚŽƌLJdĞůůƐ
͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
hŶĐŽǀĞƌŝŶŐƚŚĞZŽůĞŽĨŽŶŶĞĐƟǀĞdŝƐƐƵĞƐŝŶŚƌŽŶŝĐ>Žǁ
PM ͘ ͘ ͘ ͘ ͘ ͘ ͘
ĂĐŬWĂŝŶ͗&ƌŽŵĞĚƐŝĚĞƚŽĞŶĐŚƚŽĞĚƐŝĚĞ
WĂŝŶĞ
;>ŽďďLJͿ
KƟƐ
;>ŽďďLJͿ
,ĂŶĐŽĐŬ
;>ŽďďLJͿ
ZĞǀĞƌĞ
;>ŽďďLJͿ
^ƚŽŶĞ
;>ŽďďLJͿ
Webster
;>ŽďďLJͿ
Adams
;DĞnjnjĂŶŝŶĞͿ
ůĐŽƩ
;DĞnjnjĂŶŝŶĞͿ
ŽƵŐůĂƐ
;DĞnjnjĂŶŝŶĞͿ
&ĂŶĞƵŝů
;DĞnjnjĂŶŝŶĞͿ
CME/Hours
of Participation
…
ϭ͘ϱŚƌƐ͘
…
ϭ͘ϬŚƌ͘
Ballroom
East
džŚŝďŝƚ,Ăůů
Ϯϱϯ
ϮϭϬ
ARHP Sessions
ƟŽůŽŐLJĂŶĚDĂŶĂŐĞŵĞŶƚŽĨWĞƌŝƉŚĞƌĂůEĞƵƌŽƉĂƚŚLJ
ŝŶWĂƟĞŶƚƐǁŝƚŚZŚĞƵŵĂƟĐŝƐĞĂƐĞ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ Ϯϱϱ
PS ͘ ͘ ͘ ͘ Ϯϱϳ
WŚĂƌŵĂĐŽƚŚĞƌĂƉLJ͗tŚĂƚ͛ƐEĞǁŝŶZŚĞƵŵĂƚŽůŽŐLJ
…
ϭ͘ϬŚƌ͘
ͶĚĞŶŽƚĞƐtĞƐƟŶtĂƚĞƌĨƌŽŶƚƌŽŽŵůŽĐĂƟŽŶ
session
29
tracker
TUESDAY, NOVEMBER 18, 2014
Meeting At-A-Glance
Location
Time
Title
ϭ͗ϬϬÖÃʹ
Ϯ͗ϬϬÖÃ
^ƚƵĚLJ'ƌŽƵƉƐ
ZͲh>Z^ƚƵĚLJ'ƌŽƵƉ͗dŽǁĂƌĚĂEĞǁhŶĚĞƌƐƚĂŶĚŝŶŐ
ŽĨDLJŽƐŝƟƐdŚƌŽƵŐŚ/ŶƚĞƌŶĂƟŽŶĂůŽůůĂďŽƌĂƟŽŶ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
ƵƚŽĂŶƟďŽĚŝĞƐŝŶŝĂŐŶŽƐŝƐĂŶĚ&ŽůůŽǁͲhƉŽĨZŚĞƵŵĂƟĐ
ŝƐĞĂƐĞƐ^ƚƵĚLJ'ƌŽƵƉ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
ĞŚĕĞƚ͛ƐŝƐĞĂƐĞ^ƚƵĚLJ'ƌŽƵƉ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
ŝŽƐŝŵŝůĂƌƐŝŶZŚĞƵŵĂƚŽůŽŐLJ͗hƉĚĂƚĞ^ƚƵĚLJ'ƌŽƵƉ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
ůŽƐŝŶŐƚŚĞ'ĂƉʹWƐŽƌŝĂƐŝƐƚŽWƐŽƌŝĂƟĐƌƚŚƌŝƟƐ
^ƚƵĚLJ'ƌŽƵƉ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
'ůŽďĂůDƵƐĐƵůŽƐŬĞůĞƚĂů,ĞĂůƚŚ/ŶŝƟĂƟǀĞƐ^ƚƵĚLJ'ƌŽƵƉ͘ ͘ ͘ ͘ ͘ ͘
,ŝŐŚͲZĞƐŽůƵƟŽŶWĞƌŝƉŚĞƌĂůYƵĂŶƟƚĂƟǀĞŽŵƉƵƚĞĚ
dŽŵŽŐƌĂƉŚLJ;,ZͲƉYdͿ/ŵĂŐŝŶŐŝŶƌƚŚƌŝƟƐ^ƚƵĚLJ'ƌŽƵƉ͘ ͘ ͘ ͘
:ƵǀĞŶŝůĞƌƚŚƌŝƟƐtŽƌŬŐƌŽƵƉ;:tͿ^ƚƵĚLJ'ƌŽƵƉ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
>ĂƟŶŵĞƌŝĐĂŶ^ƚƵĚLJ'ƌŽƵƉ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
EĞƵƌŽĞŶĚŽĐƌŝŶĞ/ŵŵƵŶŽůŽŐLJ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
WĞĚŝĂƚƌŝĐZŚĞƵŵĂƚŽůŽŐLJ/ŵĂŐŝŶŐ^ƚƵĚLJ'ƌŽƵƉ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
WŽůLJŵLJĂůŐŝĂZŚĞƵŵĂƟĐĂ^ƚƵĚLJ'ƌŽƵƉ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
^ũƂŐƌĞŶ͛Ɛ^LJŶĚƌŽŵĞ^ƚƵĚLJ'ƌŽƵƉ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
ϭ͗ϭϱÖÃʹ
ϯ͗ϭϱÖÃ
ZͬZ,WtŽƌŬƐŚŽƉƐ
ĞƌŵĂƚŽƉĂƚŚŽůŽŐLJŽĨZŚĞƵŵĂƟĐŝƐĞĂƐĞƐ;ϮϯϲͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
DĂŐŶĞƟĐZĞƐŽŶĂŶĐĞ/ŵĂŐŝŶŐŽĨWĞƌŝƉŚĞƌĂů:ŽŝŶƚƐŝŶ
ZŚĞƵŵĂƚŽůŽŐLJWƌĂĐƟĐĞ;ϮϯϳͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
DƵƐĐƵůŽƐŬĞůĞƚĂůhůƚƌĂƐŽŶŽŐƌĂƉŚLJ͗ĂƐŝĐ;ϮϯϴͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
dŚĞZŚĞƵŵĂƚŽůŽŐŝĐDƵƐĐƵůŽƐŬĞůĞƚĂů^ĐƌĞĞŶŝŶŐdžĂŵ͕
ǁŝƚŚŵƉŚĂƐŝƐŽŶKďũĞĐƟǀĞŝƐĞĂƐĞͲƐƉĞĐŝĮĐ
DĞĂƐƵƌĞŵĞŶƚƐ;ϮϯϵͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
of Participation
ϭϬϵ
ϭϬϳ
ϭϲϬ
ϭϱϳ
ϭϱϭ
Ϯϱϰ
Ϯϱϵ
ϭϱϲ
ϭϱϯ
ϮϬϰ
Ϯϱϲ
ϭϬϰ
ϭϬϮ
ϭϲϭ
…
Ϯ͘ϬŚƌƐ͘
ϭϱϰ
ϭϱϵ
ϭϱϮ
ϭ͗ϯϬÖÃʹ
Ϯ͗ϭϱÖÃ
Exhibits
/ŶŶŽǀĂƟŽŶdŚĞĂƚĞƌ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ džŚŝďŝƚ,Ăůů
;ŽŽƚŚηϭϰϬϭͿ
^ĞĞƉĂŐĞϰϰĨŽƌƚŚĞ/ŶŶŽǀĂƟŽŶdŚĞĂƚĞƌ>ŝƐƟŶŐ͘
Ϯ͗ϬϬÖÃʹ
Ϯ͗ϯϬÖÃ
ACR Session
ZƵƐŝŶĞƐƐDĞĞƟŶŐ
Ϯ͗ϯϬÖÃʹ
ϰ͗ϬϬÖÃ
ACR Sessions
ĚƵĐĂƚŽƌ͗/ŶŶŽǀĂƟǀĞĚƵĐĂƚŽƌƐ͕EŽǀĞůdĞĐŚŶŝƋƵĞƐ͗
A ZŚĞƵŵĂƚŽůŽŐLJZĞƐĞĂƌĐŚ&ŽƵŶĚĂƟŽŶ^ƉĞĐŝĂů^ĞƐƐŝŽŶ͘ ͘ ͘ ͘ ͘ ͘ Ϯϱϱ
EŽǀĞůZĞŐƵůĂƚŽƌLJĞůů^ƵďƐĞƚƐ
͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϱϮ
WƐŽƌŝĂƟĐƌƚŚƌŝƟƐ͗^ŬŝŶ͕ŶƚŚĞƐĞƐĂŶĚ:ŽŝŶƚƐ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϮϭϬ
ͶĚĞŶŽƚĞƐtĞƐƟŶtĂƚĞƌĨƌŽŶƚƌŽŽŵůŽĐĂƟŽŶ
CME/Hours
͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ Ballroom
West
…
ϭ͘ϱŚƌƐ͘
30 2014 ACR /A R H P A n n u a l M e e t i n g
Meeting At-A-Glance
TUESDAY, NOVEMBER 18, 2014
Location
CME/Hours
Time
Title
Ϯ͗ϯϬÖÃʹ
ϰ͗ϬϬÖÃ
ACR Concurrent Abstract Sessions
…
Z>ĂƚĞͲďƌĞĂŬŝŶŐďƐƚƌĂĐƚ^ĞƐƐŝŽŶ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ džŚŝďŝƚ,Ăůů ϭ͘ϱŚƌƐ͘
;ηϮϳϴϳͲϮϳϵϭͿϮϬϭϰZŚĞƵŵĂƚŽůŽŐLJZĞƐĞĂƌĐŚ&ŽƵŶĚĂƟŽŶ
ĚŵŽŶĚ>͘ƵďŽŝƐ͕D͕DĞŵŽƌŝĂů>ĞĐƚƵƌĞƐŚŝƉ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ Ballroom
East
;ηϮϳϵϮͲϮϳϵϳͿŝŽůŽŐLJĂŶĚWĂƚŚŽůŽŐLJŽĨŽŶĞĂŶĚ:ŽŝŶƚ/͗
ŽŶĞZĞŵŽĚĞůŝŶŐŝŶ/ŶŇĂŵŵĂƟŽŶĂŶĚƌƚŚƌŝƟƐ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭϬϮ
;ηϮϳϵϴͲϮϴϬϯͿLJƚŽŬŝŶĞƐ͕DĞĚŝĂƚŽƌƐ͕ĞůůͲĐĞůůĚŚĞƐŝŽŶ͕Ğůů
dƌĂĸĐŬŝŶŐĂŶĚŶŐŝŽŐĞŶĞƐŝƐ/ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭϬϳ
;ηϮϴϬϰͲϮϴϬϵͿDŝƐĐĞůůĂŶĞŽƵƐZŚĞƵŵĂƟĐĂŶĚ/ŶŇĂŵŵĂƚŽƌLJ
ŝƐĞĂƐĞƐͬ/ŶŶĂƚĞ/ŵŵƵŶŝƚLJĂŶĚZŚĞƵŵĂƟĐŝƐĞĂƐĞ͗ƐƐĞƐƐŝŶŐ
KƵƚĐŽŵĞƐŽĨ/ŶĨĞĐƟŽŶƐŝŶZŚĞƵŵĂƟĐŝƐĞĂƐĞ
͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭϱϭ
;ηϮϴϭϬͲϮϴϭϰͿZŚĞƵŵĂƚŽŝĚƌƚŚƌŝƟƐʹůŝŶŝĐĂůƐƉĞĐƚƐs͗
DŽƌƚĂůŝƚLJĂŶĚKƚŚĞƌKƵƚĐŽŵĞƐ
͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ Ϯϱϴ
;ηϮϴϭϱͲϮϴϮϬͿZŚĞƵŵĂƚŽŝĚƌƚŚƌŝƟƐʹ,ƵŵĂŶƟŽůŽŐLJĂŶĚ
WĂƚŚŽŐĞŶĞƐŝƐ/͗DĞĐŚĂŶŝƐŵƐŽĨ:ŽŝŶƚĂŵĂŐĞʹ
>ĞĞ͘,ŽǁůĞLJ͕^ƌ͘WƌŝnjĞ
͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭϬϰ
;ηϮϴϮϭͲϮϴϮϲͿZŚĞƵŵĂƚŽŝĚƌƚŚƌŝƟƐʹ^ŵĂůůDŽůĞĐƵůĞƐ͕
ŝŽůŽŐŝĐƐĂŶĚ'ĞŶĞdŚĞƌĂƉLJs͗EŽǀĞůdŚĞƌĂƉŝĞƐŝŶ
ZŚĞƵŵĂƚŽŝĚƌƚŚƌŝƟƐʹ>ĂƚĞŝŶĞǀĞůŽƉŵĞŶƚ
͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ Ϯϱϯ
;ηϮϴϮϳͲϮϴϯϮͿ^ƉŽŶĚLJůŽĂƌƚŚƌŽƉĂƚŚŝĞƐĂŶĚWƐŽƌŝĂƟĐƌƚŚƌŝƟƐ
IVʹůŝŶŝĐĂůƐƉĞĐƚƐdžŝĂů^ƉŽŶĚLJůŽĂƌƚŚƌŝƟƐ
͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ Ballroom
West
;ηϮϴϯϯͲϮϴϯϴͿ^LJƐƚĞŵŝĐ>ƵƉƵƐƌLJƚŚĞŵĂƚŽƐƵƐʹClinical
ƐƉĞĐƚƐĂŶĚdƌĞĂƚŵĞŶƚ͗EŽǀĞůdŚĞƌĂƉŝĞƐĨŽƌ^LJƐƚĞŵŝĐ>ƵƉƵƐ
Erythematosus ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϮϬϱ
;ηϮϴϯϵͲϮϴϰϰͿ^LJƐƚĞŵŝĐ>ƵƉƵƐƌLJƚŚĞŵĂƚŽƐƵƐʹ,ƵŵĂŶ
ƟŽůŽŐLJĂŶĚWĂƚŚŽŐĞŶĞƐŝƐ//͗WĂƚŚŽŐĞŶŝĐdĂƌŐĞƚƐ͕'ĞŶĞƟĐ
sĂƌŝĂŶƚƐĂŶĚƉŽƉƚŽƐŝƐ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭϱϲ
;ηϮϴϰϱͲϮϴϱϬͿdĞůůŝŽůŽŐLJĂŶĚdĂƌŐĞƚƐŝŶƵƚŽŝŵŵƵŶĞ
ŝƐĞĂƐĞ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭϬϵ
;ηϮϴϱϭͲϮϴϱϲͿsĂƐĐƵůŝƟƐ/// ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭϱϳ
Ϯ͗ϯϬÖÃʹ
ϰ͗ϬϬÖÃ
ACR/ARHP Combined Abstract Session
;ηϮϴϱϳͲϮϴϲϮͿZͬZ,WŽŵďŝŶĞĚďƐƚƌĂĐƚ^ĞƐƐŝŽŶ͗
PS ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭϲϬ
ZĞŚĂďŝůŝƚĂƟŽŶ
…
ϭ͘ϱŚƌƐ͘
Ϯ͗ϯϬÖÃʹ
ϰ͗ϬϬÖÃ
ARHP Sessions
ƌŝĞĨĐƟŽŶWůĂŶŶŝŶŐ;WͿ͗DŽƟǀĂƟŽŶĂů/ŶƚĞƌǀŝĞǁŝŶŐ;D/Ϳ
dĞĐŚŶŝƋƵĞƚŽŶŚĂŶĐĞWĂƟĞŶƚ^ĞůĨͲDĂŶĂŐĞŵĞŶƚĂŶĚ/ŵƉƌŽǀĞ
PM
Ed ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϮϬϰ
KƵƚĐŽŵĞƐ
KƐƚĞŽƉŽƌŽƐŝƐ͗ŵĞƌŐŝŶŐdƌĞĂƚŵĞŶƚƐŽƚŚWŚĂƌŵĂĐŽůŽŐŝĐĂů
ĂŶĚEŽŶͲWŚĂƌŵĂĐŽůŽŐŝĐĂů ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ Ϯϱϲ
dŚĞWƐLJĐŚŽƐŽĐŝĂů/ŵƉĂĐƚĂŶĚdƌĞĂƚŵĞŶƚKƉƟŽŶƐĨŽƌWĂƟĞŶƚƐ
ǁŝƚŚEĞƵƌŽƉƐLJĐŚŝĂƚƌŝĐ>ƵƉƵƐĂŶĚdŚĞŝƌĂƌĞŐŝǀĞƌƐ ͘ ͘ ͘ ͘ ͘ ͘ ͘ Ϯϱϳ
PM ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭϱϯ
dƌĞĂƚŵĞŶƚŽŶƐŝĚĞƌĂƟŽŶƐŝŶŚƌŽŶŝĐWĂŝŶ
…
ϭ͘ϱŚƌƐ͘
of Participation
ͶĚĞŶŽƚĞƐtĞƐƟŶtĂƚĞƌĨƌŽŶƚƌŽŽŵůŽĐĂƟŽŶ
session
31
tracker
TUESDAY, NOVEMBER 18, 2014
Meeting At-A-Glance
Location
CME/Hours
Time
Title
ϰ͗ϬϬÖÃʹ
ϲ͗ϬϬÖÃ
ZtŽƌŬƐŚŽƉƐ
'ĞƫŶŐůĞĐƚƌŽŶŝĐ,ĞĂůƚŚZĞĐŽƌĚƐZŝŐŚƚ;ϮϰϬͿ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭϱϰ
^LJƐƚĞŵŝĐ^ĐůĞƌŽƐŝƐ͗,ŽǁƚŽWĞƌĨŽƌŵ^ŬŝŶ^ĐŽƌĞƐ;ϮϰϭͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭϱϮ
hůƚƌĂƐŽƵŶĚ/ŶũĞĐƟŽŶ'ƵŝĚĂŶĐĞ;ϮϰϮͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭϱϵ
…
Ϯ͘ϬŚƌƐ͘
ϰ͗ϯϬÖÃʹ
ϲ͗ϬϬÖÃ
ACR Sessions
ƵƚŽƉŚĂŐLJŝŶZŚĞƵŵĂƟĐŝƐĞĂƐĞƐ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭϲϬ
ĞLJŽŶĚŶĂůŐĞƐŝĐƐ͗^ƚĂƚĞŽĨƚŚĞǀŝĚĞŶĐĞĨŽƌEƵƚƌŝƟŽŶ͕
sŝƚĂŵŝŶƐĂŶĚdžĞƌĐŝƐĞWƌĞƐĐƌŝƉƟŽŶƐŝŶKƐƚĞŽĂƌƚŚƌŝƟƐ
DĂŶĂŐĞŵĞŶƚ
͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϮϭϬ
hƉĚĂƚĞŽŶ^ĂĨĞƚLJ/ƐƐƵĞƐŝŶƚŚĞdƌĞĂƚŵĞŶƚŽĨZŚĞƵŵĂƟĐ
Pd
PS ͘ ͘ ͘ ͘ ͘ ͘ ϱϮ
PS
PM
ŝƐĞĂƐĞƐʹ&ƌŽŵƚŚĞ&ĂŶĚĞLJŽŶĚ
…
ϭ͘ϱŚƌƐ͘
ϰ͗ϯϬÖÃʹ
ϲ͗ϬϬÖÃ
ACR Concurrent Abstract Sessions
;ηϮϴϲϯͲϮϴϲϴͿŶƟƉŚŽƐƉŚŽůŝƉŝĚ^LJŶĚƌŽŵĞ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
;ηϮϴϲϵͲϮϴϳϰͿĞůůŝŽůŽŐLJĂŶĚdĂƌŐĞƚƐŝŶ
ƵƚŽŝŵŵƵŶĞŝƐĞĂƐĞ
͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
;ηϮϴϳϱͲϮϴϴϬͿLJƚŽŬŝŶĞƐ͕DĞĚŝĂƚŽƌƐ͕ĞůůͲĐĞůůĚŚĞƐŝŽŶ͕Ğůů
dƌĂĸĐŬŝŶŐĂŶĚŶŐŝŽŐĞŶĞƐŝƐ// ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
PM
Ed ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
;ηϮϴϴϭͲϮϴϴϲͿĚƵĐĂƟŽŶ
;ηϮϴϴϳͲϮϴϵϮͿƉŝĚĞŵŝŽůŽŐLJĂŶĚWƵďůŝĐ,ĞĂůƚŚ/s͗
ZŚĞƵŵĂƚŽŝĚƌƚŚƌŝƟƐWĂƚŚŽŐĞŶĞƐŝƐ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
;ηϮϴϵϯͲϮϴϵϴͿKƐƚĞŽĂƌƚŚƌŝƟƐʹůŝŶŝĐĂůƐƉĞĐƚƐ//͗
KƐƚĞŽĂƌƚŚƌŝƟƐZŝƐŬ&ĂĐƚŽƌƐĂŶĚdŚĞƌĂƉŝĞƐ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
;ηϮϴϵϵͲϮϵϬϰͿWĞĚŝĂƚƌŝĐZŚĞƵŵĂƚŽůŽŐLJʹClinical and
dŚĞƌĂƉĞƵƟĐƐƉĞĐƚƐ͗DŝƐĐĞůůĂŶĞŽƵƐWĞĚŝĂƚƌŝĐZŚĞƵŵĂƟĐ
Pd
PS ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
ŝƐĞĂƐĞƐ
;ηϮϵϬϱͲϮϵϭϬͿZŚĞƵŵĂƚŽŝĚƌƚŚƌŝƟƐʹŶŝŵĂůDŽĚĞůƐ// ͘ ͘ ͘ ͘
;ηϮϵϭϭͲϮϵϭϲͿZŚĞƵŵĂƚŽŝĚƌƚŚƌŝƟƐʹůŝŶŝĐĂůƐƉĞĐƚƐs/͗
/ŵƉĂĐƚŽĨdƌĞĂƚŵĞŶƚĂŶĚKƚŚĞƌ/ŶƚĞƌǀĞŶƟŽŶƐ
͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
;ηϮϵϭϳͲϮϵϮϮͿZŚĞƵŵĂƚŽŝĚƌƚŚƌŝƟƐʹ,ƵŵĂŶƟŽůŽŐLJ
ĂŶĚWĂƚŚŽŐĞŶĞƐŝƐ//͗ŝƚƌƵůůŝŶĂƟŽŶ͕ƵƚŽĂŶƟďŽĚŝĞƐ
ĂŶĚ'ĞŶĞƐ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
;ηϮϵϮϯͲϮϵϮϴͿZŚĞƵŵĂƚŽŝĚƌƚŚƌŝƟƐʹ^ŵĂůůDŽůĞĐƵůĞƐ͕
ŝŽůŽŐŝĐƐĂŶĚ'ĞŶĞdŚĞƌĂƉLJs/͗ŝŽŵĂƌŬĞƌƐĂŶĚWƌĞĚŝĐƚŽƌƐ
ŽĨZŚĞƵŵĂƚŽŝĚƌƚŚƌŝƟƐŝƐĞĂƐĞZĞƐƉŽŶƐĞĂŶĚ
KƵƚĐŽŵĞƐ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
;ηϮϵϮϵͲϮϵϯϰͿ^ũƂŐƌĞŶ͛Ɛ^LJŶĚƌŽŵĞ/͗ůŝŶŝĐĂů
WĞƌƐƉĞĐƟǀĞƐ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
;ηϮϵϯϱͲϮϵϰϬͿ^ƉŽŶĚLJůŽĂƌƚŚƌŽƉĂƚŚŝĞƐĂŶĚWƐŽƌŝĂƟĐƌƚŚƌŝƟƐ
VʹůŝŶŝĐĂůƐƉĞĐƚƐĂŶĚdƌĞĂƚŵĞŶƚ
͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
…
ϭ͘ϱŚƌƐ͘
ͶĚĞŶŽƚĞƐtĞƐƟŶtĂƚĞƌĨƌŽŶƚƌŽŽŵůŽĐĂƟŽŶ
ϭϬϰ
ϭϬϵ
ϭϬϳ
ϭϱϲ
Ϯϱϴ
ϭϱϯ
ϮϬϱ
ϭϱϭ
Ballroom
East
ϭϱϳ
Ϯϱϯ
ϭϬϮ
Ballroom
West
of Participation
32 2014 ACR /A R H P A n n u a l M e e t i n g
Meeting At-A-Glance
TUESDAY, NOVEMBER 18, 2014
Location
Time
Title
ϰ͗ϯϬÖÃʹ
ϲ͗ϬϬÖÃ
ACR Meet the Professor Sessions
ĚƵůƚ/ŶŇĂŵŵĂƚŽƌLJDLJŽƉĂƚŚLJ;ϬϴϭͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
ĞŚĕĞƚ͛Ɛ^LJŶĚƌŽŵĞ;ϬϴϮͿ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
ĂůĐŝƵŵƌLJƐƚĂůƌƚŚƌŝƟƐ;ϬϴϯͿ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
:ƵǀĞŶŝůĞĞƌŵĂƚŽŵLJŽƐŝƟƐ;ϬϴϰͿ
Pd
PS
͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
DLJŽƉĂƚŚLJ͗/ƐƐƵĞƐŝŶŝĂŐŶŽƐŝƐĂŶĚdƌĞĂƚŵĞŶƚ;ϬϴϱͿ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
WƌĞŐŶĂŶĐLJĂŶĚZŚĞƵŵĂƟĐŝƐĞĂƐĞƐ;ϬϴϲͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
WƵůŵŽŶĂƌLJDĂŶŝĨĞƐƚĂƟŽŶƐŽĨZŚĞƵŵĂƟĐŝƐĞĂƐĞ;ϬϴϳͿ͘ ͘ ͘ ͘ ͘ ͘
ZĂLJŶĂƵĚ͛ƐĂŶĚŝŐŝƚĂů/ƐĐŚĞŵŝĂ;ϬϴϴͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
ZŚĞƵŵĂƚŽŝĚƌƚŚƌŝƟƐ͗ŚĂůůĞŶŐŝŶŐĂƐĞƐ;ϬϴϵͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
dĞŵƉŽƌĂůƌƚĞƌŝƟƐ;ϬϵϬͿ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
ϰ͗ϯϬÖÃʹ
ϲ͗ϬϬÖÃ
ARHP Sessions
DƵůƟĚŝƐĐŝƉůŝŶĂƌLJDĂŶĂŐĞŵĞŶƚŽĨƚŚĞ:ƵǀĞŶŝůĞ/ĚŝŽƉĂƚŚŝĐ
Pd
PS ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
ƌƚŚƌŝƟƐWĂƟĞŶƚ
WĂƟĞŶƚͲZĞƉŽƌƚĞĚKƵƚĐŽŵĞƐĂƚĂĨŽƌŽŵƉĂƌĂƟǀĞ
īĞĐƟǀĞŶĞƐƐZĞƐĞĂƌĐŚŝŶƌƚŚƌŝƟƐĂƌĞ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
^ƚĂƚĞͲŽĨͲƚŚĞͲƌƚ/ŶƚĞƌǀĞŶƟŽŶĂůZĞĐŽŵŵĞŶĚĂƟŽŶƐĨŽƌ
PM ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
ŚƌŽŶŝĐ>ŽǁĂĐŬWĂŝŶ
^ƵĐĐĞƐƐĨƵůŐŝŶŐŝŶZŚĞƵŵĂƟĐŝƐĞĂƐĞ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
ϰ͗ϯϬÖÃʹ
ϲ͗ϬϬÖÃ
ARHP Concurrent Abstract Sessions
;ηϮϵϰϭͲϮϵϰϲͿƉŝĚĞŵŝŽůŽŐLJͬWƵďůŝĐ,ĞĂůƚŚ
ϲ͗ϯϬÖÃʹ
ϵ͗ϯϬÖÃ
/ŶĚƵƐƚƌLJͲ^ƵƉƉŽƌƚĞĚ^LJŵƉŽƐŝĂ
^ĞĞƉƌŽŐƌĂŵŬƉĂŐĞϮϯϵŽƌŶŶƵĂůDĞĞƟŶŐƉƉĨŽƌƚŚĞ
ůŝƐƚŽĨƐLJŵƉŽƐŝĂ͘
WĂŝŶĞ
;>ŽďďLJͿ
KƟƐ
;>ŽďďLJͿ
,ĂŶĐŽĐŬ
;>ŽďďLJͿ
ZĞǀĞƌĞ
;>ŽďďLJͿ
^ƚŽŶĞ
;>ŽďďLJͿ
Webster
;>ŽďďLJͿ
Adams
;DĞnjnjĂŶŝŶĞͿ
ůĐŽƩ
;DĞnjnjĂŶŝŶĞͿ
ŽƵŐůĂƐ
;DĞnjnjĂŶŝŶĞͿ
&ĂŶĞƵŝů
;DĞnjnjĂŶŝŶĞͿ
CME/Hours
of Participation
…
ϭ͘ϱŚƌƐ͘
…
ϭ͘ϱŚƌƐ͘
Ϯϱϱ
Ϯϱϲ
Ϯϱϳ
ϮϬϰ
͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ Ϯϱϰ
…
ϭ͘ϱŚƌƐ͘
ͶĚĞŶŽƚĞƐtĞƐƟŶtĂƚĞƌĨƌŽŶƚƌŽŽŵůŽĐĂƟŽŶ
session
33
tracker
WEDNESDAY, NOVEMBER 19, 2014
Meeting At-A-Glance
WEDNESDAY, NOVEMBER 19, 2014
Location
CME/Hours
Time
Title
ϳ͗ϬϬƒÃʹ
ϭ͗ϬϬÖÃ
ZͬZ,WZĞŐŝƐƚƌĂƟŽŶ
džŚŝďŝƚ
͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘ >ĞǀĞů;ĂƐƚ
ZĞŐŝƐƚƌĂƟŽŶͿ
ϳ͗ϯϬƒÃʹ
ϴ͗ϯϬƒÃ
ACR Sessions
…
ϭ͘ϬŚƌ͘
ŽͲ^ƟŵƵůĂƟŽŶWĂƚŚǁĂLJƐ͗dŚĞƌĂƉĞƵƟĐKƉƉŽƌƚƵŶŝƟĞƐĨŽƌƚŚĞ
ZŚĞƵŵĂƟĐŝƐĞĂƐĞƐ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϱϮ
ZŚĞƵŵĂƚŽůŽŐLJZŽƵŶĚƵƉ͗,ŝŐŚůŝŐŚƚƐĨƌŽŵƚŚĞϮϬϭϰŶŶƵĂů
DĞĞƟŶŐ
͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ Ballroom East
ϳ͗ϯϬƒÃʹ
ϴ͗ϯϬƒÃ
ARHP Sessions
WŚLJƐŝĐĂůĂŶĚKĐĐƵƉĂƟŽŶĂůdŚĞƌĂƉLJĨŽƌ:ƵǀĞŶŝůĞ
ĞƌŵĂƚŽŵLJŽƐŝƟƐ͗dƌĞĂƚŵĞŶƚWůĂŶŶŝŶŐĂŶĚĂƐĞ
Pd
PS ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ Ϯϱϱ
WƌĞƐĞŶƚĂƟŽŶƐ
ZŚĞƵŵĂƟĐDĂŶŝĨĞƐƚĂƟŽŶƐŽĨDĂůŝŐŶĂŶĐLJ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ Ϯϱϲ
…
ϭ͘ϬŚƌ͘
ϵ͗ϬϬƒÃʹ
ϭϬ͗ϯϬƒÃ
ACR Sessions
ŽŵƉůĞŵĞŶƚŝŶZŚĞƵŵĂƟĐŝƐĞĂƐĞ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
DŽǀŝŶŐdŽǁĂƌĚWĞƌƐŽŶĂůŝnjĞĚDĞĚŝĐŝŶĞĨŽƌ^LJƐƚĞŵŝĐ>ƵƉƵƐ
ƌLJƚŚĞŵĂƚŽƐƵƐDĂŶĂŐĞŵĞŶƚ͗&ƌŽŵĞŶĐŚƚŽĞĚƐŝĚĞ
͘ ͘ ͘ ͘
WƌŝŵĂƌLJŶŐŝŝƟƐŽĨƚŚĞĞŶƚƌĂůEĞƌǀŽƵƐ^LJƐƚĞŵĂŶĚ
/ƚƐDŝŵŝĐƐ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘
…
ϭ͘ϱŚƌƐ͘
ͶĚĞŶŽƚĞƐtĞƐƟŶtĂƚĞƌĨƌŽŶƚƌŽŽŵůŽĐĂƟŽŶ
Ϯϱϯ
Ballroom
East
Ballroom
West
of Participation
34 2014 ACR /A R H P A n n u a l M e e t i n g
Meeting At-A-Glance
WEDNESDAY, NOVEMBER 19, 2014
Location
CME/Hours
Time
Title
ϵ͗ϬϬƒÃʹ
ϭϬ͗ϯϬƒÃ
ACR Concurrent Abstract Sessions
;ηϮϵϰϳͲϮϵϱϮͿŝŽůŽŐLJĂŶĚWĂƚŚŽůŽŐLJŽĨŽŶĞĂŶĚ:ŽŝŶƚ//͗
ĂƌƟůĂŐĞŝŽůŽŐLJĂŶĚ^LJŶŽǀŝĂůĐƟǀĂƟŽŶ
͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭϲϬ
;ηϮϵϱϯͲϮϵϱϴͿ'ĞŶĞƟĐƐ͕'ĞŶŽŵŝĐƐĂŶĚWƌŽƚĞŽŵŝĐƐ//͗
'ĞŶĞƟĐƐŽĨƵƚŽŝŵŵƵŶŝƚLJ
͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭϱϯ
;ηϮϵϱϵͲϮϵϲϰͿDĞƚĂďŽůŝĐĂŶĚƌLJƐƚĂůƌƚŚƌŽƉĂƚŚŝĞƐ//͗
DĞĐŚĂŶŝƐŵƐŽĨŝƐĞĂƐĞ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭϬϰ
;ηϮϵϲϱͲϮϵϳϬͿWĂŝŶ͗ĂƐŝĐĂŶĚůŝŶŝĐĂůƐƉĞĐƚƐ//ͬKƌƚŚŽƉĞĚŝĐƐ͕
PM ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭϬϳ
>ŽǁĂĐŬWĂŝŶĂŶĚZĞŚĂďŝůŝƚĂƟŽŶ
;ηϮϵϳϭͲϮϵϳϲͿZŚĞƵŵĂƚŽŝĚƌƚŚƌŝƟƐʹůŝŶŝĐĂůƐƉĞĐƚƐs//͗
EĞǁƐƉĞĐƚƐŽĨDŽŶŝƚŽƌŝŶŐŝƐĞĂƐĞ
͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ Ϯϱϴ
;ηϮϵϳϳͲϮϵϴϮͿ^ũƂŐƌĞŶ͛Ɛ^LJŶĚƌŽŵĞ//͗/ŶƐŝŐŚƚƐŝŶƚŽ
WĂƚŚŽƉŚLJƐŝŽůŽŐLJ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭϱϳ
;ηϮϵϴϯͲϮϵϴϴͿ^ƉŽŶĚLJůŽĂƌƚŚƌŽƉĂƚŚŝĞƐĂŶĚWƐŽƌŝĂƟĐƌƚŚƌŝƟƐ
VIʹ/ŵĂŐŝŶŐĂŶĚŝŽŵĂƌŬĞƌƐ
͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϮϬϱ
;ηϮϵϴϵͲϮϵϵϰͿ^LJƐƚĞŵŝĐ>ƵƉƵƐƌLJƚŚĞŵĂƚŽƐƵƐʹ
ůŝŶŝĐĂůƐƉĞĐƚƐĂŶĚdƌĞĂƚŵĞŶƚ͗E^ĂŶĚKƚŚĞƌůŝŶŝĐĂů
ƐƉĞĐƚƐ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϱϮ
;ηϮϵϵϱͲϯϬϬϬͿ^LJƐƚĞŵŝĐ^ĐůĞƌŽƐŝƐ͕&ŝďƌŽƐŝŶŐ^LJŶĚƌŽŵĞƐĂŶĚ
ZĂLJŶĂƵĚ͛ƐʹůŝŶŝĐĂůƐƉĞĐƚƐĂŶĚdŚĞƌĂƉĞƵƟĐƐ///͗hƉĚĂƚĞƐŝŶ
WƌĞĚŝĐƚŽƌƐĂŶĚKƵƚĐŽŵĞƐŝŶ^LJƐƚĞŵŝĐ^ĐůĞƌŽƐŝƐ
͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭϱϭ
;ηϯϬϬϭͲϯϬϬϲͿ^LJƐƚĞŵŝĐ^ĐůĞƌŽƐŝƐ͕&ŝďƌŽƐŝŶŐ^LJŶĚƌŽŵĞƐ
ĂŶĚZĂLJŶĂƵĚ͛ƐʹWĂƚŚŽŐĞŶĞƐŝƐ͕ŶŝŵĂůDŽĚĞůƐĂŶĚ
'ĞŶĞƟĐƐ// ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭϱϲ
…
ϭ͘ϱŚƌƐ͘
ϵ͗ϬϬƒÃʹ
ϭϬ͗ϯϬƒÃ
ARHP Sessions
džĞƌĐŝƐĞĚŚĞƌĞŶĐĞŝŶƌƚŚƌŝƟƐ͗dŚĞZŽůĞ
of Technology ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ Ϯϱϲ
EŽƚŚŝŶŐďŽƵƚhƐtŝƚŚŽƵƚhƐ͗ŶŐĂŐŝŶŐWĂƟĞŶƚƐŝŶ
PS ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ Ϯϱϱ
Rheumatology Research
…
ϭ͘ϱŚƌƐ͘
ϵ͗ϬϬƒÃʹ
ϭϬ͗ϯϬƒÃ
ARHP Concurrent Abstract Sessions
;ηϯϬϬϳͲϯϬϭϮͿůŝŶŝĐĂůWƌĂĐƟĐĞͬWĂƟĞŶƚĂƌĞ
͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ Ϯϱϳ
PM
Ed ͘ ͘ ͘ ͘ Ϯϱϵ
;ηϯϬϭϯͲϯϬϭϴͿ/ŶŶŽǀĂƟŽŶƐŝŶZŚĞƵŵĂƚŽůŽŐŝĐĂƌĞ
…
ϭ͘ϱŚƌƐ͘
of Participation
session
35
tracker
WEDNESDAY, NOVEMBER 19, 2014
Time
Meeting At-A-Glance
Location
Title
ϭϭ͗ϬϬƒÃʹ ACR Session
EŽŽŶ
/ŶŇĂŵŵĂƟŽŶĂŶĚƚŚĞƌŽƚŚƌŽŵďŽƐŝƐ
CME/Hours
of Participation
…
͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ džŚŝďŝƚ,Ăůů ϭ͘ϬŚƌ͘
ϭϭ͗ϬϬƒÃʹ ACR Sessions
…
ϭϮ͗ϯϬÖÃ
ϭ͘ϱŚƌƐ͘
ĚǀĂŶĐĞƐŝŶDŽůĞĐƵůĂƌWƌŽĮůŝŶŐĂŶĚZĞůĞǀĂŶĐĞƚŽ
ƵƚŽŝŵŵƵŶĞŝƐĞĂƐĞ
͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϱϮ
EŽŶͲZĂĚŝŽŐƌĂƉŚŝĐdžŝĂů^ƉŽŶĚLJůŽĂƌƚŚƌŝƟƐ͗dŚĞŽŶƚƌŽǀĞƌƐLJŽĨ
ŝĂŐŶŽƐŝƐĂŶĚKƉƟŵĂůdƌĞĂƚŵĞŶƚ
͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ Ballroom East
ϭϭ͗ϬϬƒÃʹ ARHP Session
ϭϮ͗ϯϬÖÃ
tŽƌŬĂŶĚtŽƌŬĞƌ,ĞĂůƚŚ͗ĂƐLJĐĐŽŵŵŽĚĂƟŽŶƐ<ĞĞƉ
WĞŽƉůĞtŝƚŚƌƚŚƌŝƟƐŵƉůŽLJĞĚ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ Ϯϱϱ
ϭ͗ϬϬÖÃʹ
ϰ͗ϬϬÖÃ
/ŶĚƵƐƚƌLJͲ^ƵƉƉŽƌƚĞĚWŽƐƚDĞĞƟŶŐ^LJŵƉŽƐŝĂ
^ĞĞƉƌŽŐƌĂŵŬƉĂŐĞϮϯϵŽƌŶŶƵĂůDĞĞƟŶŐƉƉĨŽƌƚŚĞ
ůŝƐƚŽĨƐLJŵƉŽƐŝĂ͘
…
ϭ͘ϱŚƌƐ͘
36 2014 ACR /A R H P A n n u a l M e e t i n g
MAP #PTUPO$POWFOUJPOBOE&YIJCJUJPO$FOUFS
meeting level 1
Boardroom and
.FFUJOH3PPNT
6
Nursing Mothers Room
7
Prayer Room
SW Lobby C
8
Restaurant Reservations
& Visitor Information
SW Lobby B2
9
Shuttle Bus
Open to
Exhibit Hall C
(Below)
Service Corridor
109 109 108 107 107 107 106
B A
C B A
Southwest Pre-function
Industry-Supported
Symposia Information
Southeast Pre-function
Skybridge
First Aid
5
162 162 161 160 160 160 159
B A
C B A
10 Technology Center
Recharge Area
West Side Drive
Bar
Wicked Good
Market
Open to
Exhibit Hall B
(Below)
ATM
Center East Pre-function
158 157 157 157 156 156 156 155
C B A C B A
Skybridge
Northwest Pre-function
105 104 104 104 103 102 102 101
C B A
B A
First Aid
Business Center
Service Corridor
Open to
Exhibit Hall A
(Below)
Service Corridor
Northeast Pre-function
154 153 153 153 152 151 151 150
C B A
B A
ATM
Outtakes
1
North Lobby
to
Entrance
Plaza
Stop
3
5
8
10
NW Corner Pre-function
NE Corner Pre-function
4
11 Visitor Information
East Side Drive
2
Concierge Center
4
SE Lobby B2
NW Lobby A
NE Lobby A
Coat/Baggage Check
3
SE Lobby C
NW Lobby B1
NE Lobby B1
Business Center
2
7
9
9
1
6
Foundation Donors’ Lounge
3
Newsroom
4
Speaker Ready Room
213
261
Southwest
Lobby
Skybridge
(Level 1)
212 211
Southwest Pre-function
210
210
210
C
B
A
(Ballroom 210)
Service Corridor
Open to
Exhibit Hall B
(Below)
Service Corridor
Southeast Pre-function
209 208
Northwest
Lobby
Skybridge
(Level 1)
Northeast
Lobby
205
B
205
A 204 204 203
B A
Service Corridor
205
C
Northwest Pre-function
207 206 206
B A
Open to
Exhibit Hall A
(Below)
West Boardroom
Pre-function
East BCMC
Pre-function
BCMC
Sales Dept.
North
Lobby
(Below)
Bridge
Boardroom
Suite 201,202
Kitchen
Storage
Kitchen
Bakery
Skybridge
Access
Catering
Office
253 252 252 251
B A
A
Service Corridor
253
B
Northeast Pre-function
255 254 254 253
B A
C
NW Corner Pre-function
NE Corner Pre-function
3
260 259 259 258 258 258 257 257 256
B A
B A
C
B
A
4
(Outside)
2
Southeast
Lobby
1
Open to
Exhibit Hall C
(Below)
ACR Office
Lost and Found
(Outside)
1
37
session
tracker
#PTUPO$POWFOUJPOBOE&YIJCJUJPO$FOUFSMAP
meeting level 2
Boardroom and
.FFUJOH3PPNT
Entrance
Plaza
(Below)
2
38 2014 ACR /A R H P A n n u a l M e e t i n g
MAP #PTUPO$POWFOUJPOBOE&YIJCJUJPO$FOUFS
Ballroom Level
Skybridge
(Level 1)
Low Roof
(Outside)
Exhibit Hall B
(Below)
Skybridge
(Level 1)
Exhibit Hall A
(Below)
Finishing
Kitchen
Green Room
Lobby
Ballroom West
Ballroom
Lobby
Ballroom East
Pre-function
2
1
3
Attendee Lounge
2
Late-breaking Abstracts
3
Opening Reception
Exhibit Hall C
(Below)
Low Roof
(Outside)
Skybridge Access
(Level 2)
3
1
session
tracker
#PTUPO$POWFOUJPOBOE&YIJCJUJPO$FOUFSMAP
Exhibit Level
Exhibit Hall A
Exhibit Hall
Skybridge
(Level 1 Access)
SE Lobby B2
Skybridge
(Level 1 Access)
3
Poster Hall
SE Lobby C
East Registration
4
Session Room
Session Room
– Opening Lecture
and Awards
– Plenary Sessions I, II, III
Exhibit Hall B
4
Exhibit Hall C
Registration
– Hotel Reservations
– Membership Booth
– Ribbon Distribution
051 050
3
052
A
Poster Hall
052
B
2
ATM
Exhibit Hall
Discovery Center (Booth #731)
– Career/Connection
– Foundation Booth
– Simple Tasks
– Innovation Theaters A and B
– Wi-Fi Way
– Recharge Area
Southeast
Pre-function
1
NE Lobby B1
NE Lobby A
2
1
39
40 2014 ACR /A R H P A n n u a l M e e t i n g
MAP #PTUPO$POWFOUJPOBOE&YIJCJUJPO$FOUFS
ExhibitHall
Entrance
Exhibitor
Lounge
Exhibitor
Suite A
Snack
Area
Exhibitor
Suite B
359
Innovation
Theater
A
Exhibitor V X
Suite U
W
139
655
649
643
Exhibitor Exhibitor
F Suite G Suite H
747 846
743 842
731
639 738
631
727 826
1039 1138
1055
1061 1160
Exhibitor Exhibitor L
Suite I Suite J K
1060
959 1058
1056
955 1054
943
ACR
Discovery Center
627 726
WiFi Way
1015 1114
919
1013
7
8
Food Court
6
10
11
13
1011 1110
1014
1
5
9
Exhibit Hall A
911 1010
1012
611
614
511 610
513 612
Exhibitor Exhibitor Exhibitor
Suite C Suite D Suite E
457
447
439
421
514
411 510
401
WiFi Way
333 432
WiFi Way
232
329 428
331 430
229
230
327 426
228
226
325 424
323 422
224
221
321
222
319 418
301 400
402
311 410
313
315 414
220
211
201
203 302
205 304
218
212
210
Networking
Lounge
101
2
3
4
1451
1339
1329
Exhibitor
Suite T
1580 1561
1421
1401
1551
1547
1529
1527
1525
1521
1519
1517
Innovation
Theater
B
1429
1447 1546
1548
1457 1556 1557
1554 1555
1459 1558 1559
R Exhibitor
Q Suite S
1347
1328A
1325 1324
1319
1301 1400
1402
1305 1404
1310
1328
WiFi Way
1346
Networking
Lounge
1255
N Exhibitor
P
M Suite O
1159
1147
1218
1139
1133
1111
1200
Main Entrance
Entrance
session
41
tracker
#PTUPO$POWFOUJPOBOE&YIJCJUJPO$FOUFSMAP
Exhibit Hall
List of Exhibitors
BOOTH | EXHIBITOR
1011
4%"8/$MJOJDBM4PGUXBSF
1424
#JPYZEZO
224
CNK"3%3IFVNBUPMPHZ
329
5SBOT"UMBOUJD
$BSEJPWBTDVMBSSJTL
$BMDVMBUPSGPS3IFVNBUPJE
"SUISJUJT"5"$$3"
1133
#SJTUPM.ZFST4RVJCC
1525
#SJUJTI4PDJFUZGPS
3IFVNBUPMPHZ
655
$FMHFOF$PSQPSBUJPO
401
$FMMUSJPO)FBMUIDBSF$P-5%
1527
211,
919
"CC7JF
1218
"DUFMJPO1IBSNBDFVUJDBMT
301
"MFYJPO1IBSNBDFVUJDBMT
430
"NCJ.FE*OD
3
"NFSJDBO#PBSEPG*OUFSOBM
.FEJDJOF
11
"NFSJDBO$PMMFHFPG
1IZTJDJBOT"OOBMTPG
*OUFSOBM.FEJDJOF
943,
1111
"NHFO*OD
1159
"OUBSFT1IBSNB
6
"1-"3
304
"QSJDVT#JPTDJFODFT
743
"SUISJUJT'PVOEBUJPO
400
"35)304"OOVBM
3IFVNBUPMPHZ
5IFSBQFVUJDT3FWJFXGPS
0SHBOJ[BUJPOT4PDJFUJFT
1255
"TUSB;FOFDB
4
&VSPQFBO+PVSOBMPG
3IFVNBUPMPHZ
226
&VSPQFBO-FBHVF"HBJOTU
3IFVNBUJTN&6-"3
1529
&WFSJEJT)FBMUI4DJFODFT
514
&YBHFO%JBHOPTUJDT*OD
1557
'FEFSBUJPOPG$MJOJDBM
*NNVOPMPHZ4PDJFJUFT
'0$*4
$&4"4.FEJDBM
1013
'FSSJOH1IBSNBDFVUJDBMT*OD
$IVHBJ1IBSNBDFVUJDBM
$P-UE
1457
'JEJB1IBSNB64"*OD
447
203
'JOE"$PEF
325
$MFWFMBOE$MJOJD
302
Fresenius Kabi
1039
$MJOJDBMBOE&YQFSJNFOUBM
3IFVNBUPMPHZ
1301
'6+*'*-.4POP4JUF*OD
846
(&)FBMUIDBSF
421
(FOFOUFDI".FNCFSPG
UIF3PDIF(SPVQ
842
(FO[ZNFB4BOPöDPNQBOZ
1339,
1548
(MBYP4NJUI,MJOF
311
)BXBJJBO.PPO
229
)PSJ[PO1IBSNB*OD
1421
)PTQJSB
1546
*NBHF"OBMZTJT
511
*NNDP%JBHOPTUJDT"5SJOJUZ
#JPUFDI$PNQBOZ
1060
*OPWB%JBHOPTUJDT*OD
1138
$POUFYU.FEJB)FBMUI
959
$PSSPOB--$
649
$SFBMUB1IBSNBDFVUJDBMT
643
$SFTDFOEP#JPTDJFODF*OD
1058
%JQMPNBU4QFDJBMUZ
1IBSNBDZ
221
&EBO
1110
&MTFWJFS
510
&.%4FSPOP*OD
210
"VUPJNNVOF%JTFBTFT
"TTPDJBUJPO
315
&OPWBUJWF5FDIOPMPHJFT
1347
#BZFS)FBMUIDBSF
1447
&TBPUF/PSUI"NFSJDB
428
#FTTF.FEJDBM
327
&4$&0BTCM
2014 ACR /A R H P A n n u a l M e e t i n g
MAP #PTUPO$POWFOUJPOBOE&YIJCJUJPO$FOUFS
Exhibit Hall
List of Exhibitors
BOOTH | EXHIBITOR
410
JO1SBDUJDF3FTPVSDFT--$
9
.&5&03
1114
0TTVS"NFSJDBT
8
*OUFSOBUJPOBM'PVOEBUJPOGPS
"VUPJNNVOF"SUISJUJT
313
.FUSP.FEJDBM
1451
0UUP5SBEJOH*OD
1014
*OWFTUJHBUPS%BUBCBOL
1459
.JTTJPO1IBSNBDBM
$PNQBOZ
955
0YGPSE*NNVOPUFD
411
*SPLP1IBSNBDFVUJDBMT--$
1015
.JUFL4QPSUT.FEJDJOF
1012
0YGPSE6OJWFSTJUZ1SFTT
1139
+BOTTFO#JPUFDI*OD
726
.PEFSOJ[JOH.FEJDJOF
1402
1"*(&
911
+PIOT)PQLJOT
3IFVNBUPMPHZ
228
1"/-"3
+PVSOBMPG3IFVNBUPMPHZ
5IF
2
333
.PUIFS5P#BCZ1SFHOBODZ
Studies conducted by
0SHBOJ[BUJPOPG5FSBUPMPHZ
*OGPSNBUJPO4QFDJBMJTUT
10
1BUJFOU"DDFTT/FUXPSL
Foundation
1547
-B-FUUSF%V3IVNBUPMPHVF
&%*."3,4"/5&
639
1BUJFOU1PJOU¥
611
1ö[FS*OD
402
2*"(&/
513
2VFTU%JBHOPTUJDT
212
2VJOUJMFT
323
3+'BTFONZFS$FOUFSGPS
$MJOJDBM*NNVOPMPHZ
1551
3BJOUSFF4ZTUFNT*OD
631
3%-3FGFSFODF-BCPSBUPSZ
1147
3FHFOFSPO1IBSNBDFVUJDBMT
*OD
426
3IFVNB,OPXMFEHZ
1325
3IFVNBUPMPHZ/FXT
1054
3PUUBQIBSN-UE
424
.VMUJTQFDJBMUZ1IZTJDJBO
1BSUOFST
826
-BC$PSQ
414
NZ$.&
220
-FUUFSUP&EJUPS
3IFVNBUPMPHZ
321
/BUJPOBM%BUB#BOLGPS
3IFVNBUJD%JTFBTFT
1310,
1554
-JMMZ64"--$
319
/BUJPOBM*OTUJUVUFPG"SUISJUJT
BOE.VTDVMPTLFMFUBMBOE
Skin Diseases
1160
-JQP4DJFODF
457
.BMMJODLSPEU"VUPJNNVOF
3BSF%JTFBTFTGPSNFSMZ
2VFTUDPS
1519
/BUJPOBM+FXJTI)FBMUI
1
/BUJPOBM-JCSBSZPG.FEJDJOF
1404
.#-*OUFSOBUJPOBM
205
/BUJPOBM4DMFSPEFSNB$PSF
$FOUFST
610
.D,FTTPO4QFDJBMUZ)FBMUI
747
Neovacs
1521
.%$POGFSFODF&YQSFTT
1328,
"
,1329,
1429
/PWBSUJT1IBSNBDFVUJDBMT
$PSQPSBUJPO
1319
422
.FEBD1IBSNB*OD
.FEJ/BUVSB
418
/:6-BOHPOF.FEJDBM$FOUFS
/:6)PTQJUBMGPS+PJOU%JTFBTFT
session
tracker
#PTUPO$POWFOUJPOBOE&YIJCJUJPO$FOUFSMAP
Exhibit Hall
List of Exhibitors
BOOTH | EXHIBITOR
331
Scandinavian
+PVSOBMPG
3IFVNBUPMPHZ
232
4DMFSPEFSNB'PVOEBUJPO
13
4DMFSPEFSNB3FTFBSDI
Foundation
738
4*#0/&
432
4KÚHSFOT4ZOESPNF
Foundation
1055
4PCJ*OD
218
4QPOEZMJUJT"TTPDJBUJPOPG
"NFSJDB
1305
4QSJOHFS
439
6$#*OD
1200
5BLFEB1IBSNBDFVUJDBMT
64"*OD
222
6OJWFSTJUZPG"MBCBNBBU
#JSNJOHIBN
230
5IF(PVU6SJD"DJE
&EVDBUJPO4PDJFUZ
201
643IFVNBUPMPHZ
7
5IF.ZPTJUJT"TTPDJBUJPO
627
7BMVF#BTFE$BSFJO
3IFVNBUPMPHZ
1560
5IF3"$POOFDUJPO
5
7BTDVMJUJT'PVOEBUJPO
612
5IFSB5FTU-BCPSBUPSJFT*OD
1010
8JMFZ
1517
5POJY1IBSNBDFVUJDBMT
727
8PMUFST,MVXFS)FBMUI
614
54*)FBMUIDBSF
1400
;JNNFS
Introducing the
ACR/ARHP ANNUAL MEETING
2014 ACR/ARHP Annual Meeting App!
NOW
AI
AV LABLE!
DOWNLOADING THE APP IS EASY!
For iPhone, iPod Touch, and iPad users:
From your handheld device, go to the iTunes App Store and search “ACR 2014” or
“2014 ACR Annual Meeting” to locate the app. Click on the “free” button, which will
take you to the install screen. Next, download the 2014 ACR/ARHP Annual Meeting
App as you would any other application from the iTunes App Store. It’s that easy.
For BlackBerry, Android, and all other web-enabled
smartphones and tablets:
Point your device’s browser to m.core-apps.com/tristar_acr14. On this web-based
mobile site, you will be directed to the proper download version for your device type.
Scan this QR code using
your device’s barcode
scanner application for
easy download
ACR 2014
Supported by AbbVie, the 2014 ACR/ARHP Annual Meeting App is compatible with
iPhone, BlackBerry, and Android smartphones, as well as iPad and most tablets.
Get 24-hour access to unique, on-the-go meeting information, maps, and networking.
Features include:
3 Interactive program and course schedules
3 Customizable calendar and
itinerary builder
3 Exhibitor listings and booth map
3 Social media interaction
3 Meeting alerts
44 2014 ACR /A R H P A n n u a l M e e t i n g
Innovation Theater
dŚĞƐĞŶŽŶͲDĂĐĐƌĞĚŝƚĞĚƉƌĞƐĞŶƚĂƟŽŶƐŚĂǀĞďĞĞŶƉůĂŶŶĞĚĂŶĚǁŝůůďĞŝŵƉůĞŵĞŶƚĞĚǁŝƚŚƚŚĞƌĞƋƵŝƌĞŵĞŶƚƐŽĨƚŚĞ&
ĂŶĚĂƉƉůŝĐĂďůĞƐƚĂŶĚĂƌĚƐŽĨƚŚĞWŚZDŽĚĞŽŶ/ŶƚĞƌĂĐƟŽŶƐǁŝƚŚ,ĞĂůƚŚĐĂƌĞWƌŽĨĞƐƐŝŽŶĂůƐ͘
/ŶŶŽǀĂƟŽŶdŚĞĂƚĞƌ
/ŶŶŽǀĂƟŽŶdŚĞĂƚĞƌ
ĂĐŚŽĨƚŚĞĨŽůůŽǁŝŶŐ/ŶŶŽǀĂƟŽŶdŚĞĂƚĞƌƉƌĞƐĞŶƚĂƟŽŶƐǁŝůůďĞŚĞůĚ
in džŚŝďŝƚ,Ăůů;ŽŽƚŚηϭϯϵͿ͘
ĂĐŚŽĨƚŚĞĨŽůůŽǁŝŶŐ/ŶŶŽǀĂƟŽŶdŚĞĂƚĞƌƉƌĞƐĞŶƚĂƟŽŶƐǁŝůůďĞŚĞůĚ
in džŚŝďŝƚ,Ăůů;ŽŽƚŚηϭϰϬϭͿ͘
^hEz͕EKsDZϭϲ͕ϮϬϭϰ
^hEz͕EKsDZϭϲ͕ϮϬϭϰ
ϭϬ͗ϯϬͲϭϭ͗ϭϱƒÃ
ϭϭ͗ϯϬƒÃͲϭϮ͗ϭϱÖÃ
hŶĚĞƌƐƚĂŶĚŝŶŐĂŶ/ŶĨƵƐŝŽŶdŚĞƌĂƉLJŝŶƚŚĞh͘^͘,ĞĂůƚŚĐĂƌĞ
^LJƐƚĞŵ͗&ŽĐƵƐŽŶīŽƌĚĂďŝůŝƚLJ
dŚĞZŽůĞŽĨ/>ͲϲŝŶZŚĞƵŵĂƚŽŝĚƌƚŚƌŝƟƐ͗tŚĂƚ,ĂǀĞtĞ
>ĞĂƌŶĞĚ^ŽĨĂƌ͍
WƌĞƐĞŶƚĞĚďLJ:ĂŶƐƐĞŶŝŽƚĞĐŚ͕/ŶĐ͘
WƌĞƐĞŶƚĞĚďLJZĞŐĞŶĞƌŽŶWŚĂƌŵĂĐĞƵƟĐĂůƐ
ϭϮ͗ϯϬͲϭ͗ϭϱÖÃ
ϭ͗ϯϬͲϮ͗ϭϱÖÃ
First in a New Class of JAK Inhibitors for the Treatment of
DŽĚĞƌĂƚĞƚŽ^ĞǀĞƌĞZŚĞƵŵĂƚŽŝĚƌƚŚƌŝƟƐ
tŚĞŶ/ƐƚŚĞZŝŐŚƚdŝŵĞĨŽƌKZE/Π;ĂďĂƚĂĐĞƉƚͿ͍
WƌĞƐĞŶƚĞĚďLJWĮnjĞƌ͕/ŶĐ͘
WƌĞƐĞŶƚĞĚďLJƌŝƐƚŽůͲDLJĞƌƐ^ƋƵŝďď
ϯ͗ϯϬͲϰ͗ϭϱÖÃ
Ϯ͗ϯϬͲϯ͗ϭϱÖÃ
ϮϬϭϰhƉĚĂƚĞ͗džĂŵŝŶŝŶŐƚŚĞdƌĞĂƚŵĞŶƚWĂƌĂĚŝŐŵŝŶZ
KƚĞnjůĂΠ;ĂƉƌĞŵŝůĂƐƚͿĨŽƌƚŚĞdƌĞĂƚŵĞŶƚŽĨĚƵůƚƐtŝƚŚĐƟǀĞ
WƐŽƌŝĂƟĐƌƚŚƌŝƟƐ
WƌĞƐĞŶƚĞĚďLJDĞĚĂĐWŚĂƌŵĂ͕/ŶĐ͘
WƌĞƐĞŶƚĞĚďLJĞůŐĞŶĞŽƌƉŽƌĂƟŽŶ
DKEz͕EKsDZϭϳ͕ϮϬϭϰ
DKEz͕EKsDZϭϳ͕ϮϬϭϰ
ϭϬ͗ϯϬͲϭϭ͗ϭϱƒÃ
ZŝƚƵdžĂŶΠ;ƌŝƚƵdžŝŵĂďͿĨŽƌƚŚĞdƌĞĂƚŵĞŶƚŽĨ'ƌĂŶƵůŽŵĂƚŽƐŝƐ
tŝƚŚWŽůLJĂŶŐŝŝƟƐ;'WͿĂŶĚDŝĐƌŽƐĐŽƉŝĐWŽůLJĂŶŐŝŝƟƐ;DWͿ
ǁŝƚŚhƉĚĂƚĞĚĂƚĂĨŽƌ'WͬDW
WƌĞƐĞŶƚĞĚďLJ'ĞŶĞŶƚĞĐŚ͕ĂDĞŵďĞƌŽĨƚŚĞZŽĐŚĞ'ƌŽƵƉ
ϭϭ͗ϯϬƒÃͲϭϮ͗ϭϱÖÃ
sĞĐƚƌĂΠ͗ĞƩĞƌDĞĂƐƵƌĞĨŽƌWƌĞĚŝĐƟŶŐZĂĚŝŽŐƌĂƉŚŝĐ
WƌŽŐƌĞƐƐŝŽŶŝŶZŚĞƵŵĂƚŽŝĚƌƚŚƌŝƟƐ͍
WƌĞƐĞŶƚĞĚďLJƌĞƐĐĞŶĚŽŝŽƐĐŝĞŶĐĞ͕/ŶĐ͘
ϭ͗ϯϬͲϮ͗ϭϱÖÃ
ϭϮ͗ϯϬͲϭ͗ϭϱÖÃ
ZŚĞƵŵĂƚŽůŽŐŝƐƚƐ͛WĞƌƐƉĞĐƟǀĞƐŽŶƚŚĞŝĂŐŶŽƐŝƐ
and Treatment of CAPS and SJIA
^ĞƌŝŽƵƐ/ŶĨĞĐƟŽŶƐŝŶDŽĚĞƌĂƚĞůLJƚŽ^ĞǀĞƌĞůLJĐƟǀĞ
ZŚĞƵŵĂƚŽŝĚƌƚŚƌŝƟƐ͗,ĞƉĂƟƟƐZĞĂĐƟǀĂƟŽŶ
WƌĞƐĞŶƚĞĚďLJEŽǀĂƌƟƐWŚĂƌŵĂĐĞƵƟĐĂůƐ
WƌĞƐĞŶƚĞĚďLJŵŐĞŶ͕/ŶĐ͘
Ϯ͗ϯϬͲϯ͗ϭϱÖÃ
ϯ͗ϯϬͲϰ͗ϭϱÖÃ
dŚĞEĞǁƌĂŽĨŝŽůŽŐŝĐdŚĞƌĂƉLJŝŶZŚĞƵŵĂƚŽůŽŐLJ
WƌĞƐĞŶƚĞĚďLJĞůůƚƌŝŽŶ,ĞĂůƚŚĐĂƌĞŽ͕͘>d͘
dŚĞhƌŝĐĐŝĚ:ŽƵƌŶĞLJ͗&ƌŽŵWƵƌŝŶĞƚŽƌLJƐƚĂů
WƌĞƐĞŶƚĞĚďLJƐƚƌĂĞŶĞĐĂ
dh^z͕EKsDZϭϴ͕ϮϬϭϰ
dh^z͕EKsDZϭϴ͕ϮϬϭϰ
ϭϬ͗ϯϬͲϭϭ͗ϭϱƒÃ
hŶĚĞƌƐƚĂŶĚŝŶŐƚŚĞZŽůĞŽĨƚŚĞ/>ͲϭϳZĞĐĞƉƚŽƌĂŶĚLJƚŽŬŝŶĞƐŝŶ
WƐŽƌŝĂƟĐƌƚŚƌŝƟƐ
WƌĞƐĞŶƚĞĚďLJŵŐĞŶ͕/ŶĐ͘
ϭϭ͗ϯϬͲϭϮ͗ϭϱƒÃ
^ĞƌƵŵϭϰͲϯͲϯɻ͗EŽǀĞůDĞĐŚĂŶŝƐƟĐŝŽŵĂƌŬĞƌŶĂďůĞƐĂDŽƌĞ
ĐĐƵƌĂƚĞĂŶĚĂƌůŝĞƌŝĂŐŶŽƐŝƐŽĨZ
WƌĞƐĞŶƚĞĚďLJYƵĞƐƚŝĂŐŶŽƐƟĐƐ
ϭ͗ϯϬͲϮ͗ϭϱÖÃ
ϭϮ͗ϭϱͲϭ͗ϬϬÖÃ
ĚǀĂŶĐŝŶŐƚŚĞ^ĐŝĞŶĐĞŽĨŶĂůŐĞŶƐŝĂtŝƚŚ^ŽůƵDĂƚƌŝdžΠE^/Ɛ
ĞŵLJƐƟĨLJŝŶŐŝŽƐŝŵŝůĂƌƐŝŶZŚĞƵŵĂƚŽůŽŐLJ
^ŽůƵDĂƚƌŝdžΠŝƐĂƚƌĂĚĞŵĂƌŬŽĨŝĞƵƟĐĂWƚLJ>ƚĚĂŶĚŝƐůŝĐĞŶƐĞĚƚŽ/ƌŽŬŽ͘
WƌĞƐĞŶƚĞĚďLJWĮnjĞƌ͕/ŶĐ͘
WƌĞƐĞŶƚĞĚďLJ/ƌŽŬŽWŚĂƌŵĂĐĞƵƟĐĂůƐ͕>>
45
Enbrel® (etanercept) Brief Summary
SEE PACKAGE INSERT FOR FULL PRESCRIBING INFORMATION
WARNINGS
SERIOUS INFECTIONS AND MALIGNANCIES
Patients treated with Enbrel are at increased risk for developing
serious infections that may lead to hospitalization or death [see
Warnings and Precautions and Adverse Reactions]. Most
patients who developed these infections were taking
concomitant immunosuppressants such as methotrexate or
corticosteroids.
Enbrel should be discontinued if a patient develops a serious
infection or sepsis.
Reported infections include:
I Active tuberculosis, including reactivation of latent
tuberculosis. Patients with tuberculosis have frequently
presented with disseminated or extrapulmonary disease.
Patients should be tested for latent tuberculosis before
Enbrel use and during therapy. Treatment for latent infection
should be initiated prior to Enbrel use.
I Invasive fungal infections, including histoplasmosis,
coccidioidomycosis,
candidiasis,
aspergillosis,
blastomycosis, and pneumocystosis. Patients with
histoplasmosis or other invasive fungal infections may
present with disseminated, rather than localized, disease.
Antigen and antibody testing for histoplasmosis may be
negative in some patients with active infection. Empiric antifungal therapy should be considered in patients at risk for
invasive fungal infections who develop severe systemic
illness.
I Bacterial, viral, and other infections due to opportunistic
pathogens, including Legionella and Listeria.
The risks and benefits of treatment with Enbrel should be
carefully considered prior to initiating therapy in patients with
chronic or recurrent infection.
Patients should be closely monitored for the development of
signs and symptoms of infection during and after treatment
with Enbrel, including the possible development of tuberculosis
in patients who tested negative for latent tuberculosis infection
prior to initiating therapy.
MALIGNANCIES
Lymphoma and other malignancies, some fatal, have been
reported in children and adolescent patients treated with TNF
blockers, including Enbrel.
INDICATIONS AND USAGE
Rheumatoid Arthritis
Enbrel is indicated for reducing signs and symptoms, inducing major clinical
response, inhibiting the progression of structural damage, and improving
physical function in patients with moderately to severely active rheumatoid
arthritis (RA). Enbrel can be initiated in combination with methotrexate
(MTX) or used alone.
Polyarticular Juvenile Idiopathic Arthritis
Enbrel is indicated for reducing signs and symptoms of moderately to
severely active polyarticular juvenile idiopathic arthritis (JIA) in patients
ages 2 and older.
Psoriatic Arthritis
Enbrel is indicated for reducing signs and symptoms, inhibiting the
progression of structural damage of active arthritis, and improving physical
function in patients with psoriatic arthritis (PsA). Enbrel can be used in
combination with methotrexate (MTX) in patients who do not respond
adequately to MTX alone.
Ankylosing Spondylitis
Enbrel is indicated for reducing signs and symptoms in patients with active
ankylosing spondylitis (AS).
Plaque Psoriasis
Enbrel is indicated for the treatment of adult patients (18 years or older) with
chronic moderate to severe plaque psoriasis (PsO) who are candidates for
systemic therapy or phototherapy.
CONTRAINDICATIONS
Enbrel should not be administered to patients with sepsis.
WARNINGS AND PRECAUTIONS
Serious Infections
Patients treated with Enbrel are at increased risk for developing serious
infections involving various organ systems and sites that may lead to
hospitalization or death.
Opportunistic infections due to bacterial, mycobacterial, invasive fungal,
viral, parasitic, or other opportunistic pathogens including aspergillosis,
blastomycosis,
candidiasis,
coccidioidomycosis,
histoplasmosis,
legionellosis, listeriosis, pneumocystosis, and tuberculosis have been
reported with TNF blockers. Patients have frequently presented with
disseminated rather than localized disease.
Treatment with Enbrel should not be initiated in patients with an active
infection, including clinically important localized infections. Patients greater
than 65 years of age, patients with co-morbid conditions, and/or patients
taking concomitant immunosuppressants (such as corticosteroids or
methotrexate), may be at greater risk of infection. The risks and benefits of
treatment should be considered prior to initiating therapy in patients: with
chronic or recurrent infection; who have been exposed to tuberculosis; with
a history of an opportunistic infection; who have resided or traveled in areas
of endemic tuberculosis or endemic mycoses, such as histoplasmosis,
coccidioidomycosis, or blastomycosis; or with underlying conditions that
may predispose them to infection, such as advanced or poorly controlled
diabetes [see Adverse Reactions].
Patients should be closely monitored for the development of signs and
symptoms of infection during and after treatment with Enbrel.
Enbrel should be discontinued if a patient develops a serious infection or
sepsis. A patient who develops a new infection during treatment with Enbrel
should be closely monitored, undergo a prompt and complete diagnostic
workup appropriate for an immunocompromised patient, and appropriate
antimicrobial therapy should be initiated.
Tuberculosis
Cases of reactivation of tuberculosis or new tuberculosis infections have
been observed in patients receiving Enbrel, including patients who have
previously received treatment for latent or active tuberculosis. Data from
clinical trials and preclinical studies suggest that the risk of reactivation of
latent tuberculosis infection is lower with Enbrel than with TNF-blocking
monoclonal antibodies. Nonetheless, postmarketing cases of tuberculosis
reactivation have been reported for TNF blockers, including Enbrel.
Tuberculosis has developed in patients who tested negative for latent
tuberculosis prior to initiation of therapy. Patients should be evaluated for
tuberculosis risk factors and tested for latent infection prior to initiating
Enbrel and periodically during therapy. Tests for latent tuberculosis infection
may be falsely negative while on therapy with Enbrel.
Treatment of latent tuberculosis infection prior to therapy with TNF-blocking
agents has been shown to reduce the risk of tuberculosis reactivation during
therapy. Induration of 5 mm or greater with tuberculin skin testing should be
considered a positive test result when assessing if treatment for latent
tuberculosis is needed prior to initiating Enbrel, even for patients previously
vaccinated with Bacille Calmette-Guerin (BCG).
Anti-tuberculosis therapy should also be considered prior to initiation of
Enbrel in patients with a past history of latent or active tuberculosis in whom
an adequate course of treatment cannot be confirmed, and for patients with
a negative test for latent tuberculosis but having risk factors for tuberculosis
infection. Consultation with a physician with expertise in the treatment of
tuberculosis is recommended to aid in the decision whether initiating antituberculosis therapy is appropriate for an individual patient.
Tuberculosis should be strongly considered in patients who develop a new
infection during Enbrel treatment, especially in patients who have previously
or recently traveled to countries with a high prevalence of tuberculosis, or
who have had close contact with a person with active tuberculosis.
Invasive Fungal Infections
Cases of serious and sometimes fatal fungal infections, including
histoplasmosis, have been reported with TNF blockers, including Enbrel.
For patients who reside or travel in regions where mycoses are endemic,
invasive fungal infection should be suspected if they develop a serious
systemic illness. Appropriate empiric antifungal therapy should be
considered while a diagnostic workup is being performed. Antigen and
antibody testing for histoplasmosis may be negative in some patients
with active infection. When feasible, the decision to administer empiric
antifungal therapy in these patients should be made in consultation with
a physician with expertise in the diagnosis and treatment of invasive
fungal infections and should take into account both the risk for severe
fungal infection and the risks of antifungal therapy. In 38 Enbrel clinical
trials and 4 cohort studies in all approved indications representing
27,169 patient-years of exposure (17,696 patients) from the United
States and Canada, no histoplasmosis infections were reported among
patients treated with Enbrel.
Neurologic Events
Treatment with TNF-blocking agents, including Enbrel, has been associated
with rare (< 0.1%) cases of new onset or exacerbation of central nervous
system demyelinating disorders, some presenting with mental status
changes and some associated with permanent disability. Cases of
transverse myelitis, optic neuritis, multiple sclerosis, Guillain-Barré
syndromes, other peripheral demyelinating neuropathies, and new onset or
exacerbation of seizure disorders have been reported in postmarketing
experience with Enbrel therapy. Prescribers should exercise caution in
considering the use of Enbrel in patients with preexisting or recent-onset
central or peripheral nervous system demyelinating disorders [see Adverse Reactions].
Malignancies
Lymphomas
In the controlled portions of clinical trials of TNF-blocking agents, more
cases of lymphoma have been observed among patients receiving a TNF
blocker compared to control patients. During the controlled portions of
Enbrel trials in adult patients with RA, AS, and PsA, 2 lymphomas were
observed among 3306 Enbrel-treated patients versus 0 among 1521 control
patients (duration of controlled treatment ranged from 3 to 36 months).
Among 6543 adult rheumatology (RA, PsA, AS) patients treated with Enbrel
in controlled and uncontrolled portions of clinical trials, representing
approximately 12,845 patient-years of therapy, the observed rate of
lymphoma was 0.10 cases per 100 patient-years. This was 3-fold higher
than the rate of lymphoma expected in the general US population based on
the Surveillance, Epidemiology, and End Results (SEER) Database. An
increased rate of lymphoma up to several-fold has been reported in the RA
patient population, and may be further increased in patients with more
severe disease activity.
Among 4410 adult PsO patients treated with Enbrel in clinical trials up to 36
months, representing approximately 4278 patient-years of therapy, the
observed rate of lymphoma was 0.05 cases per 100 patient-years, which is
comparable to the rate in the general population. No cases were observed in
Enbrel- or placebo-treated patients during the controlled portions of these trials.
Leukemia
Cases of acute and chronic leukemia have been reported in association with
postmarketing TNF-blocker use in rheumatoid arthritis and other
indications. Even in the absence of TNF-blocker therapy, patients with
rheumatoid arthritis may be at higher risk (approximately 2-fold) than the
general population for the development of leukemia.
During the controlled portions of Enbrel trials, 2 cases of leukemia were
observed among 5445 (0.06 cases per 100 patient-years) Enbrel-treated
patients versus 0 among 2890 (0%) control patients (duration of controlled
treatment ranged from 3 to 48 months).
Among 15,401 patients treated with Enbrel in controlled and open portions
of clinical trials representing approximately 23,325 patient-years of therapy,
the observed rate of leukemia was 0.03 cases per 100 patient-years.
Other Malignancies
Information is available from 10,953 adult patients with 17,123 patientyears and 696 pediatric patients with 1282 patient-years of experience
across 45 Enbrel clinical studies.
For malignancies other than lymphoma and non-melanoma skin cancer,
there was no difference in exposure-adjusted rates between the Enbrel and
control arms in the controlled portions of clinical studies for all indications.
Analysis of the malignancy rate in combined controlled and uncontrolled
portions of studies has demonstrated that types and rates are similar to
what is expected in the general US population based on the SEER database
and suggests no increase in rates over time. Whether treatment with Enbrel
might influence the development and course of malignancies in adults is
unknown.
Melanoma and Non-melanoma skin cancer (NMSC)
Melanoma and non-melanoma skin cancer has been reported in patients
treated with TNF antagonists including etanercept.
Among 15,401 patients treated with Enbrel in controlled and open portions
of clinical trials representing approximately 23,325 patient-years of therapy,
the observed rate of melanoma was 0.043 cases per 100 patient-years.
Among 3306 adult rheumatology (RA, PsA, AS) patients treated with Enbrel
in controlled clinical trials representing approximately 2669 patient-years of
therapy, the observed rate of NMSC was 0.41 cases per 100 patient-years
vs 0.37 cases per 100 patient-years among 1521 control-treated patients
representing 1077 patient-years. Among 1245 adult psoriasis patients
treated with Enbrel in controlled clinical trials, representing approximately
283 patient-years of therapy, the observed rate of NMSC was 3.54 cases
per 100 patient-years vs 1.28 cases per 100 patient-years among 720
control-treated patients representing 156 patient-years.
Postmarketing cases of Merkel cell carcinoma have been reported very
infrequently in patients treated with Enbrel.
Periodic skin examinations should be considered for all patients at increased
risk for skin cancer.
Pediatric Patients
Malignancies, some fatal, have been reported among children, adolescents,
and young adults who received treatment with TNF-blocking agents
(initiation of therapy at ≤ 18 years of age), including Enbrel. Approximately
half the cases were lymphomas, including Hodgkin’s and non-Hodgkin’s
lymphoma. The other cases represented a variety of different malignancies
and included rare malignancies usually associated with immunosuppression
and malignancies that are not usually observed in children and adolescents.
The malignancies occurred after a median of 30 months of therapy (range 1
to 84 months). Most of the patients were receiving concomitant
immunosuppressants. These cases were reported postmarketing and are
derived from a variety of sources, including registries and spontaneous
postmarketing reports.
In clinical trials of 1140 pediatric patients representing 1927.2 patient-years
of therapy, no malignancies, including lymphoma or NMSC, have been
reported.
Postmarketing Use
In global postmarketing adult and pediatric use, lymphoma and other
malignancies have been reported.
Patients With Heart Failure
Two clinical trials evaluating the use of Enbrel in the treatment of heart
failure were terminated early due to lack of efficacy. One of these studies
suggested higher mortality in Enbrel-treated patients compared to placebo
[see Adverse Reactions]. There have been postmarketing reports of
worsening of congestive heart failure (CHF), with and without identifiable
precipitating factors, in patients taking Enbrel. There have also been rare
(< 0.1%) reports of new onset CHF, including CHF in patients without known
preexisting cardiovascular disease. Some of these patients have been under
50 years of age. Physicians should exercise caution when using Enbrel in
patients who also have heart failure, and monitor patients carefully.
Hematologic Events
Rare (< 0.1%) reports of pancytopenia, including very rare (< 0.01%) reports
of aplastic anemia, some with a fatal outcome, have been reported in
patients treated with Enbrel. The causal relationship to Enbrel therapy
remains unclear. Although no high-risk group has been identified, caution
should be exercised in patients being treated with Enbrel who have a
previous history of significant hematologic abnormalities. All patients should
be advised to seek immediate medical attention if they develop signs and
symptoms suggestive of blood dyscrasias or infection (eg, persistent fever,
bruising, bleeding, pallor) while on Enbrel. Discontinuation of Enbrel therapy
should be considered in patients with confirmed significant hematologic
abnormalities.
Two percent of patients treated concurrently with Enbrel and anakinra
developed neutropenia (ANC < 1 x 10 9/L). While neutropenic, one patient
developed cellulitis that resolved with antibiotic therapy.
Hepatitis B Reactivation
Reactivation of hepatitis B in patients who were previously infected with the
hepatitis B virus (HBV) and had received concomitant TNF-blocking agents,
including very rare cases (< 0.01%) with Enbrel, has been reported. In some
instances, hepatitis B reactivation occurring in conjunction with TNFblocker therapy has been fatal. The majority of these reports have occurred
in patients concomitantly receiving other medications that suppress the
immune system, which may also contribute to hepatitis B reactivation.
Patients at risk for HBV infection should be evaluated for prior evidence of
HBV infection before initiating TNF-blocker therapy. Prescribers should
exercise caution in prescribing TNF blockers in patients previously infected
with HBV. Adequate data are not available on the safety or efficacy of
treating patients who are carriers of HBV with anti-viral therapy in
conjunction with TNF-blocker therapy to prevent HBV reactivation. Patients
previously infected with HBV and require treatment with Enbrel should be
closely monitored for clinical and laboratory signs of active HBV infection
throughout therapy and for several months following termination of therapy.
In patients who develop HBV reactivation, consideration should be given to
stopping Enbrel and initiating anti-viral therapy with appropriate supportive
treatment. The safety of resuming Enbrel therapy after HBV reactivation is
controlled is not known. Therefore, prescribers should weigh the risks and
benefits when considering resumption of therapy in this situation.
Allergic Reactions
Allergic reactions associated with administration of Enbrel during clinical
trials have been reported in < 2% of patients. If an anaphylactic reaction or
other serious allergic reaction occurs, administration of Enbrel should be
discontinued immediately and appropriate therapy initiated.
Caution: The following components contain dry natural rubber (a derivative
of latex), which may cause allergic reactions in individuals sensitive to latex:
the needle cover of the prefilled syringe and the needle cover within the
needle cap of the SureClick® autoinjector.
Immunizations
Live vaccines should not be given concurrently with Enbrel. It is
recommended that pediatric patients, if possible, be brought up-to-date
with all immunizations in agreement with current immunization guidelines
prior to initiating Enbrel therapy [see Drug Interactions].
Autoimmunity
Treatment with Enbrel may result in the formation of autoantibodies [see
Adverse Reactions] and, rarely (< 0.1%), in the development of a lupus-like
syndrome or autoimmune hepatitis [see Adverse Reactions], which may
resolve following withdrawal of Enbrel. If a patient develops symptoms and
findings suggestive of a lupus-like syndrome or autoimmune hepatitis
following treatment with Enbrel, treatment should be discontinued and the
patient should be carefully evaluated.
Immunosuppression
TNF mediates inflammation and modulates cellular immune responses.
TNF-blocking agents, including Enbrel, affect host defenses against
infections. The effect of TNF inhibition on the development and course of
malignancies is not fully understood. In a study of 49 patients with RA
treated with Enbrel, there was no evidence of depression of delayed-type
hypersensitivity, depression of immunoglobulin levels, or change in
enumeration of effector cell populations [see Adverse Reactions].
Use in Wegener’s Granulomatosis Patients
The use of Enbrel in patients with Wegener’s granulomatosis receiving
immunosuppressive agents is not recommended. In a study of patients with
Wegener’s granulomatosis, the addition of Enbrel to standard therapy
(including cyclophosphamide) was associated with a higher incidence of non
cutaneous solid malignancies and was not associated with improved clinical
outcomes when compared with standard therapy alone [see Drug
Interactions].
Use with Anakinra or Abatacept
Use of Enbrel with anakinra or abatacept is not recommended [see
Drug Interactions].
Use in Patients with Moderate to Severe Alcoholic Hepatitis
In a study of 48 hospitalized patients treated with Enbrel or placebo for
moderate to severe alcoholic hepatitis, the mortality rate in patients treated
with Enbrel was similar to patients treated with placebo at 1 month but
significantly higher after 6 months. Physicians should use caution when
using Enbrel in patients with moderate to severe alcoholic hepatitis.
ADVERSE REACTIONS
Across clinical studies and postmarketing experience, the most serious
adverse reactions with Enbrel were infections, neurologic events, CHF, and
hematologic events [see Warnings and Precautions]. The most common
adverse reactions with Enbrel were infections and injection site reactions.
Other Adverse Reactions
Table 3 summarizes adverse reactions reported in adult RA patients. The
types of adverse reactions seen in patients with PsA or AS were similar to
the types of adverse reactions seen in patients with RA.
Table 3. Percent of Adult RA Patients Experiencing Adverse
Reactions in Controlled Clinical Trials
Placebo Controlleda
(Studies I, II, and a
Phase 2 Study)
Clinical Studies Experience
Adverse Reactions in Adult Patients With Rheumatoid Arthritis, Psoriatic
Arthritis, Ankylosing Spondylitis, or Plaque Psoriasis
The data described below reflect exposure to Enbrel in 2219 adult patients
with RA followed for up to 80 months, in 182 patients with PsA for up to 24
months, in 138 patients with AS for up to 6 months, and in 1204 adult
patients with PsO for up to 18 months.
In controlled trials, the proportion of Enbrel-treated patients who
discontinued treatment due to adverse events was approximately 4% in the
indications studied.
Because clinical trials are conducted under widely varying conditions,
adverse reactions rates observed in the clinical trials of a drug cannot be
directly compared to rates in the clinical trials of another drug and may not
predict the rates observed in clinical practice.
Infections
Infections, including viral, bacterial, and fungal infections, have been
observed in adult and pediatric patients. Infections have been noted in all
body systems and have been reported in patients receiving Enbrel alone or
in combination with other immunosuppressive agents.
In controlled portions of trials, the types and severity of infection were
similar between Enbrel and the respective control group (placebo or MTX for
RA and PsA patients) in RA, PsA, AS and PsO patients. Rates of infections in
RA and PsO patients are provided in Table 3 and Table 4, respectively.
Infections consisted primarily of upper respiratory tract infection, sinusitis
and influenza.
In controlled portions of trials in RA, PsA, AS and PsO, the rates of serious
infection were similar (0.8% in placebo, 3.6% in MTX, and 1.4% in Enbrel/
Enbrel + MTX-treated groups). In clinical trials in rheumatologic indications,
serious infections experienced by patients have included, but are not limited
to, pneumonia, cellulitis, septic arthritis, bronchitis, gastroenteritis,
pyelonephritis, sepsis, abscess and osteomyelitis. In clinical trials in PsO,
serious infections experienced by patients have included, but are not limited
to, pneumonia, cellulitis, gastroenteritis, abscess and osteomyelitis. The
rate of serious infections was not increased in open-label extension trials
and was similar to that observed in Enbrel- and placebo-treated patients
from controlled trials.
In 66 global clinical trials of 17,505 patients (21,015 patient-years of
therapy), tuberculosis was observed in approximately 0.02% of patients. In
17,696 patients (27,169 patient-years of therapy) from 38 clinical trials and
4 cohort studies in the US and Canada, tuberculosis was observed in
approximately 0.006% of patients. These studies include reports of
pulmonary and extrapulmonary tuberculosis [see Warnings and
Precautions].
Injection Site Reactions
In placebo-controlled trials in rheumatologic indications, approximately
37% of patients treated with Enbrel developed injection site reactions. In
controlled trials in patients with PsO, 15% of patients treated with Enbrel
developed injection site reactions during the first 3 months of treatment. All
injection site reactions were described as mild to moderate (erythema,
itching, pain, swelling, bleeding, bruising) and generally did not necessitate
drug discontinuation. Injection site reactions generally occurred in the first
month and subsequently decreased in frequency. The mean duration of
injection site reactions was 3 to 5 days. Seven percent of patients
experienced redness at a previous injection site when subsequent injections
were given.
Immunogenicity
Patients with RA, PsA, AS or PsO were tested at multiple time points for
antibodies to etanercept. Antibodies to the TNF receptor portion or other
protein components of the Enbrel drug product were detected at least once
in sera of approximately 6% of adult patients with RA, PsA, AS or PsO. These
antibodies were all non-neutralizing. Results from JIA patients were similar
to those seen in adult RA patients treated with Enbrel.
In PsO studies that evaluated the exposure of etanercept for up to 120
weeks, the percentage of patients testing positive at the assessed time
points of 24, 48, 72 and 96 weeks ranged from 3.6%–8.7% and were all
non-neutralizing. The percentage of patients testing positive increased with
an increase in the duration of study; however, the clinical significance of this
finding is unknown. No apparent correlation of antibody development to
clinical response or adverse events was observed. The immunogenicity data
of Enbrel beyond 120 weeks of exposure are unknown.
The data reflect the percentage of patients whose test results were
considered positive for antibodies to etanercept in an ELISA assay, and are
highly dependent on the sensitivity and specificity of the assay. Additionally,
the observed incidence of any antibody positivity in an assay is highly
dependent on several factors, including assay sensitivity and specificity,
assay methodology, sample handling, timing of sample collection,
concomitant medications, and underlying disease. For these reasons,
comparison of the incidence of antibodies to etanercept with the incidence
of antibodies to other products may be misleading.
Autoantibodies
Patients with RA had serum samples tested for autoantibodies at multiple
time points. In RA Studies I and II, the percentage of patients evaluated for
antinuclear antibodies (ANA) who developed new positive ANA (titer ≥ 1:40)
was higher in patients treated with Enbrel (11%) than in placebo-treated
patients (5%). The percentage of patients who developed new positive antidouble-stranded DNA antibodies was also higher by radioimmunoassay
(15% of patients treated with Enbrel compared to 4% of placebo-treated
patients) and by Crithidia luciliae assay (3% of patients treated with Enbrel
compared to none of placebo-treated patients). The proportion of patients
treated with Enbrel who developed anticardiolipin antibodies was similarly
increased compared to placebo-treated patients. In RA Study III, no pattern
of increased autoantibody development was seen in Enbrel patients
compared to MTX patients [see Warnings and Precautions].
Placebo
(N = 152)
Reaction
Enbrelc
(N = 349)
Percent of Patients
Infectiond (total)
Upper Respiratory
Infectionse
Non-upper Respiratory
Infections
Injection Site
Reactions
Diarrhea
Rash
Pruritus
Pyrexia
Urticaria
Hypersensitivity
Active Controlledb
(Study III)
MTX
(N = 217)
Enbrelc
(N = 415)
Percent of Patients
39
30
50
38
86
70
81
65
15
21
59
54
11
37
18
43
9
2
1
–
1
–
8
3
2
3
–
–
16
19
5
4
4
1
16
13
5
2
2
1
a
Includes data from the 6-month study in which patients received
concurrent MTX therapy in both arms.
Study duration of 2 years.
Any dose.
d
Includes bacterial, viral, and fungal infections.
e
Most frequent Upper Respiratory Infections were upper respiratory
tract infection, sinusitis, and influenza.
b
c
In placebo-controlled PsO trials, the percentages of patients reporting
adverse reactions in the 50 mg twice a week dose group were similar to
those observed in the 25 mg twice a week dose group or placebo group.
Table 4 summarizes adverse reactions reported in adult PsO patients from
Studies I and II.
Table 4. Percent of Adult PsO Patients Experiencing Adverse
Reactions in Placebo-Controlled Portions of Clinical Trials
(Studies I & II)
Placebo
(N = 359)
Enbrela
(N = 876)
Reaction
Percent of Patients
Infectionb (total)
Non-upper Respiratory
Infections
Upper Respiratory
Infectionsc
Injection Site
Reactions
Diarrhea
Rash
Pruritus
Urticaria
Hypersensitivity
Pyrexia
28
14
a
27
12
17
17
6
15
2
1
2
–
–
1
3
1
1
1
1
–
Includes 25 mg SC QW, 25 mg SC BIW, 50 mg SC QW, and 50 mg SC
BIW doses.
Includes bacterial, viral and fungal infections.
Most frequent Upper Respiratory Infections were upper respiratory
tract infection, nasopharyngitis and sinusitis.
b
c
Adverse Reactions in Pediatric Patients
In general, the adverse reactions in pediatric patients were similar in
frequency and type as those seen in adult patients [see Warnings and
Precautions]. The types of infections reported in pediatric patients were
generally mild and consistent with those commonly seen in the general
pediatric population. Two JIA patients developed varicella infection and
signs and symptoms of aseptic meningitis, which resolved without
sequelae.
In open-label clinical studies of children with JIA, adverse reactions
reported in those ages 2 to 4 years were similar to adverse reactions
reported in older children.
Postmarketing Experience
Adverse reactions have been reported during post approval use of Enbrel
in adults and pediatric patients. Because these reactions are reported
voluntarily from a population of uncertain size, it is not always possible
to reliably estimate their frequency or establish a causal relationship to
Enbrel exposure.
Adverse reactions are listed by body system below:
Blood and lymphatic
pancytopenia, anemia,
system disorders:
leukopenia, neutropenia,
thrombocytopenia, lymphadenopathy,
aplastic anemia [see Warnings
and Precautions]
Cardiac disorders:
congestive heart failure [see Warnings
and Precautions]
Gastrointestinal disorders:
inflammatory bowel disease (IBD)
General disorders:
angioedema, chest pain
Hepatobiliary disorders:
autoimmune hepatitis, elevated
transaminases, hepatitis B reactivation
Immune disorders:
macrophage activation syndrome,
systemic vasculitis
Musculoskeletal and
lupus-like syndrome
connective tissue disorders:
Neoplasms benign,
melanoma and non-melanoma skin
malignant, and unspecified:
cancers, merkel cell carcinoma
[see Warnings and Precautions]
Nervous system disorders:
convulsions, multiple sclerosis,
demyelination, optic neuritis, transverse
myelitis, paresthesias [see Warnings
and Precautions]
Ocular disorders:
uveitis, scleritis
Respiratory, thoracic
interstitial lung disease
and mediastinal disorders:
Skin and subcutaneous
tissue disorders:
cutaneous lupus erythematous, cutaneous
vasculitis (including leukocytoclastic vasculitis),
erythema multiforme, Stevens-Johnson syndrome,
toxic epidermal necrolysis, subcutaneous nodule,
new or worsening psoriasis (all sub-types
including pustular and palmoplantar)
Opportunistic infections, including atypical mycobacterial infection, herpes
zoster, aspergillosis and Pneumocystis jiroveci pneumonia, and protozoal
infections have also been reported in postmarketing use.
DRUG INTERACTIONS
Specific drug interaction studies have not been conducted with Enbrel.
Vaccines
Most PsA patients receiving Enbrel were able to mount effective B-cell
immune responses to pneumococcal polysaccharide vaccine, but titers in
aggregate were moderately lower and fewer patients had 2-fold rises in titers
compared to patients not receiving Enbrel. The clinical significance of this is
unknown. Patients receiving Enbrel may receive concurrent vaccinations,
except for live vaccines. No data are available on the secondary transmission
of infection by live vaccines in patients receiving Enbrel.
Patients with a significant exposure to varicella virus should temporarily
discontinue Enbrel therapy and be considered for prophylactic treatment with
varicella zoster immune globulin [see Warnings and Precautions].
Immune-Modulating Biologic Products
In a study in which patients with active RA were treated for up to 24 weeks
with concurrent Enbrel and anakinra therapy, a 7% rate of serious infections
was observed, which was higher than that observed with Enbrel alone (0%)
[see Warnings and Precautions] and did not result in higher ACR response
rates compared to Enbrel alone. The most common infections consisted of
bacterial pneumonia (4 cases) and cellulitis (4 cases). One patient with
pulmonary fibrosis and pneumonia died due to respiratory failure. Two
percent of patients treated concurrently with Enbrel and anakinra developed
neutropenia (ANC < 1 x 10 9/L).
In clinical studies, concurrent administration of abatacept and Enbrel
resulted in increased incidences of serious adverse events, including
infections, and did not demonstrate increased clinical benefit [see Warnings
and Precautions].
Cyclophosphamide
The use of Enbrel in patients receiving concurrent cyclophosphamide
therapy is not recommended [see Warnings and Precautions].
Sulfasalazine
Patients in a clinical study who were on established therapy with
sulfasalazine, to which Enbrel was added, were noted to develop a mild
decrease in mean neutrophil counts in comparison to groups treated with
either Enbrel or sulfasalazine alone. The clinical significance of this
observation is unknown.
USE IN SPECIFIC POPULATIONS
Pregnancy
Pregnancy Category B
Pregnancy Surveillance Program
There is a Pregnancy Surveillance Program that monitors outcomes in
women exposed to Enbrel during pregnancy. Women who become pregnant
during Enbrel treatment are encouraged to enroll. Patients or their
physicians should call 1-800-77-AMGEN (1-800-772-6436) to enroll.
Risk Summary
There are no adequate and well controlled studies in pregnant women.
Based on limited data, etanercept concentration in cord blood at the time of
delivery showed that etanercept crossed the placenta in small amounts.
Developmental toxicity studies have been performed in rats and rabbits at
doses ranging from 60- to 100-fold higher than the human dose and have
revealed no evidence of harm to the fetus due to Enbrel. Because animal
reproduction studies are not always predictive of human response, this drug
should be used during pregnancy only if clearly needed.
Human Data
Three case reports showed that cord blood levels of etanercept at delivery in
infants, born to mothers administered etanercept during pregnancy, were
between 3 and 32% of the maternal serum level.
Nursing Mothers
Limited data from published literature show that etanercept is present in low
levels in human milk and minimally absorbed by a breastfed infant. Caution
should be exercised when Enbrel is administered to a nursing woman. The
development and health benefits of breastfeeding should be considered
along with the mother’s clinical need for Enbrel and any potential adverse
effects on the breastfed child from the drug or from the underlying maternal
condition.
Women who choose to continue Enbrel treatment while nursing are
encouraged to enroll in Amgen’s Lactation Surveillance Program. Patients or
their physicians should call 1-800-77-AMGEN (1-800-772-6436) to enroll.
Pediatric Use
Enbrel has not been studied in children < 2 years of age with JIA. The safety
and efficacy of Enbrel in pediatric patients with PsO have not been studied.
Rare (< 0.1%) cases of IBD have been reported in JIA patients receiving
Enbrel, which is not effective for the treatment of IBD [see Adverse
Reactions (6.2)].
The clinical significance of infant exposure to Enbrel in utero is unknown.
The safety of administering live or live-attenuated vaccines in exposed
infants is unknown. Risks and benefits should be considered prior to
administering live or live-attenuated vaccines to exposed infants.
Geriatric Use
A total of 480 RA patients ages 65 years or older have been studied in
clinical trials. In PsO randomized clinical trials, a total of 138 out of 1965
subjects treated with Enbrel or placebo were age 65 or older. No overall
differences in safety or effectiveness were observed between these
patients and younger patients, but the number of geriatric PsO subjects is
too small to determine whether they respond differently from younger
subjects. Because there is a higher incidence of infections in the elderly
population in general, caution should be used in treating the elderly.
Use in Diabetics
There have been reports of hypoglycemia following initiation of Enbrel
therapy in patients receiving medication for diabetes, necessitating a
reduction in anti-diabetic medication in some of these patients.
Rx Only.
This brief summary is based on ENBREL prescribing information v.53: 11/2013
US License Number 1132
© 1998 – 2013 Immunex Corporation.
All rights reserved.
US Patent Nos. 7,915,225; 5,605,690; Re. 36,755.
For more information please call
1-888-436-2735 or visit www.enbrel.com
© 2013 Amgen Inc., Thousand Oaks, CA 91320
All rights reserved.
60077-R5-V3
IMPORTANT SAFETY INFORMATION
SERIOUS INFECTIONS
Patients treated with ENBREL (etanercept) are at increased risk for
developing serious infections that may lead to hospitalization or death.
Most patients who developed these infections were taking concomitant
immunosuppressants such as methotrexate or corticosteroids or were
predisposed to infection because of their underlying disease. ENBREL
should not be initiated in the presence of sepsis, active infections, or
allergy to ENBREL or its components. ENBREL should be discontinued if a
patient develops a serious infection or sepsis. Reported infections include:
1) Active tuberculosis (TB), including reactivation of latent TB. Patients
with TB have frequently presented with disseminated or extrapulmonary
disease. Patients should be tested for latent TB before ENBREL use and
periodically during therapy. Treatment for latent infection should be
initiated prior to ENBREL use, 2) Invasive fungal infections, including
histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis,
blastomycosis, and pneumocystosis. Patients with histoplasmosis or
other invasive fungal infections may present with disseminated, rather
than localized, disease. Antigen and antibody testing for histoplasmosis
may be negative in some patients with active infection. Empiric
antifungal therapy should be considered in patients at risk for invasive
fungal infections who develop severe systemic illness, and 3) Bacterial,
viral, and other infections due to opportunistic pathogens, including
Legionella and Listeria.
The risks and benefi ts of treatment with ENBREL should be carefully
considered prior to initiating therapy in patients 1) with chronic or
recurrent infection, 2) who have been exposed to TB, 3) who have resided
or traveled in areas of endemic TB or endemic mycoses, or 4) with
underlying conditions that may predispose them to infections such as
advanced or poorly controlled diabetes. Patients should be closely
monitored for the development of signs and symptoms of infection during
and after treatment with ENBREL, including the possible development of
TB in patients who tested negative for latent TB prior to initiating therapy.
MALIGNANCIES
Lymphoma and other malignancies, some fatal, have been reported in
children and adolescent patients treated with tumor necrosis factor
(TNF) blockers, including ENBREL.
In adult clinical trials of all TNF blockers, more cases of lymphoma were seen
compared to control patients. The risk of lymphoma may be up to several-fold
higher in RA and psoriasis patients. The role of TNF blocker therapy in the
development of malignancies is unknown.
Cases of acute and chronic leukemia have been reported in association
with postmarketing TNF blocker use in RA and other indications. The risk of
leukemia may be higher in patients with RA (approximately 2-fold) than the
general population.
Melanoma and non-melanoma skin cancer (NMSC) have been reported
in patients treated with TNF blockers, including ENBREL. Periodic skin
examinations should be considered for all patients at increased risk for
skin cancer.
Pediatric Patients
In patients who initiated therapy at ≤18 years of age, approximately
half of the reported malignancies were lymphomas (Hodgkin’s and
non-Hodgkin’s lymphoma). Other cases included rare malignancies
usually associated with immunosuppression and malignancies that
are not usually observed in children and adolescents. Most of the patients
were receiving concomitant immunosuppressants.
NEUROLOGIC EVENTS
Treatment with TNF-blocking agents, including ENBREL, has been associated
with rare (<0.1%) cases of new onset or exacerbation of central nervous
system demyelinating disorders, some presenting with mental status changes
and some associated with permanent disability, and with peripheral nervous
system demyelinating disorders. Cases of transverse myelitis, optic neuritis,
multiple sclerosis, Guillain-Barré syndromes, other peripheral demyelinating
neuropathies, and new onset or exacerbation of seizure disorders have been
©2014 Amgen Inc., Thousand Oaks, CA 91320 All rights reserved. 81818-R1-V1
reported in postmarketing experience with ENBREL therapy. Prescribers should
exercise caution in considering the use of ENBREL in patients with preexisting
or recent-onset central or peripheral nervous system demyelinating disorders.
CONGESTIVE HEART FAILURE
Cases of worsening congestive heart failure (CHF) and, rarely, new-onset
cases have been reported in patients taking ENBREL. Caution should be
used when using ENBREL in patients with CHF. These patients should be
carefully monitored.
HEMATOLOGIC EVENTS
Rare cases of pancytopenia, including aplastic anemia, some fatal, have
been reported. The causal relationship to ENBREL therapy remains unclear.
Exercise caution when considering ENBREL in patients who have a previous
history of significant hematologic abnormalities. Advise patients to seek
immediate medical attention if they develop signs or symptoms of blood
dyscrasias or infection. Consider discontinuing ENBREL if significant
hematologic abnormalities are confirmed.
HEPATITIS B REACTIVATION
Reactivation of hepatitis B has been reported in patients who were previously
infected with hepatitis B virus (HBV) and received concomitant TNF-blocking
agents, including ENBREL. Most reports occurred in patients also taking
immunosuppressive agents, which may contribute to hepatitis B reactivation.
Exercise caution when considering ENBREL in these patients.
ALLERGIC REACTIONS
Allergic reactions associated with administration of ENBREL during clinical
trials have been reported in <2% of patients. If an anaphylactic reaction or
other serious allergic reaction occurs, administration of ENBREL should be
discontinued immediately and appropriate therapy initiated.
IMMUNIZATIONS
Live vaccines should not be administered to patients on ENBREL. JIA patients,
if possible, should be brought up to date with all immunizations prior to
initiating ENBREL. In patients with exposure to varicella virus, consider
temporary discontinuation of ENBREL and prophylactic treatment with
Varicella Zoster Immune Globulin.
AUTOIMMUNITY
Autoantibodies may develop with ENBREL, and rarely lupus-like syndrome
or autoimmune hepatitis may occur. These may resolve upon withdrawal
of ENBREL. Stop ENBREL if lupus-like syndrome or autoimmune
hepatitis develops.
WEGENER’S GRANULOMATOSIS PATIENTS
The use of ENBREL in patients with Wegener’s granulomatosis receiving
immunosuppressive agents (eg, cyclophosphamide) is not recommended.
MODERATE TO SEVERE ALCOHOLIC HEPATITIS
Based on a study of patients treated for alcoholic hepatitis, exercise caution
when using ENBREL in patients with moderate to severe alcoholic hepatitis.
ADVERSE EVENTS
The most commonly reported adverse events in RA clinical trials were injection
site reaction, infection, and headache. In clinical trials of all other adult
indications, adverse events were similar to those reported in RA clinical trials.
DRUG INTERACTIONS
The use of ENBREL in patients receiving concurrent cyclophosphamide
therapy is not recommended. The risk of serious infection may increase
with concomitant use of abatacept therapy. Concurrent therapy with
ENBREL and anakinra is not recommended. Hypoglycemia has been
reported following initiation of ENBREL therapy in patients receiving
medication for diabetes, necessitating a reduction in antidiabetic
medication in some of these patients.
Please see Brief Summary of Prescribing Information on the
preceding pages.
References: 1. Enbrel® (etanercept) Prescribing Information, Immunex Corporation, Thousand
Oaks, Calif. November 2013. 2. Data on file, Amgen; #1 Biologic for Rheumatologists: May 2, 2014.
3. Data on file, Amgen; TEMPO CSR 57599 3 yr Clinical: June 21, 2005.
In moderately to severely active rheumatoid arthritis (RA)
Help patients get back to
many of the activities they love
ACTIVE
;
MOVEMENT
;
ENABLE
;
EXPLORE
;
SUPPORT
;
ENBREL
ENBREL + MTX achieved significant improvements in physical function vs MTX
alone as measured by HAQ-DI by Week 2 and out to Year 31*
Whether your patients are practicing their putt, spending time with family, or walking
their dog, ENBREL has been a symbol of change for your patients with moderate
to severe RA. Since 1998, ENBREL was the first and is still the only FDA-approved
soluble TNF receptor treatment for appropriate patients. Because of you, ENBREL
is the #1 prescribed biologic by rheumatologists today.2†
ENBREL is indicated for reducing signs and symptoms, inducing major clinical response,
inhibiting the progression of structural damage, and improving physical function in patients
with moderately to severely active rheumatoid arthritis. ENBREL can be initiated in combination
with methotrexate (MTX) or used alone. Prescription ENBREL is administered by injection.
Important Safety Considerations: ENBREL suppresses the immune system and has been associated with
serious and sometimes fatal infections, including TB and other opportunistic infections. Other serious and
sometimes fatal adverse events including malignancies, neurologic events, hematologic events, congestive heart
failure, hepatitis B reactivation, allergic reactions, lupus-like syndrome and autoimmune hepatitis have also been
reported. ENBREL is contraindicated in patients with sepsis.
Please see additional Important Safety Information and Brief Summary on preceding pages.
*In the TEMPO study, mean HAQ scores at baseline, week 2, and year 3 were 1.7, 1.5, and 1.1 in the MTX arm (n = 228) and 1.8, 1.3, and 0.8 in the
ENBREL + MTX arm (n = 231), respectively.3
HAQ-DI = Health Assessment Questionnaire-Disability Index.
†6-month total of IMS monthly NPA prescription data by rheumatologists. These data include only dispensed total scripts.
Visit Booth #943
to see how you can help patients get back to many of the activities they love.
Enbrel® and the Enbrel® logo are registered trademarks of Immunex Corporation.
`